NZ613087B2 - Histone deacetylase inhibitors and compositions and methods of use thereof - Google Patents
Histone deacetylase inhibitors and compositions and methods of use thereof Download PDFInfo
- Publication number
- NZ613087B2 NZ613087B2 NZ613087A NZ61308712A NZ613087B2 NZ 613087 B2 NZ613087 B2 NZ 613087B2 NZ 613087 A NZ613087 A NZ 613087A NZ 61308712 A NZ61308712 A NZ 61308712A NZ 613087 B2 NZ613087 B2 NZ 613087B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- henyl
- alkyl
- hydroxy
- optionally substituted
- phenylcyclopropanecarboxamide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 161
- 239000003276 histone deacetylase inhibitor Substances 0.000 title description 4
- 229940121372 histone deacetylase inhibitors Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 482
- 239000011780 sodium chloride Substances 0.000 claims abstract description 138
- 150000003839 salts Chemical class 0.000 claims abstract description 136
- 201000010099 disease Diseases 0.000 claims abstract description 84
- 230000001404 mediated Effects 0.000 claims abstract description 51
- GCBXAQLZTBLSGE-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboxamide Chemical class C=1C=CC=CC=1C1(C(=O)N)CC1 GCBXAQLZTBLSGE-UHFFFAOYSA-N 0.000 claims abstract description 39
- 102000003964 Histone deacetylases Human genes 0.000 claims abstract description 38
- 108090000353 Histone deacetylases Proteins 0.000 claims abstract description 38
- 201000001971 Huntington's disease Diseases 0.000 claims abstract description 9
- 230000000626 neurodegenerative Effects 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 415
- -1 2-trifluoromethylphenyl Chemical group 0.000 claims description 322
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 126
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 59
- 125000001072 heteroaryl group Chemical group 0.000 claims description 58
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 45
- 125000005843 halogen group Chemical group 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000004076 pyridyl group Chemical group 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 17
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 14
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 8
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 6
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 5
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000006394 4-(5-methylpyrimidinyl) group Chemical group [H]C([H])([H])C1=CN=CN=C1* 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 3
- 102100016430 HDAC4 Human genes 0.000 claims description 3
- 101700050702 HDAC4 Proteins 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 3
- DNHVFNDOHJKATM-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)pyrazole Chemical compound FC(F)(F)CN1C=CC=N1 DNHVFNDOHJKATM-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000006391 4-(5-chloropyrimidinyl) group Chemical group ClC1=CN=CN=C1* 0.000 claims 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 3
- XQQBUAPQHNYYRS-UHFFFAOYSA-N 2-Methylthiophene Chemical compound CC1=CC=CS1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 claims 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 claims 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- MUUIBXOQEIWHGQ-UHFFFAOYSA-N FC1=C(C=CC=C1)C1(CC1)C(=O)NO Chemical compound FC1=C(C=CC=C1)C1(CC1)C(=O)NO MUUIBXOQEIWHGQ-UHFFFAOYSA-N 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 27
- 239000003112 inhibitor Substances 0.000 abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 308
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 183
- 238000000746 purification Methods 0.000 description 178
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 173
- 238000010828 elution Methods 0.000 description 158
- 239000000377 silicon dioxide Substances 0.000 description 152
- 238000004440 column chromatography Methods 0.000 description 151
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 111
- 235000019439 ethyl acetate Nutrition 0.000 description 107
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 107
- 239000007787 solid Substances 0.000 description 104
- 239000003921 oil Substances 0.000 description 88
- 235000019198 oils Nutrition 0.000 description 88
- MNTZZDOKIWMNIM-UHFFFAOYSA-N phenyl cyclopropanecarboxylate Chemical compound C1CC1C(=O)OC1=CC=CC=C1 MNTZZDOKIWMNIM-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 82
- 238000004458 analytical method Methods 0.000 description 74
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 65
- 239000012044 organic layer Substances 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 229910052757 nitrogen Inorganic materials 0.000 description 39
- 238000002953 preparative HPLC Methods 0.000 description 39
- 235000019253 formic acid Nutrition 0.000 description 37
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- 239000012071 phase Substances 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000007792 addition Methods 0.000 description 23
- 125000004429 atoms Chemical group 0.000 description 23
- 125000004432 carbon atoms Chemical group C* 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 238000004296 chiral HPLC Methods 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 20
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 20
- 239000012267 brine Substances 0.000 description 19
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 17
- 125000003367 polycyclic group Chemical group 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 125000001246 bromo group Chemical group Br* 0.000 description 15
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical class [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrugs Drugs 0.000 description 11
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- XQQZRZQVBFHBHL-UHFFFAOYSA-N 12-Crown-4 Chemical compound C1COCCOCCOCCO1 XQQZRZQVBFHBHL-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 201000002674 obstructive nephropathy Diseases 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 208000009956 Adenocarcinoma Diseases 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- 206010025310 Other lymphomas Diseases 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- 239000012455 biphasic mixture Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000008177 pharmaceutical agent Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- SYKCQQWUZTYFTG-UHFFFAOYSA-M 1-benzylthiolan-1-ium;bromide Chemical compound [Br-].C=1C=CC=CC=1C[S+]1CCCC1 SYKCQQWUZTYFTG-UHFFFAOYSA-M 0.000 description 7
- 229960004063 Propylene glycol Drugs 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 201000009030 carcinoma Diseases 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000005842 heteroatoms Chemical group 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- 230000002335 preservative Effects 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- XOVNRDYATTWJCF-UHFFFAOYSA-M 1-[(2-fluorophenyl)methyl]thiolan-1-ium;bromide Chemical compound [Br-].FC1=CC=CC=C1C[S+]1CCCC1 XOVNRDYATTWJCF-UHFFFAOYSA-M 0.000 description 6
- 206010001897 Alzheimer's disease Diseases 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- WYQWDIGTZPCMIU-UHFFFAOYSA-M O1C=CN(CC=C1)C(=O)[O-] Chemical compound O1C=CN(CC=C1)C(=O)[O-] WYQWDIGTZPCMIU-UHFFFAOYSA-M 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- KVZLZFPAYKOMPY-UHFFFAOYSA-N (2-fluorophenyl) cyclopropanecarboxylate Chemical compound FC1=CC=CC=C1OC(=O)C1CC1 KVZLZFPAYKOMPY-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229960005150 glycerol Drugs 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 229940067606 Lecithin Drugs 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 230000001969 hypertrophic Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- XQYHLDPIBNCPQW-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-iodopyrazole Chemical compound N1=C(I)C=CN1CC1CC1 XQYHLDPIBNCPQW-UHFFFAOYSA-N 0.000 description 3
- BHXSHKSHMWUZEX-UHFFFAOYSA-M 1-[(3-chlorophenyl)methyl]thiolan-1-ium;bromide Chemical compound [Br-].ClC1=CC=CC(C[S+]2CCCC2)=C1 BHXSHKSHMWUZEX-UHFFFAOYSA-M 0.000 description 3
- AGHMCBHLZUJTAH-UHFFFAOYSA-M 1-benzylthiolan-1-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C=1C=CC=CC=1C[S+]1CCCC1 AGHMCBHLZUJTAH-UHFFFAOYSA-M 0.000 description 3
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 3
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 3
- HXBAGLRPNSWXRY-UHFFFAOYSA-N 2-chloro-4-fluoropyrimidine Chemical compound FC1=CC=NC(Cl)=N1 HXBAGLRPNSWXRY-UHFFFAOYSA-N 0.000 description 3
- WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 description 3
- UXRAFGWKICWQBK-UHFFFAOYSA-N 4-bromo-2-(hydroxymethyl)-N-(2,2,2-trifluoroethyl)benzamide Chemical compound OCC1=CC(Br)=CC=C1C(=O)NCC(F)(F)F UXRAFGWKICWQBK-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 229960000836 Amitriptyline Drugs 0.000 description 3
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 3
- 229940039856 Aricept Drugs 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- 229940084238 Eldepryl Drugs 0.000 description 3
- 229940108366 Exelon Drugs 0.000 description 3
- 206010016629 Fibroma Diseases 0.000 description 3
- 229960002464 Fluoxetine Drugs 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 101700036927 HDAC1 Proteins 0.000 description 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 208000005264 Motor Neuron Disease Diseases 0.000 description 3
- 206010028003 Motor neurone disease Diseases 0.000 description 3
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 229960001158 Nortriptyline Drugs 0.000 description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Quinoform Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 229960001534 Risperidone Drugs 0.000 description 3
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- BGRJTUBHPOOWDU-UHFFFAOYSA-N Sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N Tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 229960001685 Tacrine Drugs 0.000 description 3
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 3
- MENUHMSZHZBYMK-VAWYXSNFSA-N [(E)-2-cyclohexylethenyl]benzene Chemical compound C1CCCCC1\C=C\C1=CC=CC=C1 MENUHMSZHZBYMK-VAWYXSNFSA-N 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001499 aryl bromides Chemical class 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000000271 cardiovascular Effects 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 229960005228 clioquinol Drugs 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 3
- 229960003530 donepezil Drugs 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 201000008808 fibrosarcoma Diseases 0.000 description 3
- 230000003176 fibrotic Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 201000004681 psoriasis Diseases 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- 229960004136 rivastigmine Drugs 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical group [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960002784 thioridazine Drugs 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- VJVZPTPOYCJFNI-UHFFFAOYSA-M (2-ethoxy-2-oxoethyl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC(=O)OCC)C1=CC=CC=C1 VJVZPTPOYCJFNI-UHFFFAOYSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 2
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 2
- YVPJCJLMRRTDMQ-ONEGZZNKSA-N (E)-2-diazonio-1-ethoxyethenolate Chemical compound CCO\C([O-])=C\[N+]#N YVPJCJLMRRTDMQ-ONEGZZNKSA-N 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N (E)-Stilbene Chemical compound C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 2
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- IXQYBUDWDLYNMA-UHFFFAOYSA-N 1-Butyl-3-methylimidazolium hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCCCN1C=C[N+](C)=C1 IXQYBUDWDLYNMA-UHFFFAOYSA-N 0.000 description 2
- TYFZIFNDZZPBDX-UHFFFAOYSA-M 1-[(4-fluorophenyl)methyl]thiolan-1-ium;bromide Chemical compound [Br-].C1=CC(F)=CC=C1C[S+]1CCCC1 TYFZIFNDZZPBDX-UHFFFAOYSA-M 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- MSFVEEFXECBJPG-UHFFFAOYSA-N 2-(chloromethyl)pyrimidine Chemical compound ClCC1=NC=CC=N1 MSFVEEFXECBJPG-UHFFFAOYSA-N 0.000 description 2
- FZRBTBCCMVNZBD-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(Cl)=N1 FZRBTBCCMVNZBD-UHFFFAOYSA-N 0.000 description 2
- JFZJMSDDOOAOIV-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)N=C1 JFZJMSDDOOAOIV-UHFFFAOYSA-N 0.000 description 2
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2H-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 2
- ZSYMMINAALNVSH-UHFFFAOYSA-N 2H-triazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=NNN=C21 ZSYMMINAALNVSH-UHFFFAOYSA-N 0.000 description 2
- JTZSFNHHVULOGJ-UHFFFAOYSA-N 3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CN=C1 JTZSFNHHVULOGJ-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3H-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
- BZJSAOCTEXRSME-UHFFFAOYSA-N 4-bromopyridazine Chemical compound BrC1=CC=NN=C1 BZJSAOCTEXRSME-UHFFFAOYSA-N 0.000 description 2
- LLNQWPTUJJYTTE-UHFFFAOYSA-N 4-iodopyrazole Chemical compound IC=1C=NNC=1 LLNQWPTUJJYTTE-UHFFFAOYSA-N 0.000 description 2
- RPFAUCIXZGMCFN-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)C=N1 RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 2
- IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3H-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 description 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 206010004938 Bipolar disease Diseases 0.000 description 2
- 206010005742 Blood pressure disorder Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N Bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 201000003274 CINCA Syndrome Diseases 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M Caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- 208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 description 2
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 2
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 2
- AUQDITHEDVOTCU-UHFFFAOYSA-N Cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N DABCO Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- 206010064570 Familial cold autoinflammatory syndrome Diseases 0.000 description 2
- 206010016207 Familial mediterranean fever Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102100002572 HDAC1 Human genes 0.000 description 2
- 101700061787 HDAC2 Proteins 0.000 description 2
- 102100016431 HDAC3 Human genes 0.000 description 2
- 101700081813 HDAC3 Proteins 0.000 description 2
- 101700000034 HDAC8 Proteins 0.000 description 2
- 102100007193 HDAC9 Human genes 0.000 description 2
- 101700005838 HDAC9 Proteins 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061255 Ischaemia Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 210000001117 Keloid Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 206010024190 Leiomyosarcomas Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 102100014726 MECP2 Human genes 0.000 description 2
- 101700029603 MECP2 Proteins 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027175 Memory impairment Diseases 0.000 description 2
- 206010027191 Meningioma Diseases 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- 208000001089 Multiple System Atrophy Diseases 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 208000008814 Neuronal intranuclear inclusion disease Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 208000007014 Retinitis Pigmentosa Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 Saccharin Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N Tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000008383 Wilms Tumor Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 201000003076 angiosarcoma Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 2
- 201000002055 autistic disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010870 diseases of metabolism Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- ZYUQJSZGZXWSRB-AATRIKPKSA-N ethyl (E)-3-pyridazin-3-ylprop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=CN=N1 ZYUQJSZGZXWSRB-AATRIKPKSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000004404 neurofibroma Diseases 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 201000008839 post-traumatic stress disease Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001603 reducing Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 201000001365 retinal ischemia Diseases 0.000 description 2
- 201000000582 retinoblastoma Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HQOJMTATBXYHNR-UHFFFAOYSA-M thallium(I) acetate Chemical compound [Tl+].CC([O-])=O HQOJMTATBXYHNR-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- WIJNYNBSPQMJGO-UHFFFAOYSA-N (3-phenylmethoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 WIJNYNBSPQMJGO-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-Triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- GHPWPOJLJPMISD-UHFFFAOYSA-N 1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine Chemical compound C1CCN=C2C=CNN21 GHPWPOJLJPMISD-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- UYSSHBKWAVUEGU-UHFFFAOYSA-M 1-[(3-fluorophenyl)methyl]thiolan-1-ium;bromide Chemical compound [Br-].FC1=CC=CC(C[S+]2CCCC2)=C1 UYSSHBKWAVUEGU-UHFFFAOYSA-M 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QUYJEYSRBCLJIZ-UHFFFAOYSA-N 1-methylpyrazole-3-carbaldehyde Chemical compound CN1C=CC(C=O)=N1 QUYJEYSRBCLJIZ-UHFFFAOYSA-N 0.000 description 1
- LSOLSXRUCKLZNL-UHFFFAOYSA-O 1-pentyl-1H-imidazol-1-ium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCCCC[NH+]1C=CN=C1 LSOLSXRUCKLZNL-UHFFFAOYSA-O 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1H-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- KNYHISBJRQVMAZ-UHFFFAOYSA-N 1H-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C=NNC2=C1 KNYHISBJRQVMAZ-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1H-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- QKZMLBNEFKGPOZ-UHFFFAOYSA-N 1H-pyrazolo[4,3-c]pyridine Chemical compound C1=N[CH]C2=C=NNC2=C1 QKZMLBNEFKGPOZ-UHFFFAOYSA-N 0.000 description 1
- MBOUTDLGNDOXIC-UHFFFAOYSA-N 1H-pyrrolo[2,3-b]pyridine Chemical compound C1=C[CH]C2=C=CNC2=N1 MBOUTDLGNDOXIC-UHFFFAOYSA-N 0.000 description 1
- SBYVQIAOKDDMMS-UHFFFAOYSA-N 1H-pyrrolo[2,3-c]pyridine Chemical compound C1=NC=C2NC=CC2=C1.C1=NC=C2NC=CC2=C1 SBYVQIAOKDDMMS-UHFFFAOYSA-N 0.000 description 1
- ISZHENWZNICKIC-UHFFFAOYSA-N 1H-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2N[C]=CC2=N1 ISZHENWZNICKIC-UHFFFAOYSA-N 0.000 description 1
- WFZCVZZPXZKOPL-UHFFFAOYSA-N 1H-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2N[C]=CC2=C1 WFZCVZZPXZKOPL-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- NGJXAWCQWBUULR-UHFFFAOYSA-N 2,2,2-trifluoroethyl 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S(=O)(=O)OCC(F)(F)F NGJXAWCQWBUULR-UHFFFAOYSA-N 0.000 description 1
- TVBNTFVSONEKOU-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carbaldehyde Chemical compound C1=CC=C2OC(C=O)COC2=C1 TVBNTFVSONEKOU-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N 2,3-dihydroxypropyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- CEJAHXLRNZJPQH-UHFFFAOYSA-N 2,5-dichloropyrimidine Chemical compound ClC1=CN=C(Cl)N=C1 CEJAHXLRNZJPQH-UHFFFAOYSA-N 0.000 description 1
- MVCMPKYZHKUBCL-UHFFFAOYSA-N 2,6-dichloropyridine-4-carbaldehyde Chemical compound ClC1=CC(C=O)=CC(Cl)=N1 MVCMPKYZHKUBCL-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- HCMMECMKVPHMDE-UHFFFAOYSA-N 2,7-naphthyridine Chemical compound C1=NC=C2C=NC=CC2=C1 HCMMECMKVPHMDE-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- JMIPWQWATHJTMZ-UHFFFAOYSA-N 2-(bromomethyl)-1H-imidazole Chemical compound BrCC1=NC=CN1 JMIPWQWATHJTMZ-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-Bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-Ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-Nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- QOWAMIUFBNBINS-UHFFFAOYSA-N 2-[6-[4,5-diethoxy-2-(ethoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(OC)C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)O1 QOWAMIUFBNBINS-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- UFPOSTQMFOYHJI-UHFFFAOYSA-N 2-chloropyridine-4-carbaldehyde Chemical compound ClC1=CC(C=O)=CC=N1 UFPOSTQMFOYHJI-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2H-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-Bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- DAZQBQQNIUAQAV-UHFFFAOYSA-N 3-bromo-2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=C(Br)C=CC=C1C=O DAZQBQQNIUAQAV-UHFFFAOYSA-N 0.000 description 1
- ILYSUJOMLYXAOC-UHFFFAOYSA-N 3-bromopyridazine Chemical compound BrC1=CC=CN=N1 ILYSUJOMLYXAOC-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- IZMZHRJBBYCHOO-UHFFFAOYSA-N 4,5-didehydro-3H-thiophene Chemical group [CH]1CC#CS1 IZMZHRJBBYCHOO-UHFFFAOYSA-N 0.000 description 1
- QHLLEZOPZRBCOY-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(Br)=CC=N1 QHLLEZOPZRBCOY-UHFFFAOYSA-N 0.000 description 1
- NPUZZKZKHYZOEJ-UHFFFAOYSA-N 4-bromo-2-cyclopropylpyridine Chemical compound BrC1=CC=NC(C2CC2)=C1 NPUZZKZKHYZOEJ-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- STWODXDTKGTVCJ-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1C1CCNCC1 STWODXDTKGTVCJ-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- SZRHWHHXVXSGMT-UHFFFAOYSA-N 5-bromo-2,2-difluoro-1,3-benzodioxole Chemical compound C1=C(Br)C=C2OC(F)(F)OC2=C1 SZRHWHHXVXSGMT-UHFFFAOYSA-N 0.000 description 1
- QNMGAQWLVFYMGX-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1,4-benzodioxine-7-carbaldehyde Chemical compound O1CCOC2=C1C=C(C=O)C=C2Cl QNMGAQWLVFYMGX-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1H-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- 229940048299 ACETYLATED LANOLIN ALCOHOLS Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N Acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000002718 Adenomatoid Tumor Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- 208000002353 Alcoholic Hepatitis Diseases 0.000 description 1
- 229960000458 Allantoin Drugs 0.000 description 1
- 206010058284 Allergy to arthropod sting Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007368 Ataxin-7 Human genes 0.000 description 1
- 108010032953 Ataxin-7 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- BOQVVBPLYDIOQR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1C(CC=CC1)B(O)O Chemical compound C(C)(C)(C)OC(=O)N1C(CC=CC1)B(O)O BOQVVBPLYDIOQR-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 210000001715 Carotid Arteries Anatomy 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 208000002849 Chondrocalcinosis Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960000978 Cyproterone Acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N Cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010067889 Dementia with Lewy body Diseases 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N Dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229950004203 Droloxifene Drugs 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000001708 Dupuytren Contracture Diseases 0.000 description 1
- 208000001848 Dysentery Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010016212 Familial tremor Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 206010017374 Friedreich's ataxia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 206010061173 Gastrointestinal motility disease Diseases 0.000 description 1
- 102000004064 Geminin Human genes 0.000 description 1
- 108090000577 Geminin Proteins 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- 206010018651 Graft versus host disease Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102100002658 H2BS1 Human genes 0.000 description 1
- 101700021312 H2BS1 Proteins 0.000 description 1
- 102100013102 HDAC10 Human genes 0.000 description 1
- 101710042173 HDAC10 Proteins 0.000 description 1
- 102100013167 HDAC11 Human genes 0.000 description 1
- 108091005742 HDAC11 Proteins 0.000 description 1
- 102100016432 HDAC2 Human genes 0.000 description 1
- 102100007189 HDAC6 Human genes 0.000 description 1
- 101700002249 HDAC6 Proteins 0.000 description 1
- 101700004675 HDAC7 Proteins 0.000 description 1
- 102100007197 HDAC8 Human genes 0.000 description 1
- 206010018872 Haemochromatosis Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000006359 Hepatoblastoma Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 208000001799 Hereditary Optic Atrophy Diseases 0.000 description 1
- 208000008675 Hereditary Spastic Paraplegia Diseases 0.000 description 1
- 206010019895 Hereditary optic atrophy Diseases 0.000 description 1
- 102000018561 Histone deacetylase 4 Human genes 0.000 description 1
- 108050007818 Histone deacetylase 4 Proteins 0.000 description 1
- 102000016182 Histone deacetylase 5 Human genes 0.000 description 1
- 108050004676 Histone deacetylase 5 Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020630 Hypergammaglobulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940078545 ISOCETYL STEARATE Drugs 0.000 description 1
- 229940093629 ISOPROPYL ISOSTEARATE Drugs 0.000 description 1
- 229940089456 ISOPROPYL STEARATE Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 206010022498 Insulinoma Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 241001058354 Inti Species 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- UJPPXNXOEVDSRW-UHFFFAOYSA-N Isopropyl_laurate Chemical compound CCCCCCCCCCCC(=O)OC(C)C UJPPXNXOEVDSRW-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 201000008166 Kennedy's disease Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 206010068202 Leukodystrophy Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010024627 Liposarcoma Diseases 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 201000009324 Loeffler syndrome Diseases 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 229940078812 MYRISTYL MYRISTATE Drugs 0.000 description 1
- 229940078555 MYRISTYL PROPIONATE Drugs 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000002418 Meninges Anatomy 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000010492 Mucinous Cystadenocarcinoma Diseases 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 208000006625 Myoclonic Epilepsy Diseases 0.000 description 1
- 206010054859 Myoclonic epilepsy Diseases 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000009091 Myxoma Diseases 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- KGCNVGDHOSFKFT-UHFFFAOYSA-N Nitrosonium tetrafluoroborate Chemical compound [O+]#N.F[B-](F)(F)F KGCNVGDHOSFKFT-UHFFFAOYSA-N 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 229910004755 ORb Inorganic materials 0.000 description 1
- RZJRJXONCZWCBN-UHFFFAOYSA-N Octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 1
- 206010030032 Ocular disorder Diseases 0.000 description 1
- 206010030047 Ocular injury Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940054534 Ophthalmic Solution Drugs 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 208000003388 Osteoid Osteoma Diseases 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 1
- 229940030490 PROGESTOGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 201000001146 Paget's disease of bone Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 201000011585 Pick's disease Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000003055 Prion Disease Diseases 0.000 description 1
- 229940095055 Progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 208000002574 Reactive Arthritis Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000004548 Serous Cystadenocarcinoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig Cell Tumor Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N Simethicone Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 210000003625 Skull Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M Sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000006045 Spondylarthropathy Diseases 0.000 description 1
- 206010052775 Spondyloarthropathy Diseases 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000003755 Striatonigral Degeneration Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N Triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 102100015249 VEGFA Human genes 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 208000009540 Villous Adenoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 208000009311 Vipoma Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 201000005634 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- XUTIDUCSRSNKKP-UHFFFAOYSA-N [1,2]oxazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NOC2=C1 XUTIDUCSRSNKKP-UHFFFAOYSA-N 0.000 description 1
- AMIWTKBQVQQBBS-UHFFFAOYSA-N [1,2]oxazolo[4,5-c]pyridine Chemical compound C1=NC=C2C=NOC2=C1 AMIWTKBQVQQBBS-UHFFFAOYSA-N 0.000 description 1
- DITTYRBIXKVOTK-UHFFFAOYSA-N [1,2]oxazolo[5,4-b]pyridine Chemical compound C1=CC=C2C=NOC2=N1 DITTYRBIXKVOTK-UHFFFAOYSA-N 0.000 description 1
- WXTRHHSZKLAHHV-UHFFFAOYSA-N [1,2]oxazolo[5,4-c]pyridine Chemical compound N1=CC=C2C=NOC2=C1 WXTRHHSZKLAHHV-UHFFFAOYSA-N 0.000 description 1
- ZTAPFURKEMZRSQ-UHFFFAOYSA-N [1,2]thiazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NSC2=C1 ZTAPFURKEMZRSQ-UHFFFAOYSA-N 0.000 description 1
- HUMJZSMCTXGAMD-UHFFFAOYSA-N [1,2]thiazolo[4,5-c]pyridine Chemical compound C1=NC=C2C=NSC2=C1 HUMJZSMCTXGAMD-UHFFFAOYSA-N 0.000 description 1
- VTIVYUBSVCXRPI-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine Chemical compound C1=CC=C2C=NSC2=N1 VTIVYUBSVCXRPI-UHFFFAOYSA-N 0.000 description 1
- YBAGZQVTZXUQEU-UHFFFAOYSA-N [1,2]thiazolo[5,4-c]pyridine Chemical compound N1=CC=C2C=NSC2=C1 YBAGZQVTZXUQEU-UHFFFAOYSA-N 0.000 description 1
- ZATXVRSLQDRAHZ-UHFFFAOYSA-N [1,3]oxazolo[4,5-c]pyridine Chemical compound N1=CC=C2OC=NC2=C1 ZATXVRSLQDRAHZ-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- XRVDKIQEFCJTBZ-UHFFFAOYSA-N [1,3]oxazolo[5,4-c]pyridine Chemical compound C1=NC=C2OC=NC2=C1 XRVDKIQEFCJTBZ-UHFFFAOYSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- FIPLAFRCDDWERW-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridine Chemical compound N1=CC=C2SC=NC2=C1 FIPLAFRCDDWERW-UHFFFAOYSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- FHIMYVFGWKCROK-UHFFFAOYSA-N [1,3]thiazolo[5,4-c]pyridine Chemical compound C1=NC=C2SC=NC2=C1 FHIMYVFGWKCROK-UHFFFAOYSA-N 0.000 description 1
- OZDMFSDAVYNSHX-UHFFFAOYSA-N [4-(9H-carbazol-1-yl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=CC2=C1NC1=CC=CC=C12 OZDMFSDAVYNSHX-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002555 anti-neurodegenerative Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N azanium;hydron;carbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 201000003861 cerebellar disease Diseases 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 201000005262 chondroma Diseases 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- IQZKJBMCSKESJI-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane Chemical class [Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O IQZKJBMCSKESJI-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- KARVSHNNUWMXFO-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane;hydrate Chemical class O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Al]O[Al]=O KARVSHNNUWMXFO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 201000009051 embryonal carcinoma Diseases 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 229940046079 endocrine therapy drugs Progestogens Drugs 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HQSFGCUUTBCFPF-UHFFFAOYSA-N ethane-1,2-diol;octadecanoic acid Chemical compound OCCO.CCCCCCCCCCCCCCCCCC(O)=O HQSFGCUUTBCFPF-UHFFFAOYSA-N 0.000 description 1
- LDLDYFCCDKENPD-UHFFFAOYSA-N ethenylcyclohexane Chemical compound C=CC1CCCCC1 LDLDYFCCDKENPD-UHFFFAOYSA-N 0.000 description 1
- QJIKOBDFPMTGGU-UHFFFAOYSA-N ethyl 2-nitro-3-phenylprop-2-enoate Chemical compound CCOC(=O)C([N+]([O-])=O)=CC1=CC=CC=C1 QJIKOBDFPMTGGU-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000011240 frontotemporal dementia Diseases 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RCFDIXKVOHJQPP-UHFFFAOYSA-N furo[2,3-b]pyridine Chemical compound C1=CN=C2OC=CC2=C1 RCFDIXKVOHJQPP-UHFFFAOYSA-N 0.000 description 1
- ZYXBIOIYWUIXSM-UHFFFAOYSA-N furo[2,3-c]pyridine Chemical compound C1=NC=C2OC=CC2=C1 ZYXBIOIYWUIXSM-UHFFFAOYSA-N 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- WJDMEHCIRPKRRQ-UHFFFAOYSA-N furo[3,2-c]pyridine Chemical compound N1=CC=C2OC=CC2=C1 WJDMEHCIRPKRRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000003895 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- MFKOGXVHZUSUAF-QPJJXVBHSA-N methyl (E)-3-(4-bromophenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(Br)C=C1 MFKOGXVHZUSUAF-QPJJXVBHSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- OGIKSURTYJLRMP-UHFFFAOYSA-N oxadiazolo[4,5-b]pyridine Chemical compound C1=CN=C2N=NOC2=C1 OGIKSURTYJLRMP-UHFFFAOYSA-N 0.000 description 1
- LBWZSUHDRDWJEC-UHFFFAOYSA-N oxadiazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=C1N=NO2 LBWZSUHDRDWJEC-UHFFFAOYSA-N 0.000 description 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 description 1
- SVMOLIXMHXABPH-UHFFFAOYSA-N oxadiazolo[5,4-c]pyridine Chemical compound C1=NC=CC2=C1ON=N2 SVMOLIXMHXABPH-UHFFFAOYSA-N 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9Z,12Z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 1
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 1
- JBDKAABFESSFMV-UHFFFAOYSA-N pyrrolo[1,2-a]pyrimidine Chemical compound N1=CC=CN2C=CC=C21 JBDKAABFESSFMV-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 210000004176 reticulum cell Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 201000011056 retinal disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-M sulfinate Chemical compound [O-]S=O BUUPQKDIAURBJP-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- GNXPUXGOQIHJLJ-UHFFFAOYSA-N thiadiazolo[4,5-b]pyridine Chemical compound C1=CN=C2N=NSC2=C1 GNXPUXGOQIHJLJ-UHFFFAOYSA-N 0.000 description 1
- HKMXLNRHGNWKJG-UHFFFAOYSA-N thiadiazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=C1N=NS2 HKMXLNRHGNWKJG-UHFFFAOYSA-N 0.000 description 1
- QKTRRACPJVYJNU-UHFFFAOYSA-N thiadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SN=NC2=C1 QKTRRACPJVYJNU-UHFFFAOYSA-N 0.000 description 1
- DNWLQCBSEZHTMF-UHFFFAOYSA-N thiadiazolo[5,4-c]pyridine Chemical compound C1=NC=CC2=C1SN=N2 DNWLQCBSEZHTMF-UHFFFAOYSA-N 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical compound C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical compound N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tri(ortho-tolyl)phosphine Substances CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- YOWGRWHKDCHINP-UHFFFAOYSA-N tributyl(1,3-oxazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CO1 YOWGRWHKDCHINP-UHFFFAOYSA-N 0.000 description 1
- KFWFYOPKNSYTMV-UHFFFAOYSA-N tributyl-(1-methylimidazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CN1C KFWFYOPKNSYTMV-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000004066 vascular targeting agent Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
The disclosure relates to substituted phenylcyclopropanecarboxamide derivatives of formula (I) and pharmaceutically acceptable salt thereof, which are histone deacetylase (HDAC) inhibitors, wherein the variables are as defined in the specification. These compounds of formula (I) are suitable for treating a condition or disorder mediated by at least one histone deacetylase in a subject, and therefore useful for treating a neurodegenerative pathology, particularly Huntington's disease. ating a condition or disorder mediated by at least one histone deacetylase in a subject, and therefore useful for treating a neurodegenerative pathology, particularly Huntington's disease.
Description
HISTONE DEACETYLASE INHIBITORS AND
COMPOSITIONS AND METHODS OF USE THEREOF
This application claims the benefit of priority of U.S. Application No.
61/435,678, filed January 24, 2011, which is incorporated herein by reference for
all purposes.
Provided herein are certain histone deacetylase (HDAC) inhibitors,
compositions thereof, and methods of their use.
Histone deacetylases (HDACs) are zinc-containing enzymes which
catalyse the removal of acetyl groups from the s-arnino termini of lysine residues
clustered near the amino terminus of nucleosomal histones. There are 11 known
metal-dependent human histone deacetylases, grouped into four classes based
on the structure of their accessory domains. Class I includes HDAC1, HDAC2,
HDAC3, and HDAC8 and have homology to yeast RPD3. HDAC4, HDAC5,
HDAC7, and HDAC9 belong to Class Ila and have homology to yeast HDAC1.
HDAC6 and HDAC10 contain two catalytic sites and are classified as Class llb,
whereas HDAC11 has conserved residues in its catalytic center that are shared
by both Class I and Class II deacetylases and is sometimes placed in Class IV.
Provided is a compound of Formula I
Formula I
or a pharmaceutically acceptable salt thereof wherein
R1 and R2 are independently chosen from optionally substituted alkyl,
optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl, and optionally
substituted heteroaryl;
R3 is chosen from -COOH, -C(O)NH(OH) and -N(OH)C(O)R4;
R3a is chosen from hydrogen and lower alkyl optionally substituted with
halo; and
R4 is chosen from hydrogen and lower alkyl;
wherein if R1 and R2 are both phenyl and R3a is hydrogen, then R3 is
-N(OH)C(O)H or -C(O)NH(OH).
Also provided is a pharmaceutical composition comprising a
compound, or a pharmaceutically acceptable salt thereof, described herein and at
least one pharmaceutically acceptable excipient.
Also provided is a method of treating a condition or disorder
mediated by at least one histone deacetylase in a subject in need of such a
treatment which method comprises administering to the subject a therapeutically
effective amount of a compound, or a pharmaceutically acceptable salt thereof,
described herein.
As used in the present specification, the following words, phrases
and symbols are generally intended to have the meanings as set forth below,
except to the extent that the context in which they are used indicates otherwise.
A dash ("-") that is not between two letters or symbols is used to
indicate a point of attachment for a substituent. For example, -CONH2 is attached
through the carbon atom.
By "optional" or "optionally" is meant that the subsequently
described event or circumstance may or may not occur, and that the description
includes instances where the event or circumstance occurs and instances in
which it does not. For example, "optionally substituted alkyl" encompasses both
"alkyl" and "substituted alkyl" as defined below. It will be understood by those
skilled in the art, with respect to any group containing one or more substituents,
that such groups are not intended to introduce any substitution or substitution
patterns that are sterically impractical, synthetically non-feasible and/or inherently
unstable.
"Alkyl" encompasses straight chain and branched chain having the
indicated number of carbon atoms, usually from 1 to 20 carbon atoms, for
example 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. For example C1-C6
alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon
atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl,
sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl,
3-methylpentyl, and the like. Alkylene is another subset of alkyl, referring to the
same residues as alkyl, but having two points of attachment. Alkylene groups will
usually have from 2 to 20 carbon atoms, for example 2 to 8 carbon atoms, such
as from 2 to 6 carbon atoms. For example, Co alkylene indicates a covalent bond
and C1 alkylene is a methylene group. When an alkyl residue having a specific
number of carbons is named, all geometric isomers having that number of
carbons are intended to be encompassed; thus, for example, "butyl" is meant to
include n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" includes n-propyl and
isopropyl. "Lower alkyl" refers to alkyl groups having 1 to 4 carbons.
"Cycloalkyl" indicates a non-aromatic, fully saturated carbocyclic
ring having the indicated number of carbon atoms, for example, 3 to 10, or 3 to 8,
or 3 to 6 ring carbon atoms. Cycloalkyl groups may be monocyclic or polycyclic
(e.g., bicyclic, tricyclic). Examples of cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclopentenyl and cyclohexyl, as well as bridged and
caged ring groups (e.g., norbornane, bicyclo[2.2.2]octane). In addition, one ring
of a polycyclic cycloalkyl group may be aromatic, provided the polycyclic
cycloalkyl group is bound to the parent structure via a non-aromatic carbon. For
example, a 1,2,3,4-tetrahydronaphthalenyl group (wherein the moiety is bound
to the parent structure via a non-aromatic carbon atom) is a cycloalkyl group,
while 1,2,3,4-tetrahydronaphthalenyl (wherein the moiety is bound to the
parent structure via an aromatic carbon atom) is not considered a cycloalkyl
group.
By "alkoxy" is meant an alkyl group of the indicated number of
carbon atoms attached through an oxygen bridge such as, for example, methoxy,
ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-
pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-
methylpentoxy, and the like. Alkoxy groups will usually have from 1 to 6 carbon
atoms attached through the oxygen bridge. "Lower alkoxy" refers to alkoxy
groups having 1 to 4 carbons.
"Aryl" indicates an aromatic carbon ring having the indicated
number of carbon atoms, for example, 6 to 12 or 6 to 10 carbon atoms. Aryl
groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some
instances, both rings of a polycyclic aryl group are aromatic (e.g., naphthyl). In
other instances, polycyclic aryl groups may include a non-aromatic ring (e.g.,
cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to an
aromatic ring, provided the polycyclic aryl group is bound to the parent structure
via an atom in the aromatic ring. Thus, a 1,2,3,4-tetrahydronaphthalenyl group
(wherein the moiety is bound to the parent structure via an aromatic carbon atom)
is considered an aryl group, while 1,2,3,4-tetrahydronaphthalenyl (wherein the
moiety is bound to the parent structure via a non-aromatic carbon atom) is not
considered an aryl group. Similarly, a 1,2,3,4-tetrahydroquinolinyl group
(wherein the moiety is bound to the parent structure via an aromatic carbon atom)
is considered an aryl group, while 1,2,3,4-tetrahydroquinolinyl group (wherein
the moiety is bound to the parent structure via a non-aromatic nitrogen atom) is
not considered an aryl group. However, the term "aryl" does not encompass or
overlap with "heteroaryl", as defined herein, regardless of the point of attachment
(e.g., both quinolinyl and quinolinyl are heteroaryl groups). In some
instances, aryl is phenyl or naphthyl. In certain instances, aryl is phenyl.
Bivalent radicals formed from substituted benzene derivatives and
having the free valences at ring atoms are named as substituted phenylene
radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals
whose names end in "-yl" by removal of one hydrogen atom from the carbon atom
with the free valence are named by adding "-idene" to the name of the
corresponding univalent radical, e.g., a naphthyl group with two points of
attachment is termed naphthylidene.
The term "halo" includes fluoro, chloro, bromo, and iodo, and the
term "halogen" includes fluorine, chlorine, bromine, and iodine.
"Heteroaryl" indicates an aromatic ring containing the indicated
number of atoms (e.g., 5 to 12, or 5 to 10 membered heteroaryl) made up of one
or more heteroatoms (e.g., 1, 2, 3 or 4 heteroatoms) selected from N, 0 and S
and with the remaining ring atoms being carbon. Heteroaryl groups do not
contain adjacent Sand 0 atoms. In some embodiments, the total number of S
and 0 atoms in the heteroaryl group is not more than 2. In some embodiments,
the total number of S and 0 atoms in the heteroaryl group is not more than 1.
Unless otherwise indicated, heteroaryl groups may be bound to the parent
structure by a carbon or nitrogen atom, as valency permits. For example,
"pyridyl" includes 2-pyridyl, 3-pyridyl and 4-pyridyl groups, and "pyrrolyl" includes
1-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl groups. When nitrogen is present in a
heteroaryl ring, it may, where the nature of the adjacent atoms and groups
permits, exist in an oxidized state (i.e., N+-0} Additionally, when sulfur is
present in a heteroaryl ring, it may, where the nature of the adjacent atoms and
groups permits, exist in an oxidized state (i.e., s-o or 802). Heteroaryl groups
may be monocyclic or polycyclic (e.g., bicyclic, tricyclic).
In some instances, a heteroaryl group is monocyclic. Examples
include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole,
1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-
oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole,
thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine,
pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine) and
tetrazine.
In some instances, both rings of a polycyclic heteroaryl group are
aromatic. Examples include indole, isoindole, indazole, benzoimidazole,
benzotriazole, benzofuran, benzoxazole, benzoisoxazole, benzoxadiazole,
benzothiophene, benzothiazole, benzoisothiazole, benzothiadiazole, 1 H
pyrrolo[2,3-b]pyridine, 1 H-pyrazolo[3,4-b]pyridine, 3H-imidazo[4,5-b]pyridine, 3H
[1,2,3]triazolo[4,5-b]pyridine, 1 H-pyrrolo[3,2-b]pyridine, 1 H-pyrazolo[4,3-
b]pyridine, 1 H-imidazo[4,5-b]pyridine, 1 H-[1,2,3]triazolo[4,5-b]pyridine, 1 H
pyrrolo[2,3-c]pyridine, 1 H-pyrazolo[3,4-c]pyridine, 3H-imidazo[4,5-c]pyridine, 3H
[1,2,3]triazolo[4,5-c]pyridine, 1 H-pyrrolo[3,2-c]pyridine, 1 H-pyrazolo[4,3-
c]pyridine, 1 H-imidazo[4,5-c]pyridine, 1 H-[1,2,3]triazolo[4,5-c]pyridine, furo[2,3-
b]pyridine, oxazolo[5,4-b]pyridine, isoxazolo[5,4-b]pyridine, [1,2,3]oxadiazolo[5,4-
b]pyridine, furo[3,2-b]pyridine, oxazolo[4,5-b]pyridine, isoxazolo[4,5-b]pyridine,
[1,2,3]oxadiazolo[4,5-b]pyridine, furo[2,3-c]pyridine, oxazolo[5,4-c]pyridine,
isoxazolo[5,4-c]pyridine, [1,2,3]oxadiazolo[5,4-c]pyridine, furo[3,2-c]pyridine,
oxazolo[4,5-c]pyridine, isoxazolo[4,5-c]pyridine, [1,2,3]oxadiazolo[4,5-c]pyridine,
thieno[2,3-b]pyridine, thiazolo[5,4-b]pyridine, isothiazolo[5,4-b]pyridine,
[1,2,3]thiadiazolo[5,4-b]pyridine, thieno[3,2-b]pyridine, thiazolo[4,5-b]pyridine,
isothiazolo[4,5-b]pyridine, [1,2,3]thiadiazolo[4,5-b]pyridine, thieno[2,3-c]pyridine,
thiazolo[5,4-c]pyridine, isothiazolo[5,4-c]pyridine, [1,2,3]thiadiazolo[5,4-c]pyridine,
thieno[3,2-c]pyridine, thiazolo[4,5-c]pyridine, isothiazolo[4,5-c]pyridine,
[1,2,3]thiadiazolo[4,5-c]pyridine, quinoline, isoquinoline, cinnoline, quinazoline,
quinoxaline, phthalazine, naphthyridine (e.g., 1,8-naphthyridine, 1,7-
naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, 2,7-naphthyridine, 2,6-
naphthyridine), imidazo[1,2-a]pyridine, 1 H-pyrazolo[3,4-d]thiazole, 1 H
pyrazolo[4,3-d]thiazole and imidazo[2, 1-b]thiazole.
In other instances, polycyclic heteroaryl groups may include a non
aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl)
fused to a heteroaryl ring, provided the polycyclic heteroaryl group is bound to the
parent structure via an atom in the aromatic ring. For example, a 4,5,6,7-
tetrahydrobenzo[d]thiazolyl group (wherein the moiety is bound to the parent
structure via an aromatic carbon atom) is considered a heteroaryl group, while
4,5,6,7-tetrahydrobenzo[d]thiazolyl (wherein the moiety is bound to the parent
structure via a non-aromatic carbon atom) is not considered a heteroaryl group.
"Heterocycloalkyl" indicates a non-aromatic, fully saturated ring
having the indicated number of atoms (e.g., 3 to 10, or 3 to 7, membered
heterocycloalkyl) made up of one or more heteroatoms (e.g., 1, 2, 3 or 4
heteroatoms) selected from N, 0 and Sand with the remaining ring atoms being
carbon. Heterocycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic,
tricyclic).
Examples of monocyclic heterocycloalkyl groups include oxiranyl,
aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl,
piperazinyl, morpholinyl and thiomorpholinyl.
When nitrogen is present in a heterocycloalkyl ring, it may, where
the nature of the adjacent atoms and groups permits, exist in an oxidized state
(i.e., N+-0} Examples include piperidinyl N-oxide and morpholinyl-N-oxide.
Additionally, when sulfur is present in a heterocycloalkyl ring, it may, where the
nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e.,
s-o or -S02-). Examples include thiomorpholine S-oxide and thiomorpholine
S,S-dioxide.
In addition, one ring of a polycyclic heterocycloalkyl group may be
aromatic (e.g., aryl or heteroaryl), provided the polycyclic heterocycloalkyl group
is bound to the parent structure via a non-aromatic carbon or nitrogen atom. For
example, a 1,2,3,4-tetrahydroquinolinyl group (wherein the moiety is bound to
the parent structure via a non-aromatic nitrogen atom) is considered a
heterocycloalkyl group, while 1,2,3,4-tetrahydroquinolinyl group (wherein the
moiety is bound to the parent structure via an aromatic carbon atom) is not
considered a heterocycloalkyl group.
"Heterocycloalkenyl" indicates a non-aromatic ring having the
indicated number of atoms (e.g., 3 to 10, or 3 to 7, membered heterocycloalkyl)
made up of one or more heteroatoms (e.g., 1, 2, 3 or 4 heteroatoms) selected
from N, 0 and Sand with the remaining ring atoms being carbon, and at least
one double bond derived by the removal of one molecule of hydrogen from
adjacent carbon atoms, adjacent nitrogen atoms, or adjacent carbon and nitrogen
atoms of the corresponding heterocycloalkyl. Heterocycloalkenyl groups may be
monocyclic or polycyclic (e.g., bicyclic, tricyclic). When nitrogen is present in a
heterocycloalkenyl ring, it may, where the nature of the adjacent atoms and
groups permits, exist in an oxidized state (i.e., N+-0} Additionally, when sulfur
is present in a heterocycloalkenyl ring, it may, where the nature of the adjacent
atoms and groups permits, exist in an oxidized state (i.e., s-o or-S02-).
Examples of heterocycloalkenyl groups include dihydrofuranyl (e.g., 2,3-
dihydrofuranyl, 2,5-dihydrofuranyl), dihydrothiophenyl (e.g., 2,3-
dihydrothiophenyl, 2,5-dihydrothiophenyl), dihydropyrrolyl (e.g., 2,3-dihydro-1 H
pyrrolyl, 2,5-dihydro-1 H-pyrrolyl), dihydroimidazolyl (e.g., 2,3-dihydro-1 H
imidazolyl, 4,5-dihydro-1 H-imidazolyl), pyranyl, dihydropyranyl (e.g., 3,4-dihydro-
2H-pyranyl, 3,6-dihydro-2H-pyranyl), tetrahydropyridinyl (e.g., 1,2,3,4-
tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl) and dihydropyridine (e.g., 1,2-
dihydropyridine, 1,4-dihydropyridine). In addition, one ring of a polycyclic
heterocycloalkenyl group may be aromatic (e.g., aryl or heteroaryl), provided the
polycyclic heterocycloalkenyl group is bound to the parent structure via a non
aromatic carbon or nitrogen atom. For example, a 1,2-dihydroquinolinyl group
(wherein the moiety is bound to the parent structure via a non-aromatic nitrogen
atom) is considered a heterocycloalkenyl group, while 1,2-dihydroquinolinyl
group (wherein the moiety is bound to the parent structure via an aromatic carbon
atom) is not considered a heterocycloalkenyl group.
The term "substituted", as used herein, means that any one or more
hydrogens on the designated atom or group is replaced with a selection from the
indicated group, provided that the designated atom's normal valence is not
exceeded. When a substituent is oxo (i.e., =O) then 2 hydrogens on the atom are
replaced. Combinations of substituents and/or variables are permissible only if
such combinations result in stable compounds or useful synthetic intermediates.
A stable compound or stable structure is meant to imply a compound that is
sufficiently robust to survive isolation from a reaction mixture, and subsequent
formulation as an agent having at least practical utility. Unless otherwise
specified, substituents are named into the core structure. For example, it is to be
understood that when (cycloalkyl)alkyl is listed as a possible substituent, the point
of attachment of this substituent to the core structure is in the alkyl portion.
The terms "substituted" alkyl (including without limitation lower
alkyl), cycloalkyl, aryl, heterocycloalkyl, and heteroaryl, unless otherwise
expressly defined, refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl,
and heteroaryl wherein one or more (such as up to 5, for example, up to 3)
hydrogen atoms are replaced by a substituent independently chosen from
-Ra, -ORb, -O(C1-C2 alkyl)O- (e.g., methylenedioxy-), -SRb, guanidine,
guanidine wherein one or more of the guanidine hydrogens are replaced with a
lower-alkyl group, -NRbRc, halo, cyano, oxo (as a substituent for
heterocycloalkyl), nitro, -CORb, -C02Rb, -CONRbRc, -OCORb, -OC02Ra,
-OCONRbRc, -NRcCORb, -NRcC02Ra, -NRcCONRbRc, -SORa, -S02Ra,
-S02NRbRc, and -NRcS02Ra,
where Ra is chosen from optionally substituted C1-C6 alkyl, optionally
substituted cycloalkyl, optionally substituted aryl, optionally substituted
heterocycloalkyl, and optionally substituted heteroaryl;
Rb is chosen from H, optionally substituted C1-C6 alkyl, optionally
substituted aryl, and optionally substituted heteroaryl; and
Re is chosen from hydrogen and optionally substituted C1-C4 alkyl; or
Rb and Re, and the nitrogen to which they are attached, form an optionally
substituted heterocycloalkyl group; and
where each optionally substituted group is unsubstituted or independently
substituted with one or more, such as one, two, or three, substituents
independently selected from C1-C4 alkyl, C3-C5 cycloalkyl, aryl, heteroaryl,
aryl-C1-C4 alkyl-, heteroaryl-Cr-C, alkyl-, C1-C4 haloalkyl-, -OC1-C4 alkyl,
-OC1-C4 alkylphenyl, -C1-C4 alkyl-OH, -C1-C4 alkyl-O-C1-C4 alkyl,
-OC1-C4 haloalkyl, halo, -OH, -NH2, -C1-C4 alkyl-NH2, -N(C1-C4 alkyl)(C1-C4 alkyl),
-NH(C1-C4 alkyl), -N(C1-C4 alkyl)(C1-C4 alkylphenyl), -NH(C1-C4 alkylphenyl),
cyano, nitro, oxo (as a substitutent for heteroaryl), -C02H, -C(O)OC1-C4 alkyl,
-CON(C1-C4 alkyl)(C1-C4 alkyl), -CONH(C1-C4 alkyl), -CONH2,
-NHC(O)(C1-C4 alkyl), -NHC(O)(phenyl), -N(C1-C4 alkyl)C(O)(C1-C4 alkyl),
-N(C1-C4 alkyl)C(O)(phenyl), -C(O)C1-C4 alkyl, -C(O)C1-C4 phenyl,
-C(O)C1-C4 haloalkyl, -OC(O)C1-C4 alkyl, -S02(C1-C4 alkyl), -S02(phenyl), -
S02(C1-C4 haloalkyl), -S02NH2, -S02NH(C1-C4 alkyl), -S02NH(phenyl), -
NHS02(C1-C4 alkyl), -NHS02(phenyl), and -NHS02(C1-C4 haloalkyl).
The term "substituted alkoxy" refers to alkoxy wherein the alkyl
constituent is substituted (i.e., (substituted alkyl)) wherein "substituted alkyl" is
as described herein.
The term "substituted amino" refers to the group -NH Rd or -NRdRd
where each Rd is independently chosen from hydroxy, optionally substituted alkyl,
optionally substituted cycloalkyl, optionally substituted acyl, aminocarbonyl,
optionally substituted aryl, optionally substituted heteroaryl, optionally substituted
heterocycloalkyl, optionally substituted alkoxycarbonyl, sulfinyl and sulfonyl, each
as described herein, and provided that only one Rd may be hydroxyl. The term
"substituted amino" also refers to N-oxides of the groups -NH Rd, and NRdRd each
as described above. N-oxides can be prepared by treatment of the
corresponding amino group with, for example, hydrogen peroxide or m
chloroperoxybenzoic acid. The person skilled in the art is familiar with reaction
conditions for carrying out the N-oxidation.
"Aminocarbonyl" encompasses a group of the formula -
(C=O)(optionally substituted amino) wherein substituted amino is as described
herein.
"Acyl" refers to the groups (alkyl)-C(O)-; (cycloalkyl)-C(O)-; (aryl)-
C(O)-; (heteroaryl)-C(O)-; and (heterocycloalkyl)-C(O)-, wherein the group is
attached to the parent structure through the carbonyl functionality and wherein
alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are as described herein.
Acyl groups have the indicated number of carbon atoms, with the carbon of the
keto group being included in the numbered carbon atoms. For example a C2 acyl
group is an acetyl group having the formula CH3(C=O)-.
By "alkoxycarbonyl" is meant an ester group of the formula
(alkoxy)(C=O)- attached through the carbonyl carbon wherein the alkoxy group
has the indicated number of carbon atoms. Thus a C1-C5alkoxycarbonyl group is
an alkoxy group having from 1 to 6 carbon atoms attached through its oxygen to
a carbonyl linker.
By "amino" is meant the group -NH2.
The term "sulfinyl" includes the groups -S(O)-H, -S(O)-(optionally
substituted (C1-C5)alkyl), -S(O)-optionally substituted aryl), -S(O)-optionally
substituted heteroaryl), -S(O)-(optionally substituted heterocycloalkyl); and -S(O)
(optionally substituted amino).
The term "sulfonyl" includes the groups -S(02)-H, -S(02)-(optionally
substituted (C1-C5)alkyl), -S(02)-optionally substituted aryl), -S(02)-optionally
substituted heteroaryl), -8(02)-(optionally substituted heterocycloalkyl),
-8(02)-(optionally substituted alkoxy), -8(02)-optionally substituted aryloxy),
-S(02)-optionally substituted heteroaryloxy), -S(02)-(optionally substituted
heterocyclyloxy); and -S(02)-(optionally substituted amino).
The term "substituted acyl" refers to the groups (substituted alkyl)-
C(O)-; (substituted cycloalkyl)-C(O)-; (substituted aryl)-C(O)-; (substituted
heteroaryl)-C(O)-; and (substituted heterocycloalkyl)-C(O)-, wherein the group is
attached to the parent structure through the carbonyl functionality and wherein
substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are as
described herein.
The term "substituted alkoxy" refers to alkoxy wherein the alkyl
constituent is substituted (i.e., (substituted alkyl)) wherein "substituted alkyl" is
as described herein.
The term "substituted alkoxycarbonyl" refers to the group
(substituted alkyl)C(O)- wherein the group is attached to the parent structure
through the carbonyl functionality and wherein substituted alkyl is as described
herein.
Compounds described herein include, but are not limited to, their
optical isomers, racemates, and other mixtures thereof. In those situations, the
single enantiomers or diastereomers, i.e., optically active forms, can be obtained
by asymmetric synthesis or by resolution of the racemates. Resolution of the
racemates can be accomplished, for example, by conventional methods such as
crystallization in the presence of a resolving agent, or chromatography, using, for
example a chiral high-pressure liquid chromatography (HPLC) column. In
addition, such compounds include Z- and E- forms (or cis- and trans- forms) of
compounds with carbon-carbon double bonds. Where compounds described
herein exist in various tautomeric forms, the term "compound" is intended to
include all tautomeric forms of the compound. Such compounds also include
crystal forms including polymorphs and clathrates. Similarly, the term "salt" is
intended to include all tautomeric forms and crystal forms of the compound.
"Pharmaceutically acceptable salts" include, but are not limited to
salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate,
hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an
organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate,
acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate,
benzoate, salicylate, stearate, and alkanoate such as acetate, HOOC-(CH2)n
COOH where n is 0-4, and like salts. Similarly, pharmaceutically acceptable
cations include, but are not limited to sodium, potassium, calcium, aluminum,
lithium, and ammonium.
In addition, if the compounds described herein are obtained as an
acid addition salt, the free base can be obtained by basifying a solution of the
acid salt. Conversely, if the product is a free base, an addition salt, particularly a
pharmaceutically acceptable addition salt, may be produced by dissolving the
free base in a suitable organic solvent and treating the solution with an acid, in
accordance with conventional procedures for preparing acid addition salts from
base compounds. Those skilled in the art will recognize various synthetic
methodologies that may be used to prepare non-toxic pharmaceutically
acceptable addition salts.
"Prodrugs" described herein include any compound that becomes a
compound of Formula I when administered to a patient, e.g., upon metabolic
processing of the prodrug. Examples of prodrugs include derivatives of functional
groups, such as a carboxylic acid group, in the compounds of Formula I.
Exemplary prodrugs of a carboxylic acid group include, but are not limited to,
carboxylic acid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters,
and aryloxyalkyl esters. Other exemplary prodrugs include lower alkyl esters
such as ethyl ester, acyloxyalkyl esters such as pivaloyloxymethyl (POM),
glycosides, and ascorbic acid derivatives. The term "compound" is intended to
include prodrugs.
Other exemplary prodrugs include amides of carboxylic acids.
Exemplary amide prodrugs include metabolically labile amides that are formed,
for example, with an amine and a carboxylic acid. Exemplary amines include
NH2, primary, and secondary amines such as NHRx, and NRxRy, wherein Rx is
hydrogen, (C1-C18)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl-, (C5-
C14)-aryl which is unsubstituted or substituted by a residue (C1-C2)-alkyl, (C1-C2)
alkoxy, fluoro, or chloro; heteroaryl-, (C5-C14)-aryl-(C1-C4)-alkyl- where aryl is
unsubstituted or substituted by a residue (C1-C2)-alkyl, (C1-C2)-alkoxy, fluoro, or
chloro; or heteroaryl-(C1-C4)-alkyl- and in which RY has the meanings indicated for
Rx with the exception of hydrogen or wherein Rx and RY, together with the
nitrogen to which they are bound, form an optionally substituted 4- to?
membered heterocycloalkyl ring which optionally includes one or two additional
heteroatoms chosen from nitrogen, oxygen, and sulfur. A discussion of prodrugs
is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems,
Vol. 14 of the A.C.S. Symposium Series, in Edward B. Roche, ed.,
Bioreversible Carriers in Drug Design, American Pharmaceutical Association and
Pergamon Press, 1987, and in Design of Prodrugs, ed. H. Bundgaard, Elsevier,
1985.
A "solvate" is formed by the interaction of a solvent and a
compound. The term "compound" is intended to include solvates of compounds.
Similarly, "salts" includes solvates of salts. Suitable solvates are
pharmaceutically acceptable solvates, such as hydrates, including monohydrates
and hemi-hydrates.
A "chelate" is formed by the coordination of a compound to a metal
ion at two (or more) points. The term "compound" is intended to include chelates
of compounds. Similarly, "salts" includes chelates of salts.
A "non-covalent complex" is formed by the interaction of a
compound and another molecule wherein a covalent bond is not formed between
the compound and the molecule. For example, complexation can occur through
van der Waals interactions, hydrogen bonding, and electrostatic interactions (also
called ionic bonding). Such non-covalent complexes are included in the term
"compound'.
The term "hydrogen bond" refers to a form of association between
an electronegative atom (also known as a hydrogen bond acceptor) and a
hydrogen atom attached to a second, relatively electronegative atom (also known
as a hydrogen bond donor). Suitable hydrogen bond donor and acceptors are
well understood in medicinal chemistry.
"Hydrogen bond acceptor" refers to a group comprising an oxygen
or nitrogen, such as an oxygen or nitrogen that is sp2 -hybridized, an ether
oxygen, or the oxygen of a sulfoxide or N-oxide.
The term "hydrogen bond donor" refers to an oxygen, nitrogen, or
heteroaromatic carbon that bears a hydrogen.group containing a ring nitrogen or
a heteroaryl group containing a ring nitrogen.
As used herein the terms "group", "radical" or "fragment" are
synonymous and are intended to indicate functional groups or fragments of
molecules attachable to a bond or other fragments of molecules.
The term "active agent" is used to indicate a compound or a
pharmaceutically acceptable salt thereof which has biological activity. In some
embodiments, an "active agent" is a compound or pharmaceutically acceptable
salt thereof having pharmaceutical utility. For example an active agent may be
an anti-neurodegenerative therapeutic.
The term "therapeutically effective amount" means an amount
effective, when administered to a human or non-human patient, to provide a
therapeutic benefit such as amelioration of symptoms, slowing of disease
progression, or prevention of disease e.g., a therapeutically effective amount may
be an amount sufficient to decrease the symptoms of a disease responsive to
inhibition of HOAG activity.
As used herein, the terms "histone deacetylase" and "HOAG" are
intended to refer to anyone of a family of enzymes that remove N°-acetyl groups
from the s-arnino groups of lysine residues of a protein (for example, a histone, or
tubulin). Unless otherwise indicated by context, the term "histone" is meant to
refer to any histone protein, including H1, H2A, H2B, H3, H4, and H5, from any
species. In some embodiments, the histone deacetylase is a human HOAG,
including, but not limited to, HOAG-4, HOAG-5, HOAG-6, HOAG-7, HOAG-9, and
HOAG-10. In some embodiments, the at least one histone deacetylase is
selected from HOAG-4, HOAG-5, HOAG-7, and HOAG-9. In some embodiments,
the histone deacetylase is a class Ila HOAG. In some embodiments, the histone
deacetylase is HOAG-4. In some embodiments, the histone deacetylase is
HOAG-5. In some embodiments, the histone deacetylase is derived from a
protozoa! or fungal source.
The terms "histone deacetylase inhibitor" and "inhibitor of histone
deacetylase" are intended to mean a compound, or a pharmaceutically
acceptable salt thereof, described herein which is capable of interacting with a
histone deacetylase and inhibiting its enzymatic activity.
The term "a condition or disorder mediated by HOAG" or "a
condition or disorder mediated by histone deacetylase" as used herein refers to a
condition or disorder in which HOAG and/or the action of HOAG is important or
necessary, e.g., for the onset, progress, expression, etc. of that condition, or a
condition which is known to be treated by HOAG inhibitors (such as, e.g.,
trichostatin A).
The term "effect" describes a change or an absence of a change in
cell phenotype or cell proliferation. "Effect" can also describe a change or an
absence of a change in the catalytic activity of HOAG. "Effect" can also describe a
change or an absence of a change in an interaction between HOAG and a natural
binding partner.
The term "inhibiting histone deacetylase enzymatic activity" is
intended to mean reducing the ability of a histone deacetylase to remove an
acetyl group from a protein, such as but not limited to a histone or tubulin. The
concentration of inhibitor which reduces the activity of a histone deacetylase to
50% of that of the uninhibited enzyme is determined as the IGso value. In some
embodiments, such reduction of histone deacetylase activity is at least 50%, such
as at least about 75%, for example, at least about 90%. In some embodiments,
histone deacetylase activity is reduced by at least 95%, such as by at least 99%.
In some embodiments, the compounds and pharmaceutical acceptable salts
thereof described herein have an IG50 value less than 100 nanomolar. In some
embodiments, the compounds and pharmaceutical acceptable salts thereof
described herein have an ICso value from 100 nanomolar to 1 micromolar. In
some embodiments, the compounds and pharmaceutical acceptable salts thereof
described herein have an IC50 value from 1 to 25 micromolar.
In some embodiments, such inhibition is specific, i.e., the histone
deacetylase inhibitor reduces the ability of a histone deacetylase to remove an
acetyl group from a protein at a concentration that is lower than the concentration
of the inhibitor that is required to produce another, unrelated biological effect. In
some embodiments, the concentration of the inhibitor required for histone
deacetylase inhibitory activity is at least 2-fold lower, such as at least 5-fold lower,
for example, at least 10-fold lower, such as at least 20-fold lower than the
concentration required to produce an unrelated biological effect.
"Treatment" or "treating" means any treatment of a disease state in
a patient, including
a) preventing the disease, that is, causing the clinical symptoms of the
disease not to develop;
b) inhibiting the disease;
c) slowing or arresting the development of clinical symptoms; and/or
d) relieving the disease, that is, causing the regression of clinical
symptoms.
"Subject" or "patient' refers to an animal, such as a mammal, that
has been or will be the object of treatment, observation or experiment. The
methods described herein may be useful in both human therapy and veterinary
applications. In some embodiments, the subject is a mammal; and in some
embodiments the subject is human.
Provided is a compound of Formula I
Formula I
or a pharmaceutically acceptable salt thereof wherein
R1 and R2 are independently chosen from optionally substituted alkyl,
optionally substituted cycloalkyl, optionally substituted
heterocycloalkyl, optionally substituted aryl, and optionally
substituted heteroaryl;
R3 is chosen from -COOH, -C(O)NH(OH) and -N(OH)C(O)R4;
R3a is chosen from hydrogen and lower alkyl optionally substituted with
halo; and
R4 is chosen from hydrogen and lower alkyl;
wherein if R1 and R2 are both phenyl and R3a is hydrogen, then R3 is
-N(OH)C(O)H or -C(O)NH(OH).
In some embodiments, R1 is chosen from alkyl, cycloalkyl, aryl,
heterocycloalkyl, and heteroaryl, each of which is optionally substituted with one,
two, or three groups independently chosen from -R11, -OR12, halo, -NR12R13, -
C(O)R12, -C(O)OR12, -C(O)NR12R13, -OC(O)R12, -OC(O)OR11, -OC(O)NR12R13,
-NR13C(O)R12, -NR13C(O)OR11, -NR13C(O)NR12R13, -S(O)R11, -S02R11,
-S02NR12R13, and -NR13S02R11, wherein
R11 is chosen from optionally substituted C1-C5 alkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkenyl,
optionally substituted aryl, optionally substituted
heterocycloalkyl, optionally substituted heterocycloalkenyl,
and optionally substituted heteroaryl;
R12 is chosen from H, optionally substituted C1-C5 alkyl, optionally
substituted cycloalkyl, optionally substituted aryl, optionally
substituted arylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heteroaryl, and optionally substituted
heteroarylalkyl; and
R13 is chosen from hydrogen and optionally substituted C1-C4 alkyl.
In some embodiments, R1 is phenyl optionally substituted with one,
two, or three groups independently chosen from -R11, -OR12, halo, -C(O)R12,
-NR12R13, and -NR13S02R11.
In some embodiments, R1 is phenyl optionally substituted with one,
two or three groups independently selected from
halo,
lower alkyl,
aryl optionally substituted with one or two groups independently
chosen from lower alkyl, trifluoromethyl,cycloalkyl, phenyl,
and benzyloxy,
heteroaryl optionally substituted with one or two groups
independently chosen from lower alkyl, trifluoromethyl,
cycloalkyl, and phenyl,
(cycloalkyl)sulfonamido, and
heterocycloalkyl optionally substituted with one or two groups
independently chosen from halo, lower alkyl, trifluoromethyl,
cycloalkyl, heterocycloalkyl, and phenyl.
In some embodiments, R1 is phenyl optionally substituted with one,
two or three groups independently selected from halo, lower alkyl, oxazolyl,
oxazolyl, pyrimidinyl, pyrimidinyl, pyridazinyl, pyridazinyl, 1 H
pyrazolyl, (cycloalkyl)sulfonamido, 1 H-imidazolyl, imidazolyl, 1,2,3,6-
tetrahydropyrid inyl, azetid inyl, pyrrol id inyl, 2-oxaazaspiro[3.3]heptan-
6-yl, phenyl, hexahydropyrrolo[1,2-a]pyrazin-2(1 H)-yl, piperidinyl, piperazin
yl, and 6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl, each of which is optionally
substituted with one or two groups independently chosen from halo, lower alkyl,
trifluoromethyl, phenyl, cycloalkyl, benzyl, benzyloxy, and pyrrolidinyl.
In some embodiments, R1 is chosen from phenyl, 2-methylphenyl,
3-methylphenyl, 4-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,
2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-(1-benzyl-1,2,3,6-
tetrahydropyrid inyl )phenyl, 4-(pyrim id inyl )phenyl, 4-(pyrim id inyl )phenyl, 4-
(5-methylpyrim idinyl )phenyl ,3-(5-fluoropyrim id inyl )phenyl, 4-(5-
chloropyrimidinyl)phenyl, 4-(5-fluoropyrimidinyl)phenyl, 4-(4-
(trifl uoromethyl )pyrim id inyl )phenyl, 4-( 5-trifluoromethyl pyrim id inyl )phenyl, 4-
( 5-cyclopropyl pyrim id inyl )phenyl, 4-(pyridazinyl )phenyl, 4-(pyridazin
yl )phenyl, 4-(1 H-imidazolyl)phenyl, 4-(1-methyl-1 H-imidazolyl)phenyl, 4-(5-
methyl-1 H-im idazolyl )phenyl), 4-( 1 H-pyrazolyl )phenyl, 4-(3-methyl-1 H
pyrazolyl )phenyl, 4-(3-(trifluoromethyl)-1 H-pyrazolyl)phenyl, 3-(oxazol
yl )phenyl, 4-( oxazolyl )phenyl, 4-(oxazolyl )phenyl, 4-(2-methyloxazol
yl )phenyl ,4-(2-cyclopropyloxazolyl )phenyl, 4-(2-phenyloxazolyl )phenyl, 4-
(cyclopropanesulfonamido)phenyl, 4-(3,3-dimethylazetidinyl)phenyl, 4-(3,3-
d ifluoropyrrol id inyl )phenyl, 4-(2-oxaazaspiro[3.3]heptanyl )phenyl, 3'
(benzyloxy)biphenylyl, 3-(hexahydropyrrolo[1,2-a]pyrazin-2(1 H)-yl)phenyl, 3-
(4-(pyrrolidinyl)piperidinyl)phenyl, 4-(4-methylpiperazinyl)phenyl, 4-(4-
isopropylpiperazinyl )phenyl, and 3-(6, 7-d ihydropyrazolo[1 ,5-a]pyrim id in-4(5H )
yl )phenyl.
In some embodiments, R1 is chosen from 4-(1-benzyl-1,2,3,6-
tetrahyd ropyrid inyl )phenyl, 4-(pyrim id inyl )phenyl, 4-( 5-methyl pyrim id in
yl )phenyl, 4-(5-chloropyrimidinyl)phenyl, 4-(5-fluoropyrimidinyl)phenyl, 4-(4-
(trifluoromethyl)pyrimidinyl)phenyl, 4-(5-cyclopropylpyrimidinyl)phenyl, 4-
(pyridazinyl )phenyl, 4-(pyridazinyl )phenyl, 4-(5-methyl-1 H-im idazol
yl )phenyl), 4-(5-(trifluoromethyl )-1 H-im idazolyl )phenyl, 3-chloro(5-methyl-
1 H-imidazolyl)phenyl, 3-fluoro(5-methyl-1 H-imidazolyl)phenyl, 4-(1 H
pyrazolyl)phenyl, 3-(oxazolyl)phenyl, 4-(oxazolyl)phenyl, 4-(oxazol
yl )phenyl, 4-(2-cyclopropyloxazolyl )phenyl, 4-( 4-isopropylpiperazinyl )phenyl,
and 3-(6, 7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)phenyl.
In some embodiments, R1 is chosen from 1,2,3,4-
tetrahydroquinolinyl, 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepinyl, 1,2,3,4-
tetrahydropyrrolo[1 ,2-a]pyrazinyl, im idazo[1 ,2-a]pyrid inyl, im idazo[1 ,2-
a]pyrid inyl, pyrrolo[1,2-a]pyrimidinyl, 1,5-naphthyridinyl, 2,3-
dihydrobenzo[b][1,4]dioxinyl, benzo[d][1,3]dioxolyl, and 1-oxo-isoindolin
yl, each of which is optionally substituted with one or two groups independently
chosen from halo and lower alkyl optionally substituted with one, two, or three
halo groups.
In some embodiments, R1 is heteroaryl optionally substituted with
one, two, or three groups independently chosen from -R11, -OR12, halo, and
-NR13S02R11.
In some embodiments, R1 is chosen from pyridinyl, pyridinyl,
1 H-pyrazolyl, pyrimidinyl, pyridazinyl, benzo[d]isoxazolyl,
benzo[d]oxazolyl, and thiazolyl, each of which is optionally substituted with
one, two, or three groups independently chosen from -R11, -OR12, halo, and
-NR13S02R11.
In some embodiments, R1 is chosen from pyridinyl, pyridinyl,
1 H-pyrazolyl, pyrimidinyl, pyridazinyl, benzo[d]isoxazolyl,
benzo[d]oxazolyl, and thiazolyl, each of which is optionally substituted with
one or two groups independently chosen from halo, lower alkyl, 2,2,2-
trifluoroethylamino, trifluoromethyl, 2,2,2-trifluoroethyl, cycloalkyl,
cyclopropylmethyl, 1 H-pyrazolyl optionally substituted with lower alkyl,
pyrimidinyl optionally substituted with lower alkyl or halo, oxazolyl optionally
substituted with lower alkyl, piperazinyl optionally substituted with lower alkyl,
piperidinyl optionally substituted with 2,2,2-trifluoroethyl, and pyridinyl
optionally substituted with lower alkyl or trifluoromethyl.
In some embodiments, R1 is chosen from 2-cyclopropylpyridinyl,
6-(trifluoromethyl )pyrid inyl, 2-(trifluoromethyl )pyrid inyl, 5-
(trifluoromethyl )pyrid inyl, 2-(2,2,2-trifluoroethylamino)pyridinyl, 6-(2,2,2-
trifluoroethylamino )pyridinyl, 6-(3-methyl-1 H-pyrazolyl)pyridinyl, 6-(5-
methylpyrim id inyl )pyrid inyl, 6-(2-methyloxazolyl )pyrid inyl, 6-(5-
chloropyrimid inyl )pyrid inyl, 6-(4-isopropylpiperazinyl)pyridinyl, 2,6-
dicyclopropylpyridinyl, 6-(5-fluoropyrimidinyl)pyridinyl, 2-(5-
chloropyrimidinyl)cyclopropylpyridinyl, 1-methyl-1 H-pyrazolyl, 1-(2,2,2-
trifluoroethyl)-1 H-pyrazolyl, 1-(cyclopropylmethyl)-1 H-pyrazolyl, 1-
cyclopropyl-1 H-pyrazolyl, 1,3-dimethyl-1 H-pyrazolyl, 1-(1-(2,2,2-
trifluoroethyl)piperidinyl)-1 H-pyrazolyl, 1-(5-(trifluoromethyl)pyridinyl)-1 H
pyrazolyl, 1-(5-(trifluoromethyl)pyridinyl)-1 H-pyrazolyl, pyrimidinyl, 2-
cyclopropylpyrimidyl, 3-cyclopropylpyrimidyl, pyridazinyl, 6-
cyclopropylpyridazinyl, benzo[d] isoxazolyl, 2-isopropylbenzo[ d]oxazolyl,
and 2-methylth iazolyl.
In some embodiments, R2 is chosen from cycloalkyl,
heterocycloalkyl, alkyl, aryl and heteroaryl, each of which is optionally substituted
with one, two, or three groups independently chosen from -R21, -OR22, halo, and
-NR23S02R21, wherein
R21 is chosen from optionally substituted C1-C5 alkyl, optionally
substituted cycloalkyl, optionally substituted aryl, optionally
substituted heterocycloalkyl, and optionally substituted
heteroaryl;
R22 is chosen from H, optionally substituted C1-C5 alkyl, optionally
substituted cycloalkyl, optionally substituted aryl, optionally
substituted arylalkyl, optionally substituted heterocycloalkyl,
optionally substituted heteroaryl, and optionally substituted
heteroarylalkyl; and
R23 is chosen from hydrogen and optionally substituted C1-C4 alkyl.
In some embodiments, R2 is chosen from cyclohexyl, thiophenyl,
thiazolyl, and phenyl, each of which is optionally substituted with one, two, or
three groups independently chosen from -R21, -OR22, and halo.
In some embodiments, R2 is thiophenyl or phenyl, each of which
is optionally substituted with one, two, or three groups independently chosen from
lower alkyl, lower alkoxy, trifluoromethyl, and halo.
In some embodiments, R2 is chosen from phenyl, 2-chlorophenyl, 2-
fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 3-fluorophenyl, 3-
methylphenyl, 3-trifluoromethylphenyl, 4-fluorophenyl, 5-methylthiophenyl, 3-
fluoromethylth iophenyl, 5-methyl(trifluoromethyl )th iophenyl, and 5-
(trifluoromethyl )th iophenyl.
In some embodiments, R2 is chosen from phenyl, 2-fluorophenyl, 3-
fluorophenyl, and 4-fluorophenyl.
In some embodiments, R2 is phenyl.
In some embodiments, R3 is chosen from-C(O)NH(OH) and
-N(OH)C(O)R4.
In some embodiments, R3 is -C(O)NH(OH).
In some embodiments, R3 is -N(OH)C(O)R4 wherein R4 is
hydrogen.
In some embodiments, R3 is -N(OH)C(O)R4 wherein R4 is methyl.
In some embodiments, R3a is -CF3. In some embodiments, R3a is
hydrogen or methyl.
Also provided is a compound of Formula II or a pharmaceutically
acceptable salt thereof,
Formula II
wherein R1, R2, R3, and R3a are as described for compounds of Formula I.
Also provided is a compound of Formula Ill or a pharmaceutically
acceptable salt thereof,
Formula Ill
wherein R1, R2, R3, and R3a are as described for compounds of Formula I.
Also provided is a compound of Formula IV or a pharmaceutically
acceptable salt thereof,
Formula IV
wherein R1, R2, and R3 are as described for compounds of Formula I.
Also provided is a compound of Formula Vora pharmaceutically
acceptable salt thereof,
Formula V
wherein R1, R2, and R3 are as described for compounds of Formula l.F
Also provided is a compound chosen from
trans-N-Hydroxy-2,3-diphenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)Cyclohexyl-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N-Hydroxy(2-isopropoxyphenyl )
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)(2-Fluorophenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 S* ,2R* ,3R*)(2-Fluorophenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)(2-Bromophenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)(3-Bromophenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)( 4-Bromophenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N-Hyd roxyphenylo-tolylcyclopropanecarboxam ide;
(1 R*,2R*,3R*)-N-Hydroxyphenylm-tolylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)-N-Hyd roxyphenylp-tolylcyclopropanecarboxam ide;
(1R*,2R*,3R*)(4-(cyclopropanesulfonamido)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 S* ,2R* ,3R*)Cyclopentyl-N-hydroxy
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)-N-Hydroxy(1-methyl-1 H-pyrazolyl)
phenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl(pyrim id in
yl )cyclopropanecarboxam ide;
(1 R,2R,3R)(2,3-Dihydrobenzo[b][1,4]dioxinyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R,2R,3R)(8-Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 S,2R,3R)(8-Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)(2-
fluorophenyl)-N-hydroxycyclopropanecarboxamide;
( 1 R*,2R*,3R*)-N-Hyd roxyphenyl(pyridazin
yl )cyclopropanecarboxam ide;
( 1 R,2R,3R)(2-Cyclopropyl pyrid inyl )-N-hyd roxy
phenylcyclopropanecarboxam ide;
(1 S,2R,3R)(2-Cyclopropylpyridinyl)(2-fluorophenyl)-N
hydroxycyclopropanecarboxamide;
( 1 R,2R,3R)(2-Cyclopropyl pyrid inyl )( 4-fl uorophenyl )-N
hyd roxycyclopropanecarboxam ide;
(1 R,2R,3R)(2,2-Difluorobenzo[d][1,3]dioxolyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-Hydroxyphenyl(6-(trifluoromethyl)pyridin
yl)cyclopropanecarboxamide;
(1 R,2R,3R)-N-Hydroxyphenyl(2-(trifluoromethyl)pyridin
yl)cyclopropanecarboxamide;
(1 R,2R,3R)-N-Hydroxy(1-oxo(2,2,2-trifluoroethyl)isoindolinyl)
phenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-hydroxy(2-isopropylbenzo[d]oxazolyl)
phenylcyclopropanecarboxamide;
( 1 R,2R,3R)-N-Hydroxy(3-(oxazolyl )phenyl )
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)-N-Hydroxy(4-(oxazolyl)phenyl)
phenylcyclopropanecarboxamide;
(1 R*,2R*,3R*)(4-(1 H-imidazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R,2R,3R)(4-(2-Cyclopropyloxazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(2-phenyloxazol
yl )phenyl )cyclopropanecarboxam ide;
(1 R*,2R*,3R*)(4-(5-Fluoropyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R*,2R*,3R*)(3-(5-Fluoropyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R*,2R*,3R*)(4-(5-Cyclopropylpyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)( 4-( 4-Trifluoromethylpyrim id inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)(4-(5-Trifluoromethylpyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N -Hydroxyphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyrim id in
yl )phenyl )cyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyrim id in
yl )phenyl )cyclopropanecarboxam ide;
( 1 R,2R,3R)( 4-(5-Chloropyrim id inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N-Hydroxy( 4-( 5-methylpyrim id inyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1R*,2R*,3R*)-N-Hydroxy(4-(5-methyl-1 H-imidazolyl )phenyl )
phenylcyclopropanecarboxam ide;
(1 R*,2R*,3R*)(4-(2-cyclopropylisoindolinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1R,2R,3R)(3'-(Benzyloxy)-[1,1 '-biphenyl]yl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 R* ,2R* ,3R*)( 4'-(9H-carbazolyl )-[1 , 1 '-biphenyl]yl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxy(4-( 4-methyl-3,4-d ihydro-2H-benzo[b] [1 ,4 ]oxazin-
7-yl )phenyl )phenylcyclopropanecarboxamide;
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1R*,2R*,3R*)-N-Hydroxy(3-(4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1R*,2R*,3R*)-N-Hydroxy(4-(3,3-d ifluoropyrrol id inyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R *)( 4-(3,3-Dimethylazetid inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1 R*,2R*,3R*)( 4-(2-0xaazaspiro[3 .3] heptanyl )phenyl )-N-hydroxy-
3-phenylcyclopropanecarboxam ide;
( 1 R*,2R*,3R*)(3-(Hexahydropyrrolo[1 ,2-a]pyrazin-2( 1 H )-yl )phenyl )-N
hyd roxyphenylcyclopropanecarboxam ide;
( 1R*,2R*,3R*)-N-Hydroxyphenyl(3-(4-(pyrrol id inyl)piperid in
yl )phenyl )cyclopropanecarboxam ide;
( 1R,2R,3R)(3-(6,7-Dihydropyrazolo[1 ,5-a]pyrim id in-4(5H )-yl )phenyl )-N
hyd roxyphenylcyclopropanecarboxam ide;
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4-methylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1 R*, 2R*, 3R*J-N-Hyd roxy( 4-( oxazolyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1 R* ,2R* ,3R*)-N -Hydroxy( 4-( 1-methyl-1 H-im idazolyl )phenyl )
phenylcyclopropanecarboxam ide;
( 1R*,2S*,3S*)(4-( 5-Fluoropyrim id inyl )phenyl )-N-hydroxymethyl
phenylcyclopropanecarboxam ide;
(1 R*,2R*,3R*)(4-(1 H-pyrazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-Hydroxyphenyl(5-(trifluoromethyl)pyridin
yl)cyclopropanecarboxamide;
( 1R,2R,3R)(4-( 1-Benzyl-1 ,2,3,6-tetrahydropyrid inyl )phenyl )-N
hyd roxyphenylcyclopropanecarboxam ide;
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-(2-methyloxazol
yl )phenyl )cyclopropanecarboxam ide;
( 1 S,2R,3S)(2-fluorophenyl )-N-hydroxymethyl( 4-(2-methyloxazol
yl )phenyl )cyclopropanecarboxam ide;
( 1 S,2R,3R)(2-fluorophenyl )-N-hydroxy( 4-(3-methyl-1 H-pyrazol
yl )phenyl )cyclopropanecarboxam ide;
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-(3-(trifluoromethyl)-1 H
pyrazolyl )phenyl )cyclopropanecarboxam ide;
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-(isopropyl(2-
morphol inoethyl )amino )phenyl )cyclopropanecarboxam ide;
( 1 R,2R,3R)(2-cyclopropyl pyrim id inyl )-N-hyd roxy
phenylcyclopropanecarboxam ide;
( 1 R,2R,3R)(benzo[ d] isoxazolyl )-N-hyd roxy
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)(6-cyclopropylpyridazinyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 S,2R,3R)(2-fluorophenyl )-N-hydroxy(6-(3-methyl-1 H-pyrazol
yl )pyrid inyl )cyclopropanecarboxam ide;
( 1 S,2R,3R)(6-( 5-ch loropyrim id inyl )pyrid inyl )(2-fl uorophenyl )-N
hyd roxycyclopropanecarboxam ide;
( 1 R,2R,3R)( 5-chloro( 4-isopropylpiperazinyl )pyrid inyl )-N
hyd roxyphenylcyclopropanecarboxam ide;
( 1 S,2R,3R)(2-fl uorophenyl )( 6-( 5-fl uoropyrim id inyl )pyrid inyl )-N
hyd roxycyclopropanecarboxam ide;
( 1 S,2R,3R)(2-fl uorophenyl )-N-hyd roxy( 6-( 5-methylpyrim id in
yl )pyrid inyl )cyclopropanecarboxam ide;
( 1 R,2R,3R)-N-hyd roxy( 6-(2-methyloxazolyl )pyrid inyl )
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)(5-chloro(2-methyloxazolyl)pyridinyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(2-(2,2,2-
trifl uoroethylam ino )pyrid inyl )cyclopropanecarboxam ide;
(1 R,2R,3R)-N-hydroxyphenyl(1-(2,2,2-trifluoroethyl)-1 H-pyrazol
yl)cyclopropanecarboxamide;
( 1R,2R,3R)(1-cyclopropyl-1 H-pyrazolyl )-N-hydroxy
phenylcyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxyphenyl(1-( 1-(2,2,2-trifluoroethyl )pipe rid inyl )-
1 H-pyrazolyl )cyclopropanecarboxam ide;
(1 R,2R,3R)(1,3-dimethyl-1 H-pyrazolyl)-N-hydroxy
phenylcyclopropanecarboxamide;
( 1 R,2R,3S)-N-hyd roxy(2-methylth iazolyl )
phenylcyclopropanecarboxam ide;
(1 R,2R,3R)(8-chloro-1,2,3,4-tetrahydroquinolinyl)-N-hydroxy
phenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-hydroxyphenyl(4-(2,2,2-trifluoroethyl)-2,3,4,5-
tetrahydrobenzo[f] [1,4 ]oxazepinyl )cyclopropanecarboxam ide;
(1 R,2R,3R)-N-hydroxy(1-methyl(2,2,2-trifluoroethyl)-1,2,3,4-
tetrahydropyrrolo[1,2-a]pyrazinyl)
phenylcyclopropanecarboxamide;
(1 R,2R,3R)(1-fluoro(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydropyrrolo[1,2-
a]pyrazinyl)-N-hydroxyphenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-hydroxyphenyl(2-(2,2,2-trifluoroethyl)-1,2,3,4-
tetrahydropyrrolo[1,2-a]pyrazinyl)cyclopropanecarboxamide;
( 1 R,2R,3R)-N-hydroxyphenyl(7-(2,2,2-trifluoroethyl )-5,6, 7 ,8-
tetrahydroimidazo[1 ,2-a] pyrazinyl )cyclopropanecarboxam ide;
(1 R,2R,3R)-N-hydroxyphenyl(2-(trifluoromethyl)imidazo[1,2-a]pyridin-
7-yl )cyclopropanecarboxam ide;
(1 R,2R,3R)-N-hydroxy(imidazo[1,2-a]pyridinyl)
phenylcyclopropanecarboxamide;
(1 R,2R,3R)-N-hydroxyphenyl(pyrrolo[1,2-a]pyrimidin
yl)cyclopropanecarboxamide;
( 1R,2R,3R)-N-hydroxy(1 ,5-naphthyrid inyl )
phenylcyclopropanecarboxam ide;
( 1 S ,2S ,3R )(2-cyclopropyl pyrid inyl )-N-hyd roxy(2-methylth iazol
yl )cyclopropanecarboxam ide;
( 1 S,2S ,3R)(2-cyclopropyl pyrid inyl )-N-hyd roxy( 5-
(trifl uoromethyl )th iophenyl )cyclopropanecarboxam ide;
(1 R,2R,3R)(1-((5-fluoropyridinyl)methyl)-1 H-pyrazolyl)-N-hydroxy-
3-phenylcyclopropanecarboxam ide;
( 1 S,2R,3S)(3-fluoromethylth iophenyl )-N-hydroxy( 1-methyl-1 H
pyrazolyl )cyclopropanecarboxam ide;
( 1S,2S,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )( 5-methyl
(trifl uoromethyl )th iophenyl )cyclopropanecarboxam ide;
( 1S,2S,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )( 5-methylth iophen
yl )cyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )o
tolylcyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )(2-
(trifl uoromethyl )phenyl )cyclopropanecarboxam ide;
(1 S,2R,3R)(2-chlorophenyl)-N-hydroxy(1-methyl-1 H-pyrazol
yl)cyclopropanecarboxamide;
( 1 R,2R,3R)(3-fluorophenyl )-N-hydroxy( 1-methyl-1 H-pyrazol
yl )cyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )m
tolylcyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl )(3-
(trifl uoromethyl )phenyl )cyclopropanecarboxam ide;
( 1 R,2R,3R)(3-chlorophenyl )-N-hydroxy( 1-methyl-1 H-pyrazol
yl )cyclopropanecarboxam ide;
( 1 S,2S ,3R)(2-cyclopropyl pyrid inyl )(3-fl uoromethylth iophenyl )
N-hyd roxycyclopropanecarboxam ide;
( 1 S,2S ,3R)(2-cyclopropyl pyrid inyl )-N-hyd roxy( 5-methyl
(trifl uoromethyl )th iophenyl )cyclopropanecarboxam ide;
( 1 S,2S ,3R)(2-cyclopropyl pyrid inyl )-N-hyd roxy( 5-methylth iophen
yl )cyclopropanecarboxam ide;
( 1R,2R,3R)-N-hydroxyphenyl(4-(5-(trifluoromethyl )-1 H-im idazol
yl )phenyl )cyclopropanecarboxam ide;
( 1R,2R,3R)(3-chloro(5-methyl-1 H-im idazolyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide; and
(1 R,2R,3R)(3-fluoro(5-methyl-1 H-imidazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide,
or a pharmaceutically acceptable salt thereof.
Methods for obtaining the compounds, or pharmaceutically
acceptable salts thereof, described herein will be apparent to those of ordinary
skill in the art, suitable procedures being described, for example, in examples
below, and in the references cited herein.
Also provided is a method for inhibiting at least one histone
deacetylase. In some embodiments, the at least one histone deacetylase is a
class Ila HDAC. In some embodiments, the at least one histone deacetylase is
selected from HDAC-4, HDAC-5, HDAC-7, and HDAC-9. In some embodiments,
the inhibition is in a cell. In some embodiments, the compound, or
pharmaceutically acceptable salt thereof, described herein is selective for
inhibiting at least one class II histone deacetylase. In some embodiments, the
compound, or pharmaceutically acceptable salt thereof, described herein is a
selective inhibitor of HDAC-4 and/or HDAC-5.
Also provided is a method of treating a condition or disorder
mediated by HDAC in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HDAC
comprises a neurodegenerative pathology. Accordingly, also provided is a
method of treating a neurodegenerative pathology mediated by HDAC in a
subject in need of such a treatment, comprising administering to the subject a
therapeutically effective amount of at least one compound, or pharmaceutically
acceptable salt thereof, described herein.
In some embodiments, the neurodegenerative pathology is chosen
from Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion
disease (NllD), Dentatorubral pallidolusyian atrophy (DRPLA), Friedreich's ataxia,
Rubenstein-Taubi Sydrome, and polyglutamine diseases such as Huntington's
disease; spinocerebellar ataxia 1 (SCA 1 ), spinocerebellar ataxia 7 (SCA 7),
seizures, striatonigral degeneration, progressive supranuclear palsy, torsion
dystonia, spasmodic torticollis, dyskinesis, familial tremor, Gilles de la Tourette
syndrome, diffuse Lewy body disease, progressive supranuclear palsy, Pick's
disease, primary lateral sclerosis, progressive neural muscular atrophy, spinal
muscular atrophy, hypertrophic interstitial polyneuropathy, retinitis pigmentosa,
hereditary optic atrophy, hereditary spastic paraplegia, Shy-Drager syndrome,
Kennedy's disease, protein-aggregation-related neurodegeneration, Machado
Joseph's disease, spongiform encephalopathy, prion-related disease, multiple
sclerosis (MS), progressive supranuclear palsy (Steel-Richardson-Olszewski
disease), llallervorden-Spdtz disease, progressive familial myoclonic epilepsy,
cerebellar degeneration, Shy-Drager syndrome, motor neuron disease, Werdnig
Hoffman disease, Wohlfart-Kugelberg-Welander disease, Gharcot-Mane-Tooth
disease, Dejenne-Sottas disease, retimtis pigmentosa, Lebei's disease,
progressive systemic sclerosis, dermatomyositis, and mixed connective tissue
disease.
In some embodiments, the neurodegenerative pathology is an acute
or chronic degenerative disease of the eye. Acute or chronic degenerative
diseases of the eye include glaucoma, dry age-related macular degeneration,
retinitis pigmentosa and other forms of heredodegenerative retinal disease,
retinal detachment, macular pucker, ischemia affecting the outer retina, cellular
damage associated with diabetic retinopathy and retinal ischemia, damage
associated with laser therapy, ocular neovascular, diabetic retinopathy, rubeosis
iritis, uveitis, Fuch's heterochromatic iridocyclitis, neovascular glaucoma, corneal
neovascularization, retinal ischemia, choroidal vascular insufficinency, choroidal
thrombosis, carotid artery ischemia, contusive ocular injury, retinopathy of
permaturity, retinal vein occlusion, proliferative vitreoretinopathy, corneal
angiogenesis, retinal microvasculopathy, and retinal eduema.
In some embodiments, the condition or disorder mediated by HOAG
comprises a fibrotic disease such as liver fibrosis, cystic fibrosis, cirrhosis, and
fibrotic skin diseases, e.g., hypertrophic scars, keloid, and Dupuytren's
contracture. Accordingly, also provided is a method of treating a fibrotic disease
mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a psychological disorder, such as depression, bipolar disease and
dementia. In some embodiments, the condition or disorder mediated by HOAG
comprises depression. Accordingly, also provided is a method of treating a
psychological disorder, such as depression, mediated by HOAG in a subject in
need of such a treatment, comprising administering to the subject a
therapeutically effective amount of at least one compound, or pharmaceutically
acceptable salt thereof, described herein. In some embodiments, the depression
is chosen from major depressive disorder, and bipolar disorder.
In some embodiments, the condition or disorder mediated by HOAG
comprises anxiety. Accordingly, also provided is a method of treating an anxiety
mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises schizophrenia. Accordingly, also provided is a method of treating a
schizophrenia mediated by HOAG in a subject in need of such a treatment,
comprising administering to the subject a therapeutically effective amount of at
least one compound, or pharmaceutically acceptable salt thereof, described
herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a motor neuron disease, muscle atrophy/muscle wasting disorders, or
amyotrophic lateral sclerosis (ALS). Accordingly, also provided is a method of
treating a motor neuron disease, muscle atrophy/muscle wasting disorders, or
amyotrophic lateral sclerosis (ALS) mediated by HOAG in a subject in need of
such a treatment, comprising administering to the subject a therapeutically
effective amount of at least one compound, or pharmaceutically acceptable salt
thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a cardiovascular condition. Accordingly, also provided is a method of
treating a cardiovascular condition mediated by HOAG in a subject in need of
such a treatment, comprising administering to the subject a therapeutically
effective amount of at least one compound, or pharmaceutically acceptable salt
thereof, described herein. In some embodiments, the cardiovascular condition is
chosen from cardiomyopathy, cardiac hypertrophy, myocardial ischemia, heart
failure, cardiac restenosis, and arteriosclerosis.
In some embodiments, the condition or disorder mediated by HOAG
comprises cancer. Accordingly, also provided is a method of treating cancer
mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein. In
some embodiments, the cancer is chosen from lymphoma, pancreatic cancer,
colorectal cancer, hepatocellular carcinoma, Waldenstrom macroglobulinemia,
hormone refractory cancer of the prostate, and leukaemia, breast cancer, lung
cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer,
gastric cancer, brain cancer, B-cell lymphoma, peripheral T-cell lymphoma, and
cutaneous T-cell lymphoma. In some further embodiments, the cancer is chosen
from the following cancer types. Cardiac: sarcoma (angiosarcoma, fibrosarcoma,
rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and
teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small
cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar)
carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous
hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell
carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma,
lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma,
glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel
(adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma,
hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma,
tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract:
kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia),
bladder and urethra (squamous cell carcinoma, transitional cell carcinoma,
adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma,
teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma,
interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
Liver: hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma,
hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma
(osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma,
Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple
myeloma, malignant giant cell tumor chordoma, osteochronfroma
(osteocartilaginous exostoses), benign chondroma, chondroblastoma,
chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system:
skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans),
meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma,
medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma
multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus
(endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical
dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous
cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors,
Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous
cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma,
melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid
sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma);
Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic
leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple
myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's
lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell
carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi,
lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands:
neuroblastoma; and the sensitization of tumors to radiotherapy by administering
the compound according to the invention before, during or after irradiation of the
tumor for treating cancer.
In some embodiments, the condition or disorder mediated by HOAG
comprises a condition or disorder treatable by immune modulation. Accordingly,
also provided is a method of treating a condition or disorder treatable by immune
modulation mediated by HOAG in a subject in need of such a treatment,
comprising administering to the subject a therapeutically effective amount of at
least one compound, or pharmaceutically acceptable salt thereof, described
herein. In some embodiments, the condition or disorder treatable by immune
modulation is chosen from asthma, irritable bowel syndrome, Grohn's disease,
ulcerative colitis, bowel motility disorders, hypertension, rheumatoid arthritis,
osteoarthritis, juvenile chronic arthritis, graft versus host disease, psoriasis,
spondyloarthropathy, inflammatory bowel disease, alcoholic hepatitis, Sjogren's
syndrome, ankylosing spondylitis, membranous glomerulopathy, discogenic pain,
systemic lupus erythematosus, allergic bowel disease, coeliac disease,
bronchitis, cystic fibrosis, rheumatoid spondylitis, osteoarthritis, uveitis, intis, and
conjunctivitis, ischemic bowel disease, psoriasis, eczema, dermatitis, septic
arthritis, gout, pseudogout, juvenile arthritis, Still's disease, Henoch-Schonlein
purpura, psoriatic arthritis, myalgia, reactive arthritis (Reiter's syndrome),
hemochromatosis, Wegener's granulomatosis, familial Mediterranean fever
(FMF), HBOS (hyperimmunoglobulinemia 0 and periodic fever syndrome),
TRAPS (TNF-alpha receptor associated periodic fever syndrome), chronic
obstructive pulmonary disease, neonatal-onset multisystem inflammatory disease
(NOMIO), cryopyrin-associated periodic syndrome (CAPS), and familial cold
autoinflammatory syndrome (FCAS).
In some embodiments, the condition or disorder mediated by HOAG
comprises an allergic disease. Accordingly, also provided is a method of treating
an allergic disease, mediated by HOAG in a subject in need of such a treatment,
comprising administering to the subject a therapeutically effective amount of at
least one compound, or pharmaceutically acceptable salt thereof, described
herein. Allergic diseases include, but are not limited to, respiratory allergic
diseases such as allergic rhinitis, hypersensitivity lung diseases, hypersensitivity
pneumonitis, eosinophilic pneumonias, Loeffler's syndrome, chronic eosinophilic
pneumonia, delayed-type hypersensitivity, interstitial lung diseases (ILO),
idiopathic pulmonary fibrosis, polymyositis, dermatomyositis, systemic
anaphylaxis, drug allergies (e.g., to penicillin or cephalosporins), and insect sting
allergies.
In some embodiments, the condition or disorder mediated by HOAG
comprises an infectious disease such as a fungal infection, bacterial infection,
viral infection, and protozoa! infection, e.g., malaria, giardiasis, leishmaniasis,
Chaga's disease, dysentery, toxoplasmosis, and coccidiosis. In some
embodiments, the condition or disorder mediated by HOAG comprises malaria.
Accordingly, also provided is a method of treating an infectious disease, such as
malaria, mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises autism or Rett syndrome. Accordingly, also provided is a method of
treating autism or Rett syndrome mediated by HOAG in a subject in need of such
a treatment, comprising administering to the subject a therapeutically effective
amount of at least one compound, or pharmaceutically acceptable salt thereof,
described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a hematological disorder such as thalassemia, anemia, and sickle cell
anemia. Accordingly, also provided is a method of treating a hematological
disorder mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a metabolic disease such as prediabetes or diabetes (type I or II).
Accordingly, also provided is a method of treating a metabolic disease, such as
prediabetes or diabetes (type I or II), mediated by HOAG in a subject in need of
such a treatment, comprising administering to the subject a therapeutically
effective amount of at least one compound, or pharmaceutically acceptable salt
thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a disorder that may also be treated by progenitor/stem cell based
therapies such as: disorders related to diabetes (organ failure, cerrosis, and
hepatitis); central nervous system (CNS) disorders associated with dysregulation
of progenitor cells in the brain (e.g., post-traumatic stress disorder (PTSO);
tumors (e.g., retinoblastomas); disorders affecting oligodendrycoyte progenitor
cells (e.g., astrocytomas and ependimal cell tumors); multiple sclerosis;
demyelinating disorders such as the leukodystrophies; neuropathies associated
with white matter loss; and cerebellar disorders such as ataxia; and olfactory
progenitor disorders (e.g., anosmic conditions). Accordingly, also provided is a
method of treating a disorder that is mediated by HOAG in a subject in need of
such a treatment, comprising administering to the subject a therapeutically
effective amount of at least one compound, or pharmaceutically acceptable salt
thereof, described herein, either before, during, or after a treatment with
progenitor/stem cell based therapies.
In some embodiments, the condition or disorder mediated by HOAG
comprises a disorder related to the proliferation of epithelial and mesenchymal
cells (e.g., tumors, wound healing, and surgeries). Accordingly, also provided is
a method of treating a disorder related to the proliferation of epithelial and
mesenchymal cells that is mediated by HOAG in a subject in need of such a
treatment, comprising administering to the subject a therapeutically effective
amount of at least one compound, or pharmaceutically acceptable salt thereof,
described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a disorder related to the proliferation of bone progenitors (e.g.,
osteoblasts and osteoclasts), disorders related to hair and epidermal progenitors
(e.g., hair loss, cutaneous tumors, skin regeneration, burns, and cosmetic
surgery); and disorders related to bone loss during menopause. Accordingly,
also provided is a method of treating disorders related to the proliferation of bone
progenitors, disorders related to hair and epidermal progenitors, or disorders
related to bone loss that are mediated by HOAG in a subject in need of such a
treatment, comprising administering to the subject a therapeutically effective
amount of at least one compound, or pharmaceutically acceptable salt thereof,
described herein.
In some embodiments, the condition or disorder mediated by HOAG
is a viral disorder for which blood cells become sensitized to other treatments
after HOAG inhibition, following administering to the subject a therapeutically
effective amount of at least one compound, or pharmaceutically acceptable salt
thereof, as described herein.
In some embodiments, the condition or disorder mediated by HOAG
is an immune disorder that may be co-treated with TN Fa or other immune
modulators, upon administering to the subject a therapeutically effective amount
of at least one compound, or pharmaceutically acceptable salt thereof, as
described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a graft rejection or transplant rejection. Accordingly, also provided is a
method of treating a disorder related to a graft rejection or a transplant rejection
that is mediated by HOAG in a subject in need of such a treatment, comprising
administering to the subject a therapeutically effective amount of at least one
compound, or pharmaceutically acceptable salt thereof, described herein.
In some embodiments, the condition or disorder mediated by HOAG
comprises a blood pressure disorder related to nitric oxide (NO) regulation (e.g.,
hypertension, erectile dysfunction, asthma; and ocular disorders as glaucoma).
Accordingly, also provided is a method of treating a blood pressure disorder
related to nitric oxide (NO) regulation that is mediated by HOAG in a subject in
need of such a treatment, comprising administering to the subject a
therapeutically effective amount of at least one compound, or pharmaceutically
acceptable salt thereof, described herein. In some embodiments, the condition
or disorder is a cardiac hypertrophic disorder. Accordingly, also provided is a
method of treating a cardiac hypertrophic disorder that is mediated by HOAG in a
subject in need of such a treatment, comprising administering to the subject a
therapeutically effective amount of at least one compound, or pharmaceutically
acceptable salt thereof, described herein.
Also provided are methods of treatment in which at least one
compound, or pharmaceutically acceptable salt thereof, described herein is the
only active agent given to the subject and also includes methods of treatment in
which at least one compound, or pharmaceutically acceptable salt thereof,
described herein is given to the subject in combination with one or more
additional active agents.
In general, the compounds, or pharmaceutically acceptable salts
thereof, described herein will be administered in a therapeutically effective
amount by any of the accepted modes of administration for agents that serve
similar utilities. The actual amount of the compound, i.e., the active ingredient,
will depend upon numerous factors such as the severity of the disease to be
treated, the age and relative health of the subject, the potency of the compound
used, the route and form of administration, and other factors well know to the
skilled artisan. The drug can be administered at least once a day, such as once
or twice a day.
In some embodiments, the compounds, or pharmaceutically
acceptable salts thereof, described herein are administered as a pharmaceutical
composition. Accordingly, provided are pharmaceutical compositions comprising
at least one compound, or pharmaceutically acceptable salt thereof, described
herein, together with at least one pharmaceutically acceptable vehicle chosen
from carriers, adjuvants, and excipients.
Pharmaceutically acceptable vehicles must be of sufficiently high
purity and sufficiently low toxicity to render them suitable for administration to the
animal being treated. The vehicle can be inert or it can possess pharmaceutical
benefits. The amount of vehicle employed in conjunction with the compound, or
pharmaceutically acceptable salt thereof, is sufficient to provide a practical
quantity of material for administration per unit dose of the compound, or
pharmaceutically acceptable salt thereof.
Exemplary pharmaceutically acceptable carriers or components
thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn
starch and potato starch; cellulose and its derivatives, such as sodium
carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered
tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and
magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as
peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as
propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic
acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting
agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting
agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic
saline; and phosphate buffer solutions.
Optional active agents may be included in a pharmaceutical
composition, which do not substantially interfere with the activity of the
compound, or pharmaceutically acceptable salt thereof, described herein.
Effective concentrations of at least one compound, or
pharmaceutically acceptable salt thereof, described herein are mixed with a
suitable pharmaceutically acceptable vehicle. In instances in which the
compound, or pharmaceutically acceptable salt thereof, exhibits insufficient
solubility, methods for solubilizing compounds may be used. Such methods are
known to those of skill in this art, and include, but are not limited to, using
cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as
TWEEN, or dissolution in aqueous sodium bicarbonate.
Upon mixing or addition of a compound, or pharmaceutically
acceptable salt thereof, described herein, the resulting mixture may be a solution,
suspension, emulsion or the like. The form of the resulting mixture depends upon
a number of factors, including the intended mode of administration and the
solubility of the compound, or pharmaceutically acceptable salt thereof, in the
chosen vehicle. The effective concentration sufficient for ameliorating the
symptoms of the disease treated may be empirically determined.
The compounds, or pharmaceutically acceptable salts thereof,
described herein may be administered orally, topically, parenterally,
intravenously, by intramuscular injection, by inhalation or spray, sublingually,
transdermally, via buccal administration, rectally, as an ophthalmic solution, or by
other means, in dosage unit formulations.
Pharmaceutical compositions may be formulated for oral use, such
as for example, tablets, troches, lozenges, aqueous or oily suspensions,
dispersible powders or granules, emulsions, hard or soft capsules, or syrups or
elixirs. Pharmaceutical compositions intended for oral use may be prepared
according to any method known to the art for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents, such as
sweetening agents, flavoring agents, coloring agents and preserving agents, in
order to provide pharmaceutically elegant and palatable preparations. In some
embodiments, oral pharmaceutical compositions contain from 0.1 to 99% of at
least one compound, or pharmaceutically acceptable salt thereof, described
herein. In some embodiments, oral pharmaceutical compositions contain at least
% (weight%) of at least one compound, or pharmaceutically acceptable salt
thereof, described herein. Some embodiments contain from 25% to 50% or from
% to 75% of at least one compound, or pharmaceutically acceptable salt
thereof, described herein.
Orally administered pharmaceutical compositions also include liquid
solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups,
and the like. The pharmaceutically acceptable carriers suitable for preparation of
such compositions are well known in the art. Oral pharmaceutical compositions
may contain preservatives, flavoring agents, sweetening agents, such as sucrose
or saccharin, taste-masking agents, and coloring agents.
Typical components of carriers for syrups, elixirs, emulsions and
suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol,
liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with
sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
Such pharmaceutical compositions may also contain a demulcent.
The compound, or pharmaceutically acceptable salt thereof,
described herein can be incorporated into oral liquid preparations such as
aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example.
Moreover, pharmaceutical compositions containing these at least one compound,
or pharmaceutically acceptable salt thereof, can be presented as a dry product
for constitution with water or other suitable vehicle before use. Such liquid
preparations can contain conventional additives, such as suspending agents
(e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl
cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated
edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia),
non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated
coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives
(e.g., methyl or propyl p-hydroxybenzoate and sorbic acid).
For a suspension, typical suspending agents include
methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth
and sodium alginate; typical wetting agents include lecithin and polysorbate 80;
and typical preservatives include methyl paraben and sodium benzoate.
Aqueous suspensions contain the active material(s) in admixture
with excipients suitable for the manufacture of aqueous suspensions. Such
excipients are suspending agents, for example sodium carboxymethylcellulose,
methylcellulose, hydropropylmethylcellulose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting
agents; may be a naturally-occurring phosphatide, for example, lecithin, or
condensation products of an alkylene oxide with fatty acids, for example
polyoxyethylene stearate, or condensation products of ethylene oxide with long
chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or
condensation products of ethylene oxide with partial esters derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation
products of ethylene oxide with partial esters derived from fatty acids and hexitol
anhydrides, for example polyethylene sorbitan substitute. The aqueous
suspensions may also contain one or more preservatives, for example ethyl, or n
propyl p-hydroxybenzoate.
Oily suspensions may be formulated by suspending the active
ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or
coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may
contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
Sweetening agents such as those set forth above, and flavoring agents may be
added to provide palatable oral preparations. These pharmaceutical
compositions may be preserved by the addition of an anti-oxidant such as
ascorbic acid.
Pharmaceutical compositions may also be in the form of oil-in-water
emulsions. The oily phase may be a vegetable oil, for example olive oil or peanut
oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example gum acacia or
gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin,
and esters or partial esters derived from fatty acids and hexitol, anhydrides, for
example sorbitan monoleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
Dispersible powders and granules suitable for preparation of an
aqueous suspension by the addition of water provide the active ingredient in
admixture with a dispersing or wetting agent, suspending agent and one or more
preservatives. Suitable dispersing or wetting agents and suspending agents are
exemplified by those already mentioned above.
Tablets typically comprise conventional pharmaceutically
acceptable adjuvants as inert diluents, such as calcium carbonate, sodium
carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and
sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants
such as magnesium stearate, stearic acid and talc. Glidants such as silicon
dioxide can be used to improve flow characteristics of the powder mixture.
Coloring agents, such as the FD&C dyes, can be added for appearance.
Sweeteners and flavoring agents, such as aspartame, saccharin, menthol,
peppermint, and fruit flavors, can be useful adjuvants for chewable tablets.
Capsules (including time release and sustained release formulations) typically
comprise one or more solid diluents disclosed above. The selection of carrier
components often depends on secondary considerations like taste, cost, and
shelf stability.
Such pharmaceutical compositions may also be coated by
conventional methods, typically with pH or time-dependent coatings, such that the
compound, or pharmaceutically acceptable salt thereof, is released in the
gastrointestinal tract in the vicinity of the desired topical application, or at various
times to extend the desired action. Such dosage forms typically include, but are
not limited to, one or more of cellulose acetate phthalate, polyvinylacetate
phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit
coatings, waxes and shellac.
Pharmaceutical compositions for oral use may also be presented as
hard gelatin capsules wherein the active ingredient is mixed with an inert solid
diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft
gelatin capsules wherein the active ingredient is mixed with water or an oil
medium, for example peanut oil, liquid paraffin or olive oil.
Pharmaceutical compositions may be in the form of a sterile
injectable aqueous or oleaginous suspension. This suspension may be
formulated according to the known art using those suitable dispersing or wetting
agents and suspending agents that have been mentioned above. The sterile
injectable preparation may also be sterile injectable solution or suspension in a
non-toxic parentally acceptable vehicle, for example as a solution in 1,3-
butanediol. Among the acceptable vehicles that may be employed are water,
Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium. For this
purpose any bland fixed oil may be employed including synthetic mono- or
diglycerides. In addition, fatty acids such as oleic acid can be useful in the
preparation of injectables.
The compound, or pharmaceutically acceptable salt thereof,
described herein may be administered parenterally in a sterile medium.
Parenteral administration includes subcutaneous injections, intravenous,
intramuscular, intrathecal injection or infusion techniques. The compound, or
pharmaceutically acceptable salt thereof, described herein, depending on the
vehicle and concentration used, can either be suspended or dissolved in the
vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and
buffering agents can be dissolved in the vehicle. In many pharmaceutical
compositions for parenteral administration the carrier comprises at least 90% by
weight of the total composition. In some embodiments, the carrier for parenteral
administration is chosen from propylene glycol, ethyl oleate, pyrrolidone, ethanol,
and sesame oil.
The compound, or pharmaceutically acceptable salt thereof,
described herein may also be administered in the form of suppositories for rectal
administration of the drug. These pharmaceutical compositions can be prepared
by mixing the drug with a suitable non-irritating excipient that is solid at ordinary
temperatures but liquid at rectal temperature and will therefore melt in the rectum
to release the drug. Such materials include cocoa butter and polyethylene
glycols.
The compound, or pharmaceutically acceptable salt thereof,
described herein may be formulated for local or topical application, such as for
topical application to the skin and mucous membranes, such as in the eye, in the
form of gels, creams, and lotions and for application to the eye. Topical
pharmaceutical compositions may be in any form including, for example,
solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays,
skin patches, and the like.
Such solutions may be formulated as 0.01% -10% isotonic
solutions, pH 5-7, with appropriate salts. The compound, or pharmaceutically
acceptable salt thereof, described herein may also be formulated for transdermal
administration as a transdermal patch.
Topical pharmaceutical compositions comprising at least one
compound, or pharmaceutically acceptable salt thereof, described herein can be
admixed with a variety of carrier materials well known in the art, such as, for
example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils,
mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
Other materials suitable for use in topical carriers include, for
example, emollients, solvents, humectants, thickeners and powders. Examples
of each of these types of materials, which can be used singly or as mixtures of
one or more materials, are as follows.
Representative emollients include stearyl alcohol, glyceryl
monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink
oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl
stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan
ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso
propyl myristate, iso-propyl palmitate, iso-propyl stearate, butyl stearate,
polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil,
castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate,
isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate,
decyl oleate, and myristyl myristate; propellants, such as propane, butane, iso
butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl
alcohol, methylene chloride, iso-propanol, castor oil, ethylene glycol monoethyl
ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether,
dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran; humectants, such as
glycerin, sorbitol, sodium 2-pyrrolidonecarboxylate, soluble collagen, dibutyl
phthalate, and gelatin; and powders, such as chalk, talc, fullers earth, kaolin,
starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium
smectites, trialkyl aryl ammonium smectites, chemically modified magnesium
aluminium silicate, organically modified montmorillonite clay, hydrated aluminium
silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, and
ethylene glycol monostearate.
The compound, or pharmaceutically acceptable salt thereof,
described herein may also be topically administered in the form of liposome
delivery systems, such as small unilamellar vesicles, large unilamellar vesicles,
and multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Other pharmaceutical compositions useful for attaining systemic
delivery of the compound, or pharmaceutically acceptable salt thereof, include
sublingual, buccal and nasal dosage forms. Such pharmaceutical compositions
typically comprise one or more of soluble filler substances such as sucrose,
sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose,
carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants,
sweeteners, colorants, antioxidants and flavoring agents disclosed above may
also be included.
Pharmaceutical compositions for inhalation typically can be
provided in the form of a solution, suspension or emulsion that can be
administered as a dry powder or in the form of an aerosol using a conventional
propellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).
The pharmaceutical compositions may also optionally comprise an
activity enhancer. The activity enhancer can be chosen from a wide variety of
molecules that function in different ways to enhance or be independent of
therapeutic effects of the compound, or pharmaceutically acceptable salt thereof,
described herein. Particular classes of activity enhancers include skin penetration
enhancers and absorption enhancers.
Pharmaceutical compositions may also contain additional active
agents that can be chosen from a wide variety of molecules, which can function in
different ways to enhance the therapeutic effects of at least one compound, or
pharmaceutically acceptable salt thereof, described herein. These optional other
active agents, when present, are typically employed in the pharmaceutical
compositions at a level ranging from 0.01 % to 15%. Some embodiments contain
from 0.1%to10% by weight of the composition. Other embodiments contain
from 0.5% to 5% by weight of the composition.
Also provided are packaged pharmaceutical compositions. Such
packaged compositions include a pharmaceutical composition comprising at least
one compound, or pharmaceutically acceptable salt thereof, described herein,
and instructions for using the composition to treat a subject (typically a human
patient). In some embodiments, the instructions are for using the pharmaceutical
composition to treat a subject suffering a condition or disorder mediated by
HDAC. The packaged pharmaceutical composition can include providing
prescribing information; for example, to a patient or health care provider, or as a
label in a packaged pharmaceutical composition. Prescribing information may
include for example efficacy, dosage and administration, contraindication and
adverse reaction information pertaining to the pharmaceutical composition.
In all of the foregoing the compound, or pharmaceutically
acceptable salt thereof, can be administered alone, as mixtures, or in
combination with other active agents.
The methods described herein include methods for treating
Huntington's disease, including treating memory and/or cognitive impairment
associated with Huntington's disease, comprising administering to a subject,
simultaneously or sequentially, at least one compound, or pharmaceutically
acceptable salt thereof, described herein and one or more additional agents used
in the treatment of Huntington's disease such as, but not limited to, Amitriptyline,
lmipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine, Setraline,
Terabenazine, Haloperidol, Chloropromazine, Thioridazine, Sulpride, Quetiapine,
Clozapine, and Risperidone. In methods using simultaneous administration, the
agents can be present in a combined composition or can be administered
separately. As a result, also provided are pharmaceutical compositions
comprising at least one compound, or pharmaceutically acceptable salt thereof,
described herein and one or more additional pharmaceutical agents used in the
treatment of Huntington's disease such as, but not limited to, Amitriptyline,
lmipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine, Setraline,
Terabenazine, Haloperidol, Chloropromazine, Thioridazine, Sulpride, Quetiapine,
Clozapine, and Risperidone. Similarly, also provided are packaged
pharmaceutical compositions containing a pharmaceutical composition
comprising at least one compound, or pharmaceutically acceptable salt thereof,
described herein, and another composition comprising one or more additional
pharmaceutical agents used in the treatment of Huntington's disease such as, but
not limited to, Amitriptyline, lmipramine, Despiramine, Nortriptyline, Paroxetine,
Fluoxetine, Setraline, Terabenazine, Haloperidol, Chloropromazine, Thioridazine,
Sulpride, Quetiapine, Clozapine, and Risperidone.
Also provided are methods for Alzheimer's disease, including
treating memory and/or cognitive impairment associated with Alzheimer's
disease, comprising administering to a subject, simultaneously or sequentially, at
least one compound, or pharmaceutically acceptable salt thereof, described
herein and one or more additional agents used in the treatment of Alzheimer's
disease such as, but not limited to, Reminyl, Cognex, Aricept, Exelon, Akatinol,
Neotropin, Eldepryl, Estrogen and Clioquinol. In methods using simultaneous
administration, the agents can be present in a combined composition or can be
administered separately. Also provided are pharmaceutical compositions
comprising at least one compound, or pharmaceutically acceptable salt thereof,
described herein, and one or more additional pharmaceutical agents used in the
treatment of Alzheimer's disease such as, but not limited to, Reminyl, Cognex,
Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen and Clioquinol.
Similarly, also provided are packaged pharmaceutical compositions containing a
pharmaceutical composition comprising at least one compound, or
pharmaceutically acceptable salt thereof, described herein, and another
composition comprising one or more additional pharmaceutical agents used in
the treatment of Alzheimer's disease such as, but not limited to Reminyl, Cognex,
Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen and Clioquinol.
Also provided are methods for treating cancer comprising
administering to a subject, simultaneously or sequentially, at least one
compound, or pharmaceutically acceptable salt thereof, described herein and one
or more additional agents used in the treatment of cancer such as, but not limited
to, the following categories of anti-tumor agents
(i) other cell cycle inhibitory agents that work by the same or different
mechanisms from those defined hereinbefore, for example cyclin dependent
kinase (CDK) inhibitors, in particular CDK2 inhibitors;
(ii) cytostatic agents such as antioestrogens (for example tamoxifen,
toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example
megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole,
vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide,
nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists
(for example goserelin acetate, luprolide), inhibitors of testosterone 5.alpha.
dihydroreductase (for example finasteride), anti-invasion agents (for example
metalloproteinase inhibitors like marimastat and inhibitors of urokinase
plasminogen activator receptor function) and inhibitors of growth factor function,
(such growth factors include for example vascular endothelial growth factor,
epithelial growth factor, platelet derived growth factor and hepatocyte growth
factor such inhibitors include growth factor antibodies, growth factor receptor
antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors);
(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used
in medical oncology, such as antimetabolites (for example antifolates like
methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine
analogues, cytosine arabinoside); antitumour antibiotics (for example
anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin,
mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example
cisplatin, carboplatin); alkylating agents (for example nitrogen mustard,
melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide,
nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like
vincrisitine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example
epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan);
(iv) antiangiogenic agents that work by different mechanisms from those
defined hereinbefore (for example receptor tyrosine kinases like Tie-2, inhibitors
of integrin .alpha.v.beta.3 function, angiostatin, razoxin, thalidomide), and
including vascular targeting agents; and
(v) differentiation agents (for example retinoic acid and vitamin D).
In methods using simultaneous administration, the agents can be
present in a combined composition or can be administered separately. Also
provided are pharmaceutical compositions comprising at least one compound, or
pharmaceutically acceptable salt thereof, described herein, and one or more anti
tumor agent as described herein. Similarly, also provided are packaged
pharmaceutical compositions containing a pharmaceutical composition
comprising at least one compound, or pharmaceutically acceptable salt thereof,
described herein, and another composition comprising one or more one or more
anti-tumor agent as described herein. When used in combination with one or
more additional pharmaceutical agent or agents, the described herein may be
administered prior to, concurrently with, or following administration of the
additional pharmaceutical agent or agents.
In some embodiments, the compounds, or pharmaceutically
acceptable salts thereof, described herein, are administered in conjunction with
surgery or radiotherapy, optionally in combination with one or more additional
agents used in the treatment of cancer.
The dosages of the compounds described herein depend upon a
variety of factors including the particular syndrome to be treated, the severity of
the symptoms, the route of administration, the frequency of the dosage interval,
the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic
profile of the compound, and the presence of any deleterious side-effects, among
other considerations.
The compound, or pharmaceutically acceptable salt thereof,
described herein is typically administered at dosage levels and in a manner
customary for HOAG inhibitors. For example, the compound, or pharmaceutically
acceptable salt thereof, can be administered, in single or multiple doses, by oral
administration at a dosage level of generally 0.001-100 mg/kg/day, for example,
0.01-100 mg/kg/day, such as 0.1-70 mg/kg/day, for example, 0.5-10 mg/kg/day.
Unit dosage forms can contain generally 0.01-1000 mg of at least one compound,
or pharmaceutically acceptable salt thereof, described herein, for example, 0.1-50
mg of at least one compound, or pharmaceutically acceptable salt thereof,
described herein. For intravenous administration, the compounds can be
administered, in single or multiple dosages, at a dosage level of, for example,
0.001-50 mg/kg/day, such as 0.001-10 mg/kg/day, for example, 0.01-1
mg/kg/day. Unit dosage forms can contain, for example, 0.1-10 mg of at least
one compound, or pharmaceutically acceptable salt thereof, described herein.
A labeled form of a compound, or pharmaceutically acceptable salt
thereof, described herein can be used as a diagnostic for identifying and/or
obtaining compounds that have the function of modulating an activity of HOAG as
described herein. The compound, or pharmaceutically acceptable salt thereof,
described herein may additionally be used for validating, optimizing, and
standardizing bioassays.
By "labeled" herein is meant that the compound is either directly or
indirectly labeled with a label which provides a detectable signal, e.g.,
radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic
particles, chemiluminescent tag, or specific binding molecules, etc. Specific
binding molecules include pairs, such as biotin and streptavidin, digoxin and
antidigoxin etc. For the specific binding members, the complementary member
would normally be labeled with a molecule which provides for detection, in
accordance with known procedures, as outlined above. The label can directly or
indirectly provide a detectable signal.
In carrying out the procedures of the methods described herein, it is
of course to be understood that reference to particular buffers, media, reagents,
cells, culture conditions and the like are not intended to be limiting, but are to be
read so as to include all related materials that one of ordinary skill in the art would
recognize as being of interest or value in the particular context in which that
discussion is presented. For example, it is often possible to substitute one buffer
system or culture medium for another and still achieve similar, if not identical,
results. Those of skill in the art will have sufficient knowledge of such systems
and methodologies so as to be able, without undue experimentation, to make
such substitutions as will optimally serve their purposes in using the methods and
procedures disclosed herein.
EXAMPLES
The compounds, or pharmaceutically acceptable salts thereof,
compositions, and methods described herein are further illustrated by the
following non-limiting examples.
As used herein, the following abbreviations have the following
meanings. If an abbreviation is not defined, it has its generally accepted
meaning.
Abbreviations
[bmim][PF5]: 1-Butylmethylimidazolium hexafluorophosphate
BOP: Benzotriazoleyl-oxy-tris-(dimethylamino)-phosphonium
hexafluorophosphate
DCM: Dichloromethane
DCE: Dichloroethane
DIPEA: Diisopropylethylamine
OMA: Dimethylacetam ide
DME: Dimethoxyethane
DMF: Dimethylformam ide
DMSO: Dimethylsulfoxide
ES+: Electrospray Positive Ionisation
ES-: Electrospray Negative Ionisation
Diethyl ether
Et20:
EtOAc: Ethyl acetate
h: Hour
HPLC: High Performance Liquid Chromatography
i-hex: iso-Hexane
LCMS: Liquid Chromatography Mass Spectrometry
LiHMDS: Lithium bis(trimethylsilyl)amide
M: Mass
MeCN: Acetonitrile
MeOH: Methanol
NMP: N-Methyl pyrrolidinone
Pd/C: Palladium on carbon
Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium(O)
Pd(dppf)Cl2: [1, 1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll)
Pd(PPh3)4: Tetrakis(triphenylphosphine)palladium(O)
o-tol: ortho-T olyl
Rh2(0Ac)4: Rhodium(ll) acetate
RT: Retention time
r.t.: Room temperature
Ru Phos: 2-Dicyclohexylphosph ino-2' ,6'-d i-iso -propoxy-1 , 1 '-biphenyl
THF: Tetrahydrofuran
Xantphos: 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
Analytical Conditions
Compounds were named with the aid of the Cambridgesoft
Chemistry Cartridge (v. 9.0.0.182) software.
All reactions involving air- or moisture-sensitive reagents were
performed under a nitrogen atmosphere using dried solvents and glassware.
Racemic mixtures of the cyclopropyl core are denoted using
asterisks e.g. (1 R*,2R*,3R*). Chirally pure compounds are denoted without
asterisks e.g. (1 R,2R,3R).
Analytical Condition Method Description
10cm ESI Formic 1
- - -
MeCN, 10cm
Solvents: Acetonitrile (far UV grade)
ESCI Formic MeCN
- - -
with 0.1 % (v/v) formic acid.
Water (high purity via
Purelab Option unit) with
0.1 % formic acid
Column: Phenomenex Luna 5 urn C18
(2), 100 x 4.6 mm (Plus guard
cartridge)
Flow Rate: 2 ml/min
gradient: A: Water/formic acid
B: MeCN/formic acid
Time A% 8%
0.00 95 5
3.50
95
.50 5 95
.60 95 5
6.50
95 5
Typical Injections 2-7 µL (concentration -
0.2-1.0 mg/ml)
15cm Bicarb GeminiN 2
X HPLC MeCN
Solvents: 100% Acetonitrile (Far UV
grade) Water (High purity via
Purelab Ultra unit) with 10
mM Ammonium Bicarbonate
Column: Phenomenex, Gemini NX, 3
urn C18,150 x 4.6 mm.
Flow Rate: 1 ml/min
gradient: A: 10 mM Ammonium
Bicarbonate in water
B: 100% MeCN
Time A% B%
0.00 95.5 4.5
3.00 95.5 4.4
9.00 0 100
13.6 0 100
13.7 95.5 4.5
95.5 4.5
Typical Injections 2-7 µL (concentration
- 0.2-1 mg/ml)
15cm Formic Ascentis
HPLC MeCN
Solvents: Acetonitrile (Far UV grade)
with 0.1 % (VN) formic acid
Water (High purity via
Purelab Ultra unit) with
0.1 % formic acid
Column: Supelco, Ascentis®
Express C18 or Hichrom
Halo C18, 2.7 urn C18, 150
x4.6mm.
Flow Rate: 1ml/min
gradient: A: Water I formic
B: MeCN/formic
Time A% 8%
0.00 96 4
3.00 96 4
9.00 100
13.6 0 100
13.7 96 4
4
Typical Injections 2-7 µL (concentration -
0.2-1 mg/ml)
1 Ocm ESCI bicarb Me 4
- - -
Solvents: Acetonitrile (Far UV grade)
Water (High purity via
Purelab Option unit) with
mM ammonium
bicarbonate (ammonium
hydrogen carbonate)
Column: Waters Xterra MS 5m
C18, 100 x 4.6 mm. (Plus
guard cartridge)
Flow Rate: 2ml/min
gradient: A: Water/Bicarb
B: MeCN
Time A% 8%
0.00 95 5
0.50
95 5
4.00
95
.50 5 95
.60 95 5
6.50 95 5
Typical Injections 2-7 µL (concentration -
0.2-1 mg/ml)
10cm Formic ACE- 5
AR HPLC CH3CN
Solvents: Acetonitrile (Far UV
grade) with 0.1 % (VN)
formic acid Water (High
purity via Purelab Ultra
unit) with 0.1 % formic
acid
Column: Hichrom ACE 3 C18-AR
mixed mode column
100x4.6 mm
Flow Rate: 1 ml/min
gradient: A: Water I formic
B: MeCN/formic
Time A% 8%
0.00 2
3.00 98 2
12.00 0 100
.4 0 100
.5 98 2
17 98 2
Typical Injections 0.2-10 µL
Analytical Condition Method Description
Solvents: Methanol (AR grade)
with 0.1% (VN)formic
acid Water (High purity
via Purelab Ultra unit)
with 0.1 % formic acid
Column: Hichrom ACE 3 C18-
AR mixed mode
column 100x4.6mm
Flow Rate: 1ml/min
1 Ocm Formic ACE-
AR HPlC CH30H Slo 6
- - -
gradient: A: Water I formic
B: MeOH/formic
Time A% 8%
0.00 2
3.00 2
12.00 0 100
.4 0 100
.5 98 2
17 98 2
Typical Injections 0.2-1 Oµl
Synthetic Section
Method A (hydroxamic acid formation)
To a stirred solution of ester (0.30 mmol) in THF/MeOH (1 :1, 3 ml)
was added hydroxylamine (0.2 ml, 50% aqueous solution, 3.00 mmol) and
potassium hydroxide (33 mg, 0.60 mmol). The mixture was stirred at r.t. for 2 h,
neutralized with 1 M HCl(aq) and extracted with DCM. The combined organic
layers were washed with brine (10 ml), passed through a phase separator and
concentrated.
Method B (hydroxamic acid formation)
To a stirred solution of acid (0.26 mmol), BOP (0.29 mmol) and
triethylamine (0.78 mmol) in pyridine (1 ml) was added hydroxylamine
hydrochloride (0.29 mmol). The reaction mixture was stirred at r.t. for 2 h, diluted
with water (10 ml) and extracted into EtOAc (3 x 20 ml). The combined organic
layers were washed with water (2 x 20 ml), dried (MgS04) and concentrated.
Method C (Wittig reaction)
To a stirred solution of triethyl phosphonoacetate (24.4 mmol) in
THF (30 ml) at 0°C was added sodium hydride (24.4 mmol) portionwise. The
mixture was stirred for 1 h before addition of aldehyde (12.2 mmol). The reaction
mixture was allowed to warm to r.t. and stirred for 17 h, before quenching with
water (50 ml) and extracting into EtOAc (2 x 50 ml). The organic layers were
combined and washed with water (2 x 50 ml), dried (MgS04), filtered and
concentrated.
Method D (Heck reaction - 1)
To a stirred solution of aryl bromide (4.42 mmol) in anhydrous DMF
(16 ml) was added ethyl acrylate (5.75 mmol), Pd(OAc)2 (0.44 mmol), DABCO
(8.84 mmol) and potassium carbonate (8.84 mmol). The solution was degassed
under nitrogen for 15 min before heating to 125°C for 17 h. The mixture was
cooled, diluted with H20 (30 ml) and extracted into DCM (2 x 30 ml). The
organic layers were washed with H20 (3 x 50 ml) and brine (2 x 50 ml), passed
through a phase separator and concentrated.
Method E (Heck reaction - 2)
A stirred mixture of aryl bromide (10.0 mmol), ethyl acrylate (15.0
mmol), palladium acetate (1.00 mmol), P(o-tol), (2.00 mmol) and triethylamine
(20.0 mmol) in MeCN (50 ml) was degassed with nitrogen for 15 min and heated
to 80°C for 3-18 h. The reaction mixture was cooled and the MeCN removed in
vacuo. The residue was partitioned between DCM and H20 and the organic
layers were passed through a phase separator and concentrated.
Method F (Cyclopropanation reaction)
A mixture of sulfonium salt (8.92 mmol), acrylate (5.96 mmol) and
12-crown-4 (8.92 mmol) in DCM (20 ml) was cooled to -20°C. LiHMDS (8.92
ml) was then added dropwise. After complete addition, the mixture was warmed
to r.t, stirred for 2 hand quenched with H20 (30 ml). The layers were separated
and the organic phase was washed with brine (2 x 30 ml), separated, dried
(MgS04), filtered and concentrated.
Method G (Suzuki coupling from boronate on scaffold)
To a stirred solution of cyclopropyl bromo scaffold (3.02 mmol) in
dioxane (5 ml) was added bis-pinacolato diboron (3.32 mmol), Pd(dppf)Cl2 (0.30
mmol) and potassium acetate (15.1 mmol). The mixture was degassed with
nitrogen and heated to 100°C for 2 h. The reaction mixture was diluted with H20
(20 ml) and extracted into DCM (2 x 20 ml). The organic layers were passed
through a phase separator and concentrated. The crude residue was dissolved
in dioxane and an aliquot (0.66 mmol) was added to a reaction tube. To this was
added heterocyclic halide (0.69 mmol), Pd(PPh3)4 (0.066 mmol), and aqueous
Na2C03 (5 ml, 1 M solution). The reaction was heated at 100°C for 2 h. The
mixture was diluted with H20 (10 ml) and extracted into DCM (20 ml). The
organic layers were passed through a phase separator and concentrated.
Method H (Suzuki coupling)
A mixture of cyclopropyl bromo scaffold (2.00 mmol), boronic ester
(or acid) (2.40 mmol), 1 N Na2C03 (6.00 mmol) and Pd(PPh3)4 (0.10 mmol) in
dioxane (6 ml) was stirred at 100°C for 3 h. The reaction mixture was diluted
with water and extracted into DCM. The organic layer was dried and
concentrated and the crude mixture was purified by flash silica column
chromatography.
Method I (Buchwald reaction)
To a stirred solution of aryl bromide (0.76 mmol) and amine (0.86
mmol) in dioxane (4 ml), was added XantPhos (0.048 mmol), cesium carbonate
(1.66 mmol) and Pd2(dba)3 (0.024 mmol). The mixture was stirred for 16 h at 90
°C, diluted with water and extracted into DCM (20 ml). The organic layers were
passed through a phase separator and concentrated and the crude mixture was
purified by flash silica column chromatography.
Example 1
Reaction Scheme 1
CONHOH
Ph'''.~Ph
trans-2,3-Diphenylcyclopropanecarboxylic acid (1)
To a stirred solution of trans-stilbene (1.0 g, 5.6 mmol) and copper
sulphate (44 mg, 0.28 mmol) in toluene (50 ml) at 75°C was added ethyl
diazoacetate (1.16 ml, 11.1 mmol) dropwise. Evolution of nitrogen was
observed. The mixture was stirred for 15 min, allowed to cool to r.t. and
concentrated in vacuo. The residue was taken-up in EtOH (25 ml) and filtered.
The filtrate was concentrated and purified by flash silica column chromatography
(gradient elution petroleum ether to 2.5% EtOAc in petroleum ether). The ethyl
ester intermediate was then dissolved in MeOH (5 ml) and aqueous 2 M LiOH
(10 ml) and stirred at 50°C for 16 h. The mixture was washed with Et20 (30 ml)
and the basic aqueous solution acidified using aqueous 1 M HCI. The resulting
precipitate was collected by filtration to give the title compound (62 mg, 5%) as a
white solid.
trans-N-Hydroxy-2,3-diphenylcyclopropanecarboxamide (2)
Following method B, from compound 1 (62 mg, 0.26 mmol). The
crude material was purified by preparative HPlC and PEAX cartridge
(DCM:MeOH, 1 :1 ). The solvent was removed in vacuo to afford the title
compound (25 mg, 38%) as a white solid. lCMS (ES+) 254 (M+H)+, (ES-) 252
(M-H)-, RT 2.97 min (Analytical method 1 ). NMR s (ppm)(DMSO-d5): 10.55 (1
H, s), 8.69 (1 H, s), 7.36-7.16 (10 H, m), 3.09 (1 H, dd, J = 6.8, 5.4 Hz), 2.83 (1
H, dd, J = 9.6, 6.8 Hz), 2.20 (1 H, dd, J = 9.6, 5.4 Hz).
Example 2
Reaction Scheme 2
QONHOH
-Ph~
(E)-(2-Cyclohexylvinyl )benzene (3)
To a stirred solution of K3P04 (11.4 g, 53.8 mmol) in OMA (15 ml)
was added bromobenzene (3.0 g, 19 mmol), vinylcyclohexane (5.04 g, 45.8
mmol) and palladium acetate (213 mg, 0.95 mmol). The mixture was stirred at
140°C for 16 h, allowed to cool to r.t., diluted with water (50 ml) and extracted
into EtOAc (2 x 50 ml). The combined organic layers were washed with water (2
x 50 ml) and brine (2 x 50 ml), separated, dried (MgS04), filtered and
concentrated. Purification by flash silica column chromatography (i-hex) gave the
title compound as a colourless oil (2.30 g, 65%).
( 1 R* ,2R* ,3R*)-Ethylcyclohexylphenylcyclopropanecarboxylate ( 4)
To a stirred solution of 3 (1.50 g, 8.06 mmol) and Rh2(0Ac)4 (106
mg, 0.806 mmol) in anhydrous DCM (10 ml) was added ethyl diazoacetate (0.85
ml, 8.06 mmol) in DCM (10 ml) at a rate of 0.2 ml/h. After complete addition
the mixture was stirred for 1 h at r.t.. Purification by flash silica column
chromatography (gradient elution of i-hex to 2% EtOAc in i-hex) gave the title
compound as a colourless oil (400 mg, 18%).
( 1 R* ,2R* ,3R*)Cyclohexyl-N-hydroxyphenylcyclopropanecarboxam ide ( 5)
Following method A from compound 4 (750 mg, 2.76 mmol).
Purification by preparative HPlC gave the title compound as a white solid (10
mg, 3%). lCMS (ES+) 260 (M+H)+, 258 (M-H)-, RT 9.41 min (Analytical method
3). NMR o (ppm)(DMSO-d5): 10.51 (1 H, s), 8.76 (1 H, s), 7.30-7.22 (2 H, m),
7.18-7.12 (1 H, m), 7.08 (2 H, d, J = 7.6 Hz), 2.33-2.27 (1 H, m), 1.82-1.58 (7 H,
m), 1.31-1.00 (6 H, m).
Example 3
Reaction Scheme 3
a R =Ph, 6a
R = 2-FPh, 6b
R = 4-FPh, 6c
1-Benzyltetrahydrothiophenium bromide (6a)
To a stirred solution of benzyl bromide (27 ml, 227 mmol) in
acetone at r.t. was added tetrahydrothiophene (10.0 ml, 114 mmol). The
solution was stirred for 16 h and the resulting precipitate filtered and washed with
acetone (3 x 50 ml) and dried under air, to give the title compound as a white
solid (51.9 g, 88%).
1-(2-Fluorobenzyl)tetrahydrothiophenium bromide (6b)
2-Fluorobenzyl bromide (8 g, 42.3 mmol) was added to
tetrahydrothiophene (25 ml, 284 mmol) and the mixture was stirred for 17 h. The
resulting precipitate was collected by vacuum filtration and then slurried in Et20
for 1 h before collecting by vacuum filtration, to give the title compound as a white
solid (7.7 g, 66%).
1-(4-Fluorobenzyl)tetrahydrothiophenium bromide (6c)
To a stirred solution of 4-fluorobenzyl bromide (4.0 g, 21.1 mmol) in
acetone (30 ml) was added tetrahydrothiophene (1.8 ml, 21.1 mmol) and the
mixture was stirred for 17 h. The resulting precipitate was filtered to give the title
compound as a white solid (160 mg, 3%).
Example 4
Reaction Scheme 4
~COzEl
CON HOH
&"''Ph
R = OiPr, 10a
R = OiPr, 11a
R = F, 10b
R = F, 11b
(E)-Ethyl(2-n itrophenyl )acrylate (7)
Following method C from 2-nitrobenzaldehyde (5.0 g, 34.2 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 50%
DCM in i-hex) gave the title compound as a white solid (2.9 g, 38%).
( 1 R* ,2R* ,3R*)-Ethyl(2-n itrophenyl )phenylcyclopropanecarboxylate (8)
To a stirred solution of 7 (2.90 g, 13.1 mmol) in anhydrous
DCM/THF (75 ml/30 ml) was added sulfonium salt 6a (5.10 g, 19.7 mmol) and
the mixture was cooled to -78°C. LiHMDS (26.2 ml, 1 M solution in THF) was
slowly added via syringe pump (1 ml/min). After complete addition, the mixture
was warmed to r.t., stirred for 16 h, quenched with water (50 ml) and extracted
into DCM (2 x 100 ml). The combined organic layers were washed with water (2
x 250 ml) and brine (100 ml). The biphasic mixture was separated and the
organic layer was dried (MgS04), fitered and concentrated. Purification by flash
silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex) gave
the title compound as a yellow oil (2.10 g, 51%).
( 1 R* ,2R* ,3R*)-Ethyl(2-am inophenyl )phenylcyclopropanecarboxylate (9)
A solution of 8 (2.10 g, 6.75 mmol) and 10% Pd/C (200 mg) in
MeOH (75 ml) was stirred at r.t. under H2 (1 atmosphere), for 17 h. The mixture
was filtered through Celite and purified by flash silica column chromatography
(gradient elution i-hex to 20% EtOAc in i-hex) to give the title compound as a red
oil (1.55 g, 82%). lCMS (ES+) 282 (M+Ht.
( 1 R* ,2R* ,3R*)-E thyl(2-isopropoxyphenyl )phenylcyclopropanecarboxylate
(10a)
To a stirred solution of compound 9 (500 mg, 1.78 mmol) in water
(10 ml) was added concentrated H2S04 (0.85 ml) and NaN02 (184 mg, 2.67
mmol). The reaction mixture was stirred at 0°C for 1 h, then poured into boiling
water (20 ml) and stirred for 30 min. The solution was allowed to cool to r.t. and
extracted into DCM (3 x 20 ml). The combined organic layers were washed with
brine (20 ml), dried (MgS04) and concentrated. The resulting red oil was
dissolved in DMF (5 ml) and 2-bromopropane (0.17 ml, 1.77 mmol) and cesium
carbonate (434 mg, 1.34 mmol) were added. The mixture was stirred at 80°C for
16 h, then diluted with water (20 ml) and extracted into DCM (2 x 30 ml). The
combined organic layers were washed with water (20 ml) and brine (20 ml),
dried (MgS04), filtered and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 5% EtOAc in i-hex) gave the title
compound as a colourless oil (125 mg, 44%). lCMS (ES+) 325 (M+H(
( 1 R* ,2R* ,3R*)-Ethyl(2-fluorophenyl )phenylcyclopropanecarboxylate ( 1 Ob)
A solution of nitrosonium tetrafluoroborate (125 mg, 1.07 mmol) and
[bmim][PF6] (1.8 ml) was cooled to 0°C. Compound 9 (300 mg, 1.07 mmol)
was added and the mixture was stirred for 30 min at 0°C, and 17 h at r.t. The
mixture was then heated to 100°C for 2 h (gas evolution observed) and cooled to
r.t. DIPEA (0.18 ml, 1.07 mmol) and Et20 (10 ml) were added. The organic layer
was decanted from the ionic liquid and this process repeated twice more. The
combined organic layers were concentrated and purified by flash silica column
chromatography (gradient elution i-hex to 5% EtOAc in i-hex) to give the title
compound as a colourless oil (135 mg, 45%). lCMS (ES+) 285 (M+H(
( 1 R* ,2R* ,3R*)-N-Hydroxy(2-isopropoxyphenyl )
phenylcyclopropanecarboxam ide ( 11 a)
Following method A from compound 10a (125 mg, 0.39 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the title compound as a white solid (28 mg, 23%). lCMS
(ES+) 312 (M+H)+, (ES-) 310 (M-H)-, RT 3.41 min (Analytical method 1).
NMR o (ppm)(CHCI 3-d): 7.99 (1 H, s), 7.41 (2 H, d, J = 7.6 Hz), 7.31 (2 H, t, J =
7.1 Hz), 7.27-7.18 (2 H, m), 7.11-7.07 (1 H, m), 6.92-6.87 (2 H, m), 4.66-4.59 (1
H, septet, J = 6.0), 3.29 (1 H, t, J = 6.4 Hz), 2.81 (1 H, dd, J = 9.2, 7.3 Hz), 2.02
(1 H, br m), 1.36 (6 H, dd, J = 10.1, 6.0 Hz), OH not observed.
( 1 R* ,2R* ,3R*)(2-FI uorophenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
(11 b)
Following method A from compound 10b (130 mg, 0.46 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 1 %
MeOH in DCM) gave the title compound as a white solid (18 mg, 14%). lCMS
(ES+) 272 (M+H)+, (ES-) 270 (M-H)-, RT 3.02 min (Analytical method 1).
NMR o (ppm)(DMSO-d6): 10.60 (1 H, s), 8.74 (1 H, s), 7.34-7.14 (9 H, m), 3.17
(1 H, dd, J = 7.0, 5.6 Hz), 2.86 (1 H, dd, J = 9.5, 7.0 Hz), 2.25 (1 H, dd, J = 9.5,
.4Hz).
Example 5
Reaction Scheme 5
(:02Et (:ON HOH
UC02Et ____:__
cr··r)
cr···O
( 1 S* ,2R* ,3R*)-Ethyl(2-fluorophenyl )phenylcyclopropanecarboxylate ( 12)
A mixture of sulfonium salt 6b (500 mg, 1.80 mmol), ethyl
cinnamate (0.20 ml, 1.20 mmol) and 12-crown-4 (0.19 ml, 1.20 mmol) in DCM
(10 ml) was cooled to -78°C. LiHMDS (2.41 ml, 1 M solution in THF) was slowly
added via syringe pump (2 ml/h). After complete addition, the mixture was
warmed to r.t. and stirred for 16 h. The reaction mixture was quenched with H20
(30 ml). The biphasic mixture was separated and the organic layers were
washed with brine (2 x 30 ml), dried (MgS04), filtered and concentrated.
Purification by flash silica column chromatography (gradient elution i-hex to 50%
EtOAc in i-hex) gave the title compound as a colourless oil (190 mg, 56%).
LCMS (ES+) 285 (M+H(
( 1 S* ,2R* ,3R*)(2-FI uorophenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
(13)
Following method A from compound 12 (190 mg, 0.67 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the title compound as a white solid (50 mg, 28%). LCMS
(ES+) 272 (M+H)+, (ES-) 270 (M-H)-, RT 3.06 min (Analytical method 1).
NMR s (ppm)(DMSO-d6): 10.60 (1 H, s), 8.73 (1 H, s), 7.42-7.20 (7 H, m), 7.13-
7.06 (2 H, m), 3.03 (1 H, dd, J = 6.8, 5.3 Hz), 2.77 (1 H, dd, J = 9.3, 6.9 Hz), 2.23
(1 H, dd, J = 9.3, 5.3 Hz).
Example 6
Reaction Scheme 6
<;;:ON HOH
~02R
BVC02R
I '°
"tr···o
"tr···o
2-Br, 16a
2-Br, R =Et, 14a 2-Br, R =Et, 15a
3-Br, 16b
3-Br, R =Et, 14b 3-Br, R = Et, 1 Sb
4-Br, 16c
4-Br, R =Me, 15c
~02R
<;;:ON HOH
Mtr.,·o
Mtr···o
I '° I '°
2-Me, R = Et, 17a 2-Me, 18a
3-Me, R = Et 17b 3-Me, 18b
4-Me, R =Me, 17c 4-Me, 18c
(E)-Ethyl(2-bromophenyl )acrylate ( 14a)
Following method C from 2-bromobenzaldehyde (4.66 g, 25.2
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to i-hex:DCM, 5:2) gave the title compound as a colourless oil (2.52 g, 39%).
LCMS (ES+) 255, 257 (M+H(
(E)-Ethyl(3-bromophenyl )acrylate ( 14b)
Following method C from 3-bromobenzaldehyde (10 g, 54.1 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to i
hex:DCM, 1 :1) gave the title compound as a colourless oil (7.8 g, 56%). lCMS
(ES+) 255, 257 (M+Ht.
( 1 R* ,2R* ,3R*)-Ethyl(2-bromophenyl )phenylcyclopropanecarboxylate ( 15a)
A mixture of sulfonium salt 6a (1.52 g, 5.88 mmol) and cinnamate
14a (1.00 g, 3.92 mmol) in DCM/THF (5:2, 35 ml) was cooled to -78°C. LiHMDS
(7.84 ml, 1 M solution in THF) was slowly added via syringe pump (1 ml/h).
After complete addition, the mixture was warmed to r.t., stirred for 16 hand
quenched with H20 (30 ml). The biphasic mixture was separated and the
aqueous portion re-extracted with DCM (30 ml). The combined organic layers
were washed with water (50 ml) and brine (50 ml), separated, dried (MgS04),
filtered and concentrated. Purification by flash silica column chromatography
(gradient elution i-hex to 2.5% EtOAc in i-hex) gave the title compound as a
colourless oil (1.05 g, 78%). lCMS (ES+) 345, 347 (M+Ht
( 1 R* ,2R* ,3R*)-Ethyl(3-bromophenyl )phenylcyclopropanecarboxylate ( 15b)
A mixture of sulfonium salt 6a (2.10 g, 8.10 mmol) and cinnamate
14b (1.03 g, 4.04 mmol) in DCM (20 ml) was cooled to -78°C. LiHMDS (6.00
ml, 1 M solution in THF) was slowly added via syringe pump (6 ml/h). After
complete addition, the mixture was warmed to r.t., stirred for 16 h and quenched
with H20 (30 ml). The biphasic mixture was separated and the aqueous layer
was re-extracted with DCM (30 ml). The combined organic layers were washed
with water (50 ml) and brine (50 ml), dried (MgS04), filtered and concentrated.
Purification by flash silica column chromatography (gradient elution i-hex to 5%
EtOAc in i-hex) gave the title compound as a colourless oil (350 mg, 25%).
lCMS (ES+) 345, 347 (M+Ht_
( 1 R* ,2R* ,3R*)-Methyl 2-( 4-bromophenyl )phenylcyclopropanecarboxylate ( 15c)
A mixture of sulfonium salt 6a (3.39 g, 13.1 mmol) and (E)-methyl 3-
(4-bromophenyl)acrylate (2.10 g, 8.71 mmol) in DCM (50 ml) was cooled to -
78°C and slowly treated with LiHMDS (13.1 ml, 1 M solution in THF) (via syringe
pump, 1 ml/h). After complete addition, the mixture was warmed to r.t., stirred
for 16 h and was quenched with H20 (50 ml). The biphasic mixture was
separated and the organic layer washed with brine (2 x 50 ml), dried (MgS04)
and concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 5% EtOAc in i-hex) gave the title compound as a colourless oil
(600 mg, 20%). LCMS (ES+) 345, 347 (M+Ht_
( 1 R* ,2R* ,3R*)(2-Bromophenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
(16a)
Following method A from compound 15a (100 mg, 0.30 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM), then passage through a PEAX cartridge (DCM:MeOH, 1 :1) gave
the title compound as a white solid (32 mg, 33%). LCMS (ES+) 332, 334 (M+H)+,
330, 332 (M-H)-, RT 10.44 min (Analytical method 3). NMR s (ppm)(DMSO
d5): 10.57 (1 H, s), 8.73 (1 H, s), 7.66 (1 H, dd, J = 7.9, 1.2 Hz), 7.41-7.33 (3 H,
m), 7.30-7.15 (5 H, m), 3.28 (1 H, dd, J = 5.9, 6.9 Hz), 2.83 (1 H, dd, J = 9.5, 7.1
Hz), 2.20 (1 H, dd, J = 9.5, 5.6 Hz).
( 1 R* ,2R* ,3R*)(3-Bromophenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
(16b)
Following method A from compound 15b (100 mg, 0.29 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the title compound as a white solid (28 mg, 28%). LCMS
(ES+) 332, 334 (M+H)+, 330, 332 (M-H)-, RT 3.81 min (Analytical method 1).
NMR s (ppm)(DMSO-d5): 10.54 (1 H, s), 8.71 (1 H, s), 7.50 (1 H, s), 7.44-7.40 (1
H, m), 7.35-7.22 (6 H, m), 7.18 (1 H, t, J = 7.2 Hz), 3.12 (1 H, dd, J = 6.8, 5.4 Hz),
2.88 (1 H, dd, J = 9.6, 6.8 Hz), 2.23 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)( 4-Bromophenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
(16c)
Following method A from compound 15c (100 mg, 0.30 mmol).
The residue after work-up was passed through a PEAX cartridge (elution DCM
MeOH, 1 :1) to give the title compound as a white solid (34 mg, 34%). LCMS
(ES+) 332, 334 (M+H)+, 330, 332 (M-H)-. RT 3.30 min (Analytical method 1).
NMR s (ppm)(DMSO-d6): 10.54 (1 H, s), 8.67 (1 H, s), 7.51-7.45 (2 H, m), 7.31-
7.18 (6 H, m), 7.15 (1 H, t, J = 7.2 Hz), 3.07 (1 H, dd, J = 6.9, 5.4 Hz), 2.81 (1 H,
dd, J = 9.6, 6.9 Hz), 2.17 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R*,2R*,3R*)-Ethylphenylo-tolylcyclopropanecarboxylate ( 17a)
To a stirred solution of 15a (200 mg, 0.58 mmol) in dioxane/water
(9:1, 3 ml) was added trimethylboroxine (80 µI, 0.58 mmol), Pd(PPh3)4 (67 mg,
0.058 mmol) and cesium carbonate (566 mg, 1.74 mmol). The mixture was
degassed with nitrogen for 10 min and heated in the microwave at 115°C for 10
min. The mixture was allowed to cool to r.t. and partitioned between DCM and
H20 (15 ml each). The organic layers were passed through a phase separator
and concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 5% EtOAc in i-hex) gave the title compound as a colourless oil
(140 mg, 86%).
( 1 R*,2R*,3R*)-Ethylphenylm-tolylcyclopropanecarboxylate ( 17b)
To a stirred solution of 15b (200 mg, 0.58 mmol) in dioxane/water
(9:1, 3 ml) was added trimethylboroxine (80 µI, 0.58 mmol), Pd(PPh3)4 (67 mg,
0.058 mmol) and cesium carbonate (566 mg, 1.74 mmol). The mixture was
degassed with nitrogen for 10 min and heated in the microwave at 115°C for 10
min. The mixture was allowed to cool to r.t. and partitioned between DCM and
H20 (15 ml each). The organic layers were passed through a phase separator
and concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 5% EtOAc in i-hex) gave the title compound as a colourless oil
(120 mg, 73%).
( 1 R*,2R*,3R*)-Methylphenylp-tolylcyclopropanecarboxylate ( 17 c)
To a stirred solution of 15c (200 mg, 0.60 mmol) in dioxane/water
(9:1, 3 ml) was added trimethylboroxine (80 µI, 0.60 mmol), Pd(PPh3)4 (69 mg,
0.06 mmol) and cesium carbonate (585 mg, 1.80 mmol). The mixture was
degassed with nitrogen for 10 min and heated in the microwave at 115°C for 10
min. The mixture was allowed to cool to r.t. and partitioned between DCM and
H20 (15 ml each). The organic layers were passed through a phase separator
and concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 10% EtOAc in i-hex) gave the title compound as a colourless oil
(120 mg, 75%).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylo-tolylcyclopropanecarboxam ide ( 18a)
Following method A from compound 17a. Purification by flash
silica column chromatography (gradient elution DCM to 5% MeOH in DCM), then
passage through a PEAX cartridge (DCM/MeOH, 1 :1) gave the title compound as
a white solid (10 mg, 7%). LCMS (ES+) 266 (M-H)-, RT 9.54 min (Analytical
method 2). NMR o (ppm)(DMSO-d5): 10.54 (1 H, s), 8.71 (1 H, s), 7.36 (2 H,
d, J = 7.5 Hz), 7.27 (2 H, t, J = 7.5 Hz), 7.21-7.10 (5 H, m), 3.12 (1 H, dd, J = 7.2,
.7 Hz), 2.76 (1 H, dd, J = 9.4, 7.3 Hz), 2.34 (3 H, s), 2.07 (1 H, dd, J = 9.4, 5.6
Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylm-tolylcyclopropanecarboxam ide ( 18b)
Following method A from compound 17b. Purification by flash
silica column chromatography (gradient elution DCM to 5% MeOH in DCM) gave
the title compound as a white solid (67 mg, 56%). LCMS (ES+) 268 (M+H)+, RT
3.71 min (Analytical method 1 ). NMR s (ppm)(DMSO-d6): 10.54 (1 H, s), 8.68
(1 H, s), 7.32 (2 H, d, J = 7.5 Hz), 7.25 (2 H, t, J = 7.4 Hz), 7.20-7.09 (5 H, m),
3.05 (1 H, dd, J = 6.9, 5.4 Hz), 2.77 (1 H, dd, J = 9.6, 6.9 Hz), 2.28 (3 H, s), 2.15
(1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylp-tolylcyclopropanecarboxam ide ( 18c)
Following method A from compound 17c. Purification by flash
silica column chromatography (gradient elution DCM to 5% MeOH in DCM)
followed by elution through PEAX cartridge (1 :1, DCM:MeOH) gave the title
compound as a white solid (21 mg, 17%). LCMS (ES+) 268 (M+H)+, RT 3.71 min
(Analytical method 1 ). NMR o (ppm)(DMSO-d5): 10.54 (1 H, s), 8.68 (1 H, s),
7.32 (2 H, d, J = 7.5 Hz), 7.25 (2 H, t, J = 7.4 Hz), 7.20-7.10 (5 H, m), 3.04 (1 H,
dd, J = 6.9, 5.4 Hz), 2.77 (1 H, dd, J = 9.6, 6.9 Hz), 2.28 (3 H, s), 2.15 (1 H, dd, J
= 9.6, 5.4 Hz).
Example 7
Reaction Scheme 7
CON HOH
( 1 R* ,2R* ,3R*)-Ethyl( 4-n itrophenyl )phenylcyclopropanecarboxylate ( 19)
A mixture of sulfonium salt 6a (1.00 g, 3.76 mmol) and ethyl
nitrocinnamate (553 mg, 2.51 mmol) in DCM (10 ml) was cooled to -78°C.
LiHMDS (3.76 ml, 1 M solution in THF) was slowly added via syringe pump (1
ml/h). After complete addition, the mixture was warmed to r.t., stirred for 1 h and
quenched with H20 (30 ml). The biphasic mixture was separated and the
aqueous layer was re-extracted with DCM (30 ml). The combined organic layers
were washed with water (50 ml) and brine (50 ml), dried (MgS04), filtered and
concentrated. Purification by flash silica column chromatography (gradient elution
i-hex to 5% EtOAc in i-hex) gave the title compound as a yellow oil (180 mg,
23%). lCMS (ES+) 312 (M+H(
( 1 R* ,2R* ,3R*)-Ethyl( 4-am inophenyl )phenylcyclopropanecarboxylate (20)
A solution of compound 19 (180 mg, 0.58 mmol) in MeOH (6 ml)
was hydrogenated using a H-cube apparatus (Full H2 mode, 10% Pd/C cartridge,
1 ml/min, r.t.). The reaction mixture was concentrated to give a yellow oil (165
mg, 100%) which was used directly in the next step of the synthesis.
(1R*,2R*,3R*)-Ethyl(4-(cyclopropanesulfonamido)phenyl)
phenylcyclopropanecarboxylate (21)
To a stirred solution of compound 20 (165 mg, 0.59 mmol) in DCM
(5 ml) was added cyclopropylsulfonyl chloride (248 mg, 1.76 mmol) and
triethylamine (0.24 ml, 1.76 mmol). The mixture was stirred at r.t. for 16 hand
washed with water (10 ml). The organic layers were collected by phase
separator and concentrated. Purification by flash silica column chromatography
(gradient elution i-hex to 50% EtOAc in i-hex) gave the title compound as a pale
yellow solid (175 mg, 77%). lCMS (ES+) 386 (M+H(
(1R*,2R*,3R*)(4-(cyclopropanesulfonamido)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide (22)
Following method A from compound 21 (175 mg, 0.45 mmol). The
carboxylic acid was obtained as the major product. The mixture was acidified
with aqueous 1 M HCI and extracted into EtOAc (3 x 10 ml). The organic layers
were combined, dried (MgS04) and concentrated. The sample was then
subjected to method B. Purification by preparative HPlC and passage through a
PEAX cartridge (DCM/MeOH, 1 :1) gave the title compound as a white solid (15
mg, 8%). lCMS (ES+) 373 (M+H)+, RT 8.20 min (Analytical method 3). NMR
o (ppm)(DMSO-d6): 10.55 (1 H, s), 9.62 (1 H, s), 8.68 (1 H, s), 7.33-7.13 (9 H,
m), 3.05 (1 H, dd, J = 6.9, 5.4 Hz), 2.79 (1 H, dd, J = 9.5, 6.9 Hz), 2.60-2.53 (1 H,
qt, J = 6.0 Hz), 2.15 (1 H, dd, J = 9.5, 5.3 Hz), 0.91 (4 H, d, J = 6.3 Hz).
Example 8
Reaction Scheme 8
QONHOH
Q02Et
~C02Et - /\
- R1~·,,R2
R1 R1~·,,R2 -
23a-e 24a-f 25a-f
Table 1
R1 R2 Compound R1 R2 Compoun
Ph 25a Ph 25d
Ph 25b Ph 25e
Ph 25c
(E )-Ethylcyclopentylacrylate (23a)
Following method C from cyclopentanecarbaldehyde (2.00 g, 20.4
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 5:2 i-hex:DCM) gave the title compound as a colourless oil (2.00 g, 58%).
LCMS (ES+) 259 (M+H(
(E)-Ethyl( 1-methyl-1 H-pyrazolyl )acrylate (23b)
[0021 O] Following method C from 1-methyl-1 H-pyrazolecarbaldehyde
(500 mg, 4.50 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to EtOAc) gave the title compound as a yellow oil (900 mg,
99%). LCMS (ES+) 181 (M+Ht_
(E)-Ethyl(pyrim id inyl )acrylate (23c)
Following method C from pyrimidinecarbaldehyde (2 g, 19.2
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 50% EtOAc in i-hex) gave the title compound as a colourless oil (2.34 g, 68%,
3:1 trans:cis). lCMS (ES+) 179 (M+Ht_
(E )-Ethyl(2,3-d ihydrobenzo[b] [1,4 ]dioxinyl )acrylate (23d)
Following method C from 2,3-dihydrobenzo[b][1,4]dioxine
carbaldehyde (2.00 g, 12.2 mmol). Purification by flash silica column
chromatography (gradient elution i-hex to 5% EtOAc in i-hex) gave the title
compound as a white solid (2.64 g, 93%). lCMS (ES+) 235 (M+Ht
(E )-Ethyl(8-chloro-2,3-d ihydrobenzo[b ][1 ,4 ]d ioxinyl )acrylate (23e)
Following method C from 8-chloro-2,3-dihydrobenzo[b][1,4]dioxine-
6-carbaldehyde (700 mg, 3.53 mmol). The resulting yellow oil was used without
further purification. lCMS (ES+) 269, 271 (M+Ht
( 1 S* ,2R* ,3R*)-Ethylcyclopentylphenylcyclopropanecarboxylate (24a)
A mixture of 6a (2.30 g, 8.92 mmol), compound 23a (1.00 g, 5.96
mmol) and 12-crown-4 (1.44 ml, 8.92 mmol) in DCM (20 ml) was cooled to -
78°C. LiHMDS (8.92 ml, 1 M solution in THF) was slowly added via syringe
pump (4 ml/h). After complete addition, the reaction mixture was warmed to r.t.
and stirred for 16 h. The reaction mixture was quenched with H20 (30 ml). The
biphasic mixture was separated and the organic layers washed with brine (2 x 30
ml), separated, dried (MgS04), filtered and concentrated. Purification by flash
silica column chromatography (gradient elution i-hex to 5% EtOAc in i-hex) gave
the title compound as a colourless oil (263 mg, 7%).
(1 R*,2R*,3R*)-Ethyl(1-methyl-1 H-pyrazolyl)
phenylcyclopropanecarboxylate (24b)
Following method F from compound 23b (810 mg, 4.50 mmol) and
6a (1.94 mg, 7.50 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 75% EtOAc in i-hex) gave the title compound as a
colourless oil (493 mg, 41%, 3:1 trans:cis). lCMS (ES+) 271 (M+Ht
( 1 R* ,2R* ,3R*)-Ethylphenyl(pyrim id inyl )cyclopropanecarboxylate (24c)
Following method F from 23c (1.00 g, 5.62 mmol) and 6a (2.18 g,
8.43 mmol). The addition was performed at -78°C and allowed to stir at RT for 17
h. Purification by flash silica column chromatography (gradient elution i-hex to
50% EtOAc in i-hex) gave the title compound as a colourless oil (270 mg, 19%).
lCMS (ES+) 269 (M+Ht_
( 1 R* ,2R* ,3R*)-Ethyl(2,3-d ihydrobenzo[b] [1 ,4 ]d ioxinyl )
phenylcyclopropanecarboxylate (24d)
Following method F from compound 23d (2.64 g, 11.3 mmol) and
6a (4.4 g, 16.9 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 7.5% EtOAc in i-hex) gave the title compound as a
colourless oil (652 mg, 18%). LCMS (ES+) 325 (M+Ht
(1 R*,2R*,3R*)-Ethyl(8-chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)
phenylcyclopropanecarboxylate (24e)
Following method F from 23e (946 mg, 3.52 mmol) and 6a (1.37
mg, 5.28 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 10% EtOAc in i-hex) gave the title compound as a colourless oil
(484 mg, 38%, 4:1 trans:cis). LCMS (ES+) 359, 361 (M+Ht_
(1 S*,2R*,3R*)-Ethyl(8-chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)(2-
fluorophenyl )-cyclopropanecarboxylate (24f)
Following method F from 23e (860 mg, 3.20 mmol) and 6b (1.33
mg, 4.80 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 10% EtOAc in i-hex) gave the title compound as a colourless oil
(472 mg, 39%, 3:1 trans:cis). LCMS (ES+) 377 (M+Ht RT 3.48 min (Analytical
method 1).
(1 S*,2R*,3R*)Cyclopentyl-N-hydroxyphenylcyclopropanecarboxamide (25a)
Using method A from compound 24a (1.05 g, 4.06 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 4%
MeOH in DCM) and preparative HPLC gave the title compound as a white solid
(23 mg, 9%). LCMS (ES+) 246 (M+H)+, RT 3.18 min (Analytical method 1 ).
NMR s (ppm)(DMSO-d6): 10.57 (1 H, s), 8.76 (1 H, s), 7.35-7.27 (2 H, m), 7.24-
7.18 (3 H, m), 1.88 (1 H, t, J = 5.0 Hz), 1.71-1.60 (1 H, m), 1.58-1.47 (2 H, m),
1.50-1.16 (8 H, m).
(1 R,2R,3R)-N-Hydroxy(1-methyl-1 H-pyrazolyl)
phenylcyclopropanecarboxam ide (25b)
Following method A from 24b (493 mg, 1.83 mmol). Purification
by flash silica column chromatography (gradient elution DCM to 5% MeOH in
DCM) and then preparative HPLC gave the racemic mixture as a white solid (235
mg, 50%). Preparative chiral HPLC gave the title compound (Chiralpak IC 30/70
IPNMeOH (50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 10.3 min). LCMS
(ES+) 258 (M+H)+, (ES-) 256 (M+H)-, RT 2.65 min (Analytical method 1 ).
NMR o (ppm)(DMSO-d5): 10.50 (1 H, s), 8.63 (1 H, s), 7.61 (1 H, s), 7.34 (1 H, s),
7.28-7.13 (5 H, m), 3.78 (3 H, s), 2.86 (1 H, dd, J = 6.9, 5.3 Hz), 2.63 (1 H, dd, J =
9.4, 6.9 Hz), 1.97 (1 H, dd, J = 9.4, 5.3 Hz).
( 1 R* ,2 R*, 3R*)-N-Hyd roxyphenyl(pyrim id inyl )cyclopropanecarboxam ide
(25c)
Using method A, from compound 24c (270 mg, 1.08 mmol).
Purification by flash silica chromatography gradient elution DCM to 7% MeOH in
DCM) and reversed phase HPLC gave the title compound as a yellow solid (9
mg, 5%). LCMS (ES+) 256 (M+H)+, RT 2.52 min (Analytical method 1 ). NMR
o (ppm)(DMSO-d5): 10.61 (1 H, s), 9.06 (1 H, s), 8.79 (2 H, s), 8.72 (1 H, s), 7.34
(2 H, d, J = 7.6 Hz), 7.27 (2 H, t, J = 7.5 Hz), 7.22-7.17 (1 H, m), 3.15 (1 H, dd, J
= 6.8, 5.5 Hz), 3.04 (1 H, dd, J = 9.6, 6.9 Hz), 2.37 (1 H, dd, J = 9.7, 5.5 Hz).
(1 R,2R,3R)(2,3-Dihydrobenzo[b][1,4]dioxinyl)-N-hydroxy
phenylcyclopropanecarboxam ide (25d)
Following method A from compound 24d (652 mg, 2.01 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (420 mg, 67%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 30/70 IPNMeOH
(50/50/0.1 % formic acid)/heptane, 1.0 ml/min, RT 8.1 min). LCMS (ES+) 312
(M+H)+, RT 8.59 min (Analytical method 5). NMR o (ppm)(DMSO-d6): 10.57
(1 H, s), 8.73 (1 H, s), 7.35 (2 H, d, J = 7.59 Hz), 7.29 (2 H, t, J = 7.5 Hz), 7.24-
7.17 (1 H, m), 6.85 (1 H, d, J = 8.5 Hz), 6.80-6.74 (2 H, m), 4.26 (4 H, s), 3.02 (1
H, dd, J = 6.8, 5.4 Hz), 2.78 (1 H, dd, J = 9.6, 6.8 Hz), 2.14 (1 H, dd, J = 9.6, 5.4
Hz).
(1 R,2R,3R)(8-Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)-N-hydroxy
phenylcyclopropanecarboxam ide (25e)
Following method A from 24e (484 mg, 1.35 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 5% MeOH in DCM)
and then preparative HPLC gave the the racemic product as a white solid (174
mg, 37%). Preparative chiral HPLC gave the title compound (Chiralpak IC 20/80
IPNMeOH (50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 10.4 min). LCMS
(ES+) 346, 348 (M+H)+, RT 3.57 min (Analytical method 1 ). NMR s
(ppm)(DMSO-d5): 10.50 (1 H, s), 8.68 (1 H, s), 7.31 (2 H, d, J = 7.6 Hz), 7.25 (2
H, t, J = 7.4 Hz), 7.21-7.13 (1 H, m), 6.93 (1 H, d, J = 2.1 Hz), 6.77 (1 H, d, J =
2.1 Hz), 4.34-4.26 (4 H, m), 3.00 (1 H, dd, J = 6.8, 5.4 Hz), 2.79 (1 H, dd, J = 9.6,
6.8 Hz), 2.14 (1 H, dd, J = 9.8, 5.4 Hz).
(1 S,2R,3R)(8-Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl)(2-fluorophenyl)-N
hydroxycyclopropanecarboxamide (25f)
Following method A from 24f (472 mg, 1.25 mmol) to yield a white
glass (480 mg). Purification by preparative HPLC gave the the racemic product
as a white glass (180 mg, 39%). Preparative chiral HPLC gave the title
compound (Chiralpak IA 50/50 EtOH (0.1 % formic acid)/Heptane, 1.0 ml/min).
LCMS (ES+) 364 (M+H)+, RT 3.60 min (Analytical method 1 ). NMR s
(ppm)(DMSO-d6): 10.55 (1 H, s), 8.72 (1 H, s), 7.38 (1 H, t, J = 7.6 Hz), 7.28-7.20
(1 H, m), 7.13-7.05 (2 H, m), 6.95 (1 H, d, J = 2.1 Hz), 6.80 (1 H, d, J = 2.1 Hz),
4.36-4.24 (4 H, m), 2.93 (1 H, dd, J = 6.9, 5.3 Hz), 2.72 (1 H, dd, J = 9.3, 6.9 Hz),
2.17 (1 H, dd, J = 9.4, 5.3 Hz).
Example 9
Reaction Scheme 9
QONHOH
Q02Et
R(L~.,'R2 Rp.,,R2
27a-g 28a-g
Table 2
R1 R2 Compound R1 R2 Compound
Ph 28a Ph 28e
Ph 28b Ph 28f
Ph 28g
(E)-Ethyl 3-(pyridazinyl)acrylate (26a)
Following method E from 4-bromopyridazine (500 mg, 3.14 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to
EtOAc) gave the title compound as a colourless oil (94 mg, 17%). LCMS (ES+)
179 (M+H(
(E)-Ethyl(2-cyclopropylpyridinyl)acrylate (26b)
Following method D from 4-bromo(cyclopropyl)pyridine (1.00 g,
.05 mmol). Purification by flash silica column chromatography (gradient elution
i-hex to 10% EtOAc in i-hex) gave the title compound as a white solid (530 mg,
48%). LCMS (ES+) 218 (M+Ht_
(E )-Ethyl(2,2-d ifluorobenzo[d] [1 ,3]d ioxolyl )acrylate (26c)
Following method E from 5-bromo-2,2-difluorobenzo[d][1,3]dioxole
(2.00 g, 8.44 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 7.5% EtOAc in i-hex) gave the title compound as a white solid
(1.62 g, 75%). LCMS (ES+) 257 (M+Ht_
(E )-Ethyl( 6-(trifl uoromethyl )pyrid inyl )acrylate (26d)
Following method D from 5-bromo(trifluoromethyl)pyridine (1.0 g,
4.42 mmol). Purification by flash silica column chromatography (gradient elution
i-hex to 10% EtOAc in i-hex) gave the title compound as a white solid (700 mg,
65%). LCMS (ES+) 246 (M+Ht_
(E)-Ethyl(2-(trifl uoromethyl )pyrid inyl )acrylate (26e)
Following method D from 4-bromo(trifluoromethyl)pyridine (1.0 g,
4.42 mmol). Purification by flash silica column chromatography (gradient elution
i-hex to 15% EtOAc in i-hex) gave the title compound as a white solid (100 mg,
9%). LCMS (ES+) 246 (M+Ht_
(1 R*,2R*,3R*)-Ethylphenyl(pyridazinyl)cyclopropanecarboxylate (27a)
Following method F from 26a (94 mg, 0.53 mmol) and 6a. As the
reaction was incomplete after 1 h, the reaction was cooled to -20°C and
additional amounts of sulfonium salt, 12-crown-4 and LiHMDS (0.5 eq each) were
added. Purification by flash silica column chromatography (gradient elution i-hex
to EtOAc) gave the title compound as a colourless oil (45 mg, 32%). LCMS
(ES+) 269 (M+H(
( 1 R*,2R*,3R*)-E thyl(2-cyclopropyl pyrid inyl )
phenylcyclopropanecarboxylate (27b)
Following method F from compound 26b (530 mg, 2.44 mmol) and
6a. Purification by flash silica column chromatography (gradient elution i-hex to
% EtOAc in i-hex) gave the title compound as a colourless oil (330 mg, 44%,
:4 trans:cis). LCMS (ES+) 308 (M+Ht_
( 1 S* ,2R* ,3R*)-Ethyl(2-cyclopropylpyrid inyl)(2-
fluorophenyl )cyclopropanecarboxylate (27 c)
Following method F from 26b (130 mg, 0.60 mmol) and 6b (249
mg, 0.90 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 25% EtOAc in i-hex) gave the title compound as a colourless oil
(150 mg, 77%, 3:1 trans:cis). LCMS (ES+) 326 (M+Ht_
( 1 R* ,2 R* ,3R*)-Ethyl(2-cyclopropyl pyrid inyl )( 4-
fluorophenyl )cyclopropanecarboxylate ( 27 d)
Following method F from 26b (481 mg, 2.22 mmol) and 6c (921
mg, 3.32 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 25% EtOAc in i-hex) gave the title compound as a colourless oil
(510 mg, 71 %, 4:1 trans:cis). LCMS (ES+) 326 (M+Ht_
( 1 R* ,2R* ,3R*)-Ethyl(2,2-d ifl uorobenzo[d] [1 ,3]d ioxolyl )
phenylcyclopropanecarboxylate (27e)
Following method F from compound 26c (1.62 g, 6.33 mmol) and
6a (2.46 g, 9.49 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 5% EtOAc in i-hex) gave the title compound as a
colourless oil (400 mg, 18%). LCMS (ES+) 347 (M+Ht
( 1 R* ,2R* ,3R*)-Ethylphenyl(6-(trifluoromethyl )pyrid in
yl )cyclopropanecarboxylate (27f)
Following method F from compound 26d (700 mg, 2.86 mmol) and
6a (1.11 g, 4.29 mmol). The reaction was incomplete after 2 h. The reaction was
cooled to 0°C and additional 1 equivalent of sulfonium salt, 12-crown-4 and
LiHMDS were added and the mixture was stirred at r.t. for 10 min. Purification by
flash silica column chromatography (gradient elution i-hex to 5% EtOAc in i-hex)
gave the title compound as a colourless oil (720 mg, 2:1 trans: cis, 65%). LCMS
(ES+) 322 (M+Ht_
( 1 R*,2R*,3R*)-Ethylphenyl(2-(trifl uoromethyl )pyrid in
yl )cyclopropanecarboxylate (27g)
Following method F from compound 26e (100 mg, 0.41 mmol) and
6a (159 mg, 0.61 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 10% EtOAc in i-hex) gave the title compound as a
colourless oil (130 mg, 2:1 trans: cis, 100%). LCMS (ES+) 322 (M+Ht
( 1 R*,2R*,3R*)-N-Hyd roxyphenyl(pyridazinyl )cyclopropanecarboxam ide
(28a)
Following method A, from 27a (45 mg, 0.17 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 4% MeOH in DCM)
and reversed phase HPLC gave the title compound as a white solid (3 mg, 21 %).
LCMS (ES+) 256 (M+H)+, RT 7.02 min (Analytical method 3). NMR s
(ppm)(DMSO-d 6 ): 10.69 (1 H, s), 9.34 (1 H, s), 9.15 (1 H, d, J = 5.4 Hz), 8.81 (1
H, s), 7.63-7.61 (1 H, m), 7.40-7.30 (4 H, m), 7.27-7.24 (1 H, m), 3.22 (1 H, dd, J
= 5.2, 6.4 Hz), 3.13 (1 H, dd, J = 6.4, 9.5 Hz), 2.45 (1 H, dd, J = 9.5, 5.3 Hz).
( 1 R,2R,3R)(2-Cyclopropyl pyrid inyl )-N-hyd roxy
phenylcyclopropanecarboxam ide (28b)
Following method A from compound 27b (330 mg, 1.07 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (60 mg, 19%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 30/70 IPNMeOH
(50/50/0.1 formic acid)/heptane, 1.0 ml/min, RT 9.6 min). LCMS (ES+) 295
(M+H)+, (ES-) 293 (M-H)-, RT 2.12 min (Analytical method 1). NMR s
(ppm)(DMSO-d 6 ): 10.65 (1 H, s), 8.78 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz), 7.37 (2
H, d, J = 7.6 Hz), 7.34-7.28 (2 H, m), 7.25 (2 H, d, J = 8.2 Hz), 7.07 (1 H, dd, J =
.2, 1.7 Hz), 3.10 (1 H, dd, J = 6.7, 5.6 Hz), 2.99 (1 H, dd, J = 9.7, 6.7 Hz), 2.34
(1 H, dd, J = 9.7, 5.6 Hz), 2.12-2.07 (1 H, m), 0.98-0.93 (4 H, m).
(1 S,2R,3R)(2-Cyclopropylpyridinyl)(2-fluorophenyl)-N
hydroxycyclopropanecarboxam ide (28c)
Following method A from 27c (150 mg, 0.46 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 5% MeOH in DCM)
gave the racemic mixture as an off-white solid (50 mg, 35%). Preparative chiral
HPLC gave the title compound (Chiralpak IC 40/60 EtOH (0.1 formic
acid)/heptanes, 1.0 ml/min, RT 9.3 min). LCMS (ES+) 313 (M+H)+, RT 2.18 min
(Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.68 (1 H, s), 8.81 (1 H, s),
8.34 (1 H, d, J = 5.1 Hz), 7.44 (1 H, t, J = 7.7 Hz), 7.34-7.27 (2 H, m), 7.18-7.08
(3 H, m), 3.04 (1 H, dd, J = 6.6, 5.0 Hz), 2.95 (1 H, dd, J = 9.2, 6.9 Hz), 2.36 (1 H,
dd, J = 9.4, 5.3 Hz), 2.14-2.09 (1 H, m), 0.99-0.92 (4 H, m).
( 1 R,2R,3R)(2-Cyclopropyl pyrid inyl )( 4-fl uorophenyl )-N
hyd roxycyclopropanecarboxam ide (28d)
Following method A from 27d (510 mg, 1.57 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 5% MeOH in DCM)
gave the racemic mixture as a white solid (145 mg, 30%). Preparative chiral
HPLC gave the title compound (Chiralpak IC 20/80 IPA/MeOH (50/50/0.1 %
formic acid)/Heptane, 1.0 ml/min, RT 13.7 min). LCMS (ES+) 313 (M+H)+, RT
2.87 min (Analytical method 4). NMR o (ppm)(DMSO-d6): 10.65 (1 H, br s),
8.82 (1 H, br s), 8.33 (1 H, d, J = 5.1 Hz), 7.40 (2 H, dd, J = 8.4, 5.6 Hz), 7.25 (1
H, s), 7.14 (2 H, t, J = 8.8 Hz), 7.07 (1 H, dd, J = 5.2, 1.7 Hz), 3.07 (1 H, dd, J =
6.8, 5.4 Hz), 2.99 (1 H, dd, J = 9.6, 6.8 Hz), 2.32 (1 H, dd, J = 9.6, 5.4 Hz), 2.14-
2.06 (1 H, m), 0.99-0.92 (4 H, m).
(1 R,2R,3R)(2,2-Difluorobenzo[d][1,3]dioxolyl)-N-hydroxy
phenylcyclopropanecarboxam ide (28e)
Following method A from compound 27e (400 mg, 1.17 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 2%
MeOH in DCM) gave the the racemic mixture as a white solid (300 mg, 78%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 20/80 IPNMeOH
(50/50/0.1 % formic acid)/Heptane, 1.5 ml/min, RT 6.3 min). LCMS (ES+) 334
(M+H)+, RT 3.89 min (Analytical method 1). NMR s (ppm)(DMSO-d6): 10.63
(1 H, s), 8.76 (1 H, s), 7.44-7.33 (4 H, m), 7.31 (2 H, t, J = 7.44 Hz), 7.25-7.18 (2
H, m), 3.21 (1 H, dd, J = 6.8, 5.4 Hz), 2.92 (1 H, dd, J = 9.6, 6.8 Hz), 2.25 (1 H,
dd, J = 9.6, 5.4 Hz).
(1 R,2R,3R)-N-Hydroxyphenyl(6-(trifluoromethyl)pyridin
yl )cyclopropanecarboxam ide (28f)
Following method A from compound 27f (720 mg, 2.24 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) followed by preparative HPLC, gave the racemic mixture as a
white solid (83 mg, 11 % ). Preparative chiral HPLC gave the title compound
(Chiralpak IC 20/80 IPNMeOH (50/50/0.1 formic acid)/heptane, 1.0 ml/min, RT
14.5 min). LCMS (ES+) 323 (M+H)+, RT 8.60 min (Analytical method 3).
NMR o (ppm)(DMSO-d 6 ): 10.70 (1 H, s), 8.84 (1 H, s), 8.82 (1 H, s), 8.02-7.97 (1
H, m), 7.91 (1 H, d, J = 8.2 Hz), 7.40 (2 H, d, J = 7.6 Hz), 7.33 (2 H, t, J = 7.5 Hz),
7.28-7.22 (1 H, m), 3.32 (1 H, dd, J = 6.7 and 5.6 Hz), 3.09 (1 H, dd, J = 9.7, 6.8
Hz), 2.43 (1 H, dd, J =9.7 and 5.6 Hz).
(1 R,2R,3R)-N-Hydroxyphenyl(2-(trifluoromethyl)pyridin
yl)cyclopropanecarboxamide (28g)
Following method A from compound 27g (130 mg, 0.41 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) followed by preparative HPLC, gave the racemic mixture as a
white solid (90 mg, 68%). Preparative chiral HPLC gave the title compound
(Chiralpak IC 20/80 IPNMeOH (50/50/0.1 formic acid)/heptane, 1.0 ml/min, RT
.3 min). LCMS (ES+) 323 (M+H)+, RT 3.50 min (Analytical method 1).
NMR o (ppm)(DMSO-d 6 ): 10.66 (1 H, s), 8.81 (1 H, s), 8.71 (1 H, d, J = 5.0 Hz),
7.92 (1 H, s), 7.70 (1 H, d, J = 5.1 Hz), 7.40 (2 H, d, J = 7.5 Hz), 7.32 (2 H, t, J =
7.5 Hz), 7.27-7.22 (1 H, m), 3.35 (1 H, dd, J = 6.6, 5.4 Hz), 3.16 (1 H, dd, J = 9.5,
6.6 Hz), 2.48 (1 H, dd, J = 9.5, 5.4 Hz).
Example 10
Reaction Scheme 10
4-Bromo(hydroxymethyl)-N-(2,2,2-trifluoroethyl)benzamide (29)
To a stirred suspension of aluminium trichloride (5.30 g, 39.8 mmol)
in DCE (50 ml) at 0°C was added 2,2,2-trifluoroethylamine (5 g, 50.5 mmol).
This was stirred for 4 h before addition of 5-bromophthalide (5.30 g, 39.8 mmol)
in one portion, and then heated to 80°C for 17 h. The mixture was quenched with
iced water (100 ml) and stirred for 30 min. DCM (50 ml) was added and the
mixture was filtered through silica. The organic layers were washed with H20 (3 x
100 ml) and the aqueous layers were back-extracted into DCM (50 ml). The
combined organic layers were dried (MgS04), filtered and concentrated to give an
off-white solid. The crude mixture (2.2 g) containing -50% residual 5-
bromophthalide was progressed to the next step. lCMS (ES+) 312, 314 (M+Ht
-Bromo(2,2,2-trifluoroethyl )isoindol inone (30)
To a stirred solution of 29 (2.2 g, 7.05 mmol) and NMP (13 ml) in
anhydrous THF (40 ml) at 5°C was added i-PrMgCl.LiCI (10.8 ml, 14.1 mmol)
keeping the temperature below 10°C. After addition (30 min), the reaction was
stirred at 5°C for 1 hand at r.t. for 1 h. The reaction was then cooled to 5°C and
N,N,N',N'-tetramethyphosphorodiamidic chloride (1.57 ml, 10.6 mmol) was
added dropwise. The reaction mixture was heated at reflux for 2 days. The
mixture was cooled, quenched with H20 (50 ml), acidified with aqueous 1 M HCI
and extracted into EtOAc (3 x 50 ml). The organic layers were dried (MgS04),
filtered and concentrated. Purification by flash silica column chromatography
(gradient elution i-hex to 20% EtOAc in i-hex) gave the title compound as a white
solid (3 g). The crude material was used in the next step. lCMS (ES+) 294, 296
(M+Ht_
(E)-Ethyl 3-(1-oxo(2,2,2-trifluoroethyl)isoindolinyl)acrylate (31)
A stirred mixture of 30 (2.96 g, 10.0 mmol), ethyl acrylate (1.62 ml,
.0 mmol), palladium acetate (224 mg, 1.00 mmol), P(o-tol)3 (608 mg, 2.00
mmol) and triethylamine (2.78 ml, 20.0 mmol) in MeCN (50 ml) was degassed
under nitrogen for 15 min and heated to 80°C for 3 h. An additional amount of
palladium acetate (224 mg, 1.00 mmol), P(o-tol), (608 mg, 2.00 mmol) and ethyl
acrylate (1.00 ml, 9.26 mmol) were added and stirred at 80°C for a further 2 h.
The reaction mixture was cooled and the MeCN was removed in vacuo. The
residue was partitioned between DCM and H20 and the organic layers were
passed through a phase separator and concentrated. Purification by flash silica
column chromatography (gradient elution i-hex to 75% EtOAc in i-hex) gave the
title compound as a white solid (1.7 g). The crude material was used in the next
step. LCMS (ES+) 314 (M+Ht.
( 1 R* ,2R* ,3R*)-Ethyl( 1-oxo(2,2,2-trifluoroethyl )isoindol inyl )
phenylcyclopropanecarboxylate (32)
Following method F from 31 (1.70 g, 5.40 mmol) and 6a (2.10 g,
8.10 mmol). Purification by flash silica column chromatography (gradient elution
i-hex to 15% EtOAc in i-hex) gave the title compound as a white solid (340 mg).
LCMS (ES+) 404 (M+Ht_
(1 R,2R,3R)-N-Hydroxy(1-oxo(2,2,2-trifluoroethyl)isoindolinyl)
phenylcyclopropanecarboxam ide (33)
Following method A from 32 (340 mg, 0.84 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 6% MeOH in DCM)
and then preparative HPLC gave the racemic mixture as a white solid.
Preparative chiral HPLC gave the title compound (Chiralpak IC 30/70 EtOH (0.1
formic acid)/heptanes, 1.0 ml/min, RT 12.1 min). LCMS (ES+) 391 (M+H)+, RT
3.47 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.61 (1 H, s), 8.72
(1 H, s), 7.70 (1 H, d, J = 7.9 Hz), 7.56 (1 H, s), 7.45 (1 H, d, J = 8.0 Hz), 7.35 (2
H, d, J = 7.6 Hz), 7.27 (2 H, t, J = 7.5 Hz), 7.19 (1 H, t, J = 7.2 Hz), 4.60 (2 H, s),
4.39 (2 H, q, J = 9.7 Hz), 3.24 (1 H, dd, J = 6.8, 5.4 Hz), 2.93 (1 H, dd, J = 9.7,
6.8 Hz), 2.30 (1 H, dd, J = 9.7, 5.4 Hz).
Example 11
Reaction Scheme 11
C02Et
"'ff''p'
H2N 36
J d C02Et
gONHOH
"'ff''ph
N 37
(E )-Ethyl(3-bromon itrophenyl )acrylate (34)
Following method C from 3-bromonitrobenzaldehyde (5 g, 21.7
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 10% EtOAc in i-hex) gave the title compound (2.4 g, 37%). lCMS (ES+) 300,
302 (M+H(
( 1 R* ,2R* ,3R*)- E thyl(3-bromon itrophenyl )phenylcyclopropanecarboxylate
(35)
Following method F from compound 34 (2.35 g, 7.8 mmol) and 6a
(4.04 g, 15.6 mmol). The reaction was incomplete after stirring at r.t. for 72 h.
The reaction was cooled to -20°C and an additional 1 equivalent of sulfonium salt,
12-crown-4 and LiHMDS were added and the mixture was stirred at r.t. for 3 h.
Purification by flash silica column chromatography (gradient elution i-hex to 5%
EtOAc in i-hex) gave the title compound as a yellow oil (630 mg, 21 %). lCMS
(ES+) 390, 391 (M+Ht_
( 1 R* ,2R* ,3R*)- Ethyl( 4-am inobromophenyl )
phenylcyclopropanecarboxylate (36)
To a solution of compound 35 (580 mg, 1.51 mmol) in ethanol (12
ml) and acetic acid (12 ml) was added iron powder (824 mg, 15.1 mmol) and the
reaction mixture was stirred at r.t. for 3 h. The reaction mixture was filtered
through Celite and concentrated. The residue was partitioned between 1 N HCI
and DCM-MeOH. The aqueous layer was extracted several times with DCM.
The combined organic layers were concentrated to afford the title compound (470
mg, 88%). lCMS (ES+) 360, 362 (M+Ht_
( 1 R* ,2R* ,3R*)- Ethyl(3-bromoisobutyram idophenyl )
phenylcyclopropanecarboxylate (37)
To a solution of compound 36 (470 mg, 1.31 mmol) in DCM (10 ml)
was added DIPEA (0.23 ml, 1.31 mmol) and isobutyryl chloride (140 mg, 1.31
mmol). The reaction mixture was stirred for 2 h, water was added, the organic
phase isolated by phase separator and concentrated to afford the title compound
(488 mg, 87%). lCMS (ES+) 430, 432 (M+Ht_
(1 R*,2R*,3R*)- Ethyl(2-isopropylbenzo[d]oxazolyl)
phenylcyclopropanecarboxylate (38)
A mixture of compound 37 (488 mg, 1.14 mmol), K2C03 (314 mg,
2.28 mmol), pyridine (5 ml) in DMF (15 ml) was degassed for 30 min. Then
copper(l)bromide (326 mg, 2.28 mmol) was added and the reaction mixture was
heated under microwave irradiation at 140 °C for 4 h. The reaction mixture was
diluted with DCM and washed several times with water and brine. The organic
layers were combined, dried (MgS04), filtered and concentrated. Purification by
flash silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex)
gave the title compound (350 mg, 88%) as a yellow oil. lCMS (ES+) 350, 352
(M+Ht_
(1 R,2R,3R)-N-hydroxy(2-isopropylbenzo[d]oxazolyl)
phenylcyclopropanecarboxam ide (39)
Following method A from compound 38 (350 mg, 1.00 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a tan solid (126 mg, 36%).
Preparative chiral HPlC gave the title compound (Chiralpak IC, 20/80 EtOH
(0.1%formic)/heptane,1.0 ml/min, RT 15.7 min). lCMS (ES+) 337 (M+H)+, RT
3.59 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.63 (1 H, s), 8.76
(1 H, s), 7.66-7.64 (2 H, m), 7.39 (2 H, d, J = 7.60 Hz), 7.35-7.29 (3 H, m), 7.26-
7.20 (1 H, m), 3.36-3.23 (2 H, m), 2.96 (1 H, dd, J = 9.6, 6.9 Hz), 2.30 (1 H, dd, J
= 9.6, 5.4 Hz), 1.42 (6 H, d, J = 6.9 Hz).
Example 12
Reaction Scheme 12
CONHOH
~)-v6''eh
3-Br, R1=Et,15b 3-0xazole, R1 = Et, 40a 3-0xazole, 41a
4-0xazole, 41b
4-Br, R1 =Me, 15c 4-0xazole, R1 =Me, 40b
( 1 R*,2R*,3R*)-Ethyl(3-( oxazolyl )phenyl )phenylcyclopropanecarboxylate
(40a)
A stirred solution of 15b (500 mg, 1.45 mmol), oxazole (0.19 ml,
2.90 mmol), Pd(OAc)2 (16 mg, 0.07 mmol), di-terl-butyl(2',4',6'-triisopropyl-
3,4,5,6-tetramethylbiphenylyl)phosphine (67 mg, 0.14 mmol), K2C03 (600 mg,
4.35 mmol), pivalic acid (59 mg, 0.58 mmol) in OMA (8 ml) was degassed with
nitrogen for 15 min before heating at 110°C for 16 h. The mixture was cooled
and diluted with DCM (20 ml) and washed with H20 (3 x 30 ml). The organic
layers were passed through a phase separator and concentrated. Purification by
flash silica column chromatography (gradient elution i-hex to 25% EtOAc in i-hex)
gave the title compound as a colourless oil (494 mg, 100%). lCMS (ES+) 334
(M+Ht_
( 1 R*,2R*,3R*)-Methyl 2-( 4-( oxazolyl )phenyl )phenylcyclopropanecarboxylate
(40b)
A stirred solution of 15c (482 mg, 1.46 mmol), oxazole (0.19 ml,
2.42 mmol), Pd(OAc)2 (16 mg, 0.07 mmol), di-terl-butyl(2',4',6'-triisopropyl-
3,4,5,6-tetramethylbiphenylyl)phosphine (70 mg, 0.146 mmol), K2C03 (604 mg,
4.38 mmol), pivalic acid (59 mg, 0.58 mmol) in OMA (7.5 ml) was degassed with
nitrogen for 15 min before heating at 110°C for 16 h. The mixture was cooled
and diluted with DCM (20 ml) and washed with H20 (3 x 30 ml). The organic
layers were passed through a phase separator and concentrated. Purification by
flash silica column chromatography (gradient elution i-hex to 25% EtOAc in i-hex)
gave the title compound as a colourless oil (300 mg, 65% ). lCMS (ES+) 320
(M+Ht_
( 1 R,2R,3R)-N-Hydroxy(3-(oxazolyl )phenyl )
phenylcyclopropanecarboxam ide ( 41 a)
Following method A from compound 40a (482 mg, 1.45 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (233 mg, 50%).
Preparative chiral HPlC gave the title compound (Chiralpak IC 40/60 EtOH (0.1
formic acid)/heptane, 1.0 ml/min, RT 7.7 min). lCMS (ES+) 321 (M+H)+, RT
2.82 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.62 (1 H, s), 8.76
(1 H, s), 8.52 (1 H, s), 7.80 (1 H, s), 7.70 (1 H, s), 7.64 (1 H, d, J = 7.8 Hz), 7.49
(1 H, t, J = 7.7 Hz), 7.42-7.28 (5 H, m), 7.24 (1 H, t, J = 7.2 Hz), 3.22 (1 H, dd, J =
6.9, 5.4 Hz), 2.98 (1 H, dd, J = 9.6, 6.9 Hz), 2.32 (1 H, dd, J = 9.6, 5.4 Hz).
(1 R,2R,3R)-N-Hydroxy(4-(oxazolyl)phenyl)
phenylcyclopropanecarboxam ide ( 41 b)
Following method A from compound 40b. Purification by flash
silica column chromatography (gradient elution DCM to 5% MeOH in DCM) gave
the racemic mixture as a white solid (88 mg, 29%). Preparative chiral HPlC gave
the title compound (Chiralpak IC 20/80 EtOH (0.1 formic acid)/heptane, 1.0
ml/min, RT 18.7 min). lCMS (ES+) 321 (M+H)+, RT 2.77 min (Analytical
method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.63 (1 H, s), 8.76 (1 H, s), 8.49 (1 H,
s), 7.76-7.72 (3 H, m), 7.47-7.36 (4 H, m), 7.35-7.29 (2 H, m), 7.25-7.20 (1 H, m),
3.18 (1 H, dd, J = 6.8, 5.4 Hz), 2.94 (1 H, dd, J = 9.6, 6.8 Hz), 2.30 (1 H, dd, J =
9.6, 5.4 Hz).
Example 13
Reaction Scheme 13
(;:ONHOH
0ff···o
ff···o
N N 42
Br 1 Sc
\:::::l
(1 R*,2R*,3R*)(4-(1 H-imidazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 42)
A stirred solution of 15c (100 mg, 0.30 mmol), CuCI (3 mg, 0.03
mmol) and K2C03 (41 mg, 0.30 mmol) in NMP (0.1 ml) was degassed with
nitrogen before addition of acetylacetone (7 µI, 0.075 mmol) and imidazole (26
mg, 0.39 mmol). The mixture was stirred at 130°C for 17 h, cooled to r.t., diluted
with DCM and washed with 1 M NaHC03 (2 x 20 ml). The organic layers were
passed through a phase separator and concentrated (150 mg). The crude
material was dissolved in THF:MeOH (1 :1, 3 ml) and hydroxylamine (0.1 ml,
50% aqueous solution, 1.51 mmol) and potassium hydroxide (67 mg, 1.20 mmol)
were added. The mixture was stirred at r.t. for 2 h. ,neutralized with 1 M HCI and
extracted into EtOAc. The organic layers were concentrated and the residue re
dissolved in pyridine (1 ml). To this solution was added hydroxylamine
hydrochloride (20 mg, 0.29 mmol), BOP (87 mg, 0.20 mmol) and triethylamine
(82 µI, 0.59 mmol). The mixture was stirred at r.t. for 2 h, concentrated and
partitioned between DCM and H20. The organic layers were isolated by phase
separator and concentrated. Purification by preparative HPlC gave the racemic
mixture as a white solid (10 mg, 11%over3 steps). lCMS (ES+) 320 (M+H)+,
RT 2.24 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.58 (1 H, s),
8.71 (1 H, s), 8.30 (1 H, s), 7.77 (1 H, s), 7.62 (2 H, d, J = 8.1 Hz), 7.43 (2 H, d, J
= 8.1 Hz), 7.35 (2 H, d, J = 7.6 Hz), 7.31-7.24 (2 H, m), 7.22-7.16 (2 H, m), 3.17
(1 H, dd, J = 6.8, 5.4 Hz), 2.89 (1 H, dd, J = 9.6, 6.9 Hz), 2.24 (1 H, dd, J = 9.5,
.3 Hz).
Example 14
Reaction Scheme 14
[>--cN pl Br
- ~/o ~ -
v-\' I
N Nol
43 N
-( 4-Bromophenyl )cyclopropyloxazole ( 43)
Triflic acid (18.6 ml, 0.113 mol) was added dropwise to a solution
of thallium acetate (14.37 g, 0.037 mol) in cyclopropylnitrile (200 ml) at r.t. under
nitrogen. The solution was stirred for 15 min before a solution of 4-
bromoacetophenone in cyclopropylnitrile (120 ml) was added and the solution
was heated to 90°C for 2 h. The reaction mixture was concentrated and the red
residue was taken up in DCM (500 ml), washed with saturated NaHC03 and
water. The organic layers were separated, dried (Mg2S04), filtered and
concentrated to give a dark red gum. Purification by flash silica column
chromatography (gradient elution i-hex to 40% EtOAc in i-hex) gave the title
compound as a pale yellow solid (3.97 g, 60%). lCMS (ES+) 264, 266 (M+Ht
(E )-Ethyl( 4-(2-cyclopropyloxazolyl )phenyl )acrylate ( 44)
Compound 43 (3.97 g, 15 mmol), ethyl acrylate (2.1 ml, 19.5
mmol), Pd(OAc)2 (337 mg, 1.5 mmol), tri-orlho-tolylphoshine (915 mg, 3 mmol),
triethylamine (4.2 ml, 30 mmol) in MeCN (55 ml) were degassed with nitrogen
for 15 min before heating the mixture to 80°C for 18 h. The reaction mixture was
concentrated and the brown residue was taken up in DCM (150 ml), washed with
water, separated, dried (Mg2S04), filtered and concentrated to give a brown gum.
Purification by flash silica column chromatography (gradient elution i-hex to
EtOAc) gave the title compound as a pale yellow solid (3.44 g, 80%). lCMS
(ES+) 284 (M+H(
( 1 R* ,2R* ,3R*)-Ethyl( 4-(2-cyclopropyloxazolyl )phenyl )
phenylcyclopropanecarboxylate (45)
Following method F from compound 44 (360 mg, 1.27 mmol) and
6a (494 mg, 1.91 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 25% EtOAc in i-hex) gave the title compound as a
colourless oil (300 mg, 7:2, trans:cis, 63%). lCMS (ES+) 374 (M+Ht
(1 R,2R,3R)(4-(2-Cyclopropyloxazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 46)
Following method A from compound 45 (300 mg, 0.80 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 3%
MeOH in DCM) gave the racemic mixture as a white solid (300 mg, 78%).
Preparative chiral HPlC gave the title compound (Chiralpak IC 30/70 EtOH (0.1
formic acid)/heptane, 1.0 ml/min, RT 19.8 min). lCMS (ES+) 361 (M+H)+, (ES-)
359 (M-H)-, RT 3.67 min (Analytical method 1 ). NMR s (ppm)(DMSO-d 6 ):
.62 (1 H, s), 8.76 (1 H, s), 7.65 (2 H, d, J = 8.2 Hz), 7.52 (1 H, s), 7.42-7.35 (4
H, m), 7.31 (2 H, t, J = 7.5 Hz), 7.23 (1 H, t, J = 7.2 Hz), 3.17 (1 H, dd, J = 6.9, 5.4
Hz), 2.92 (1 H, dd, J = 9.7, 6.9 Hz), 2.28 (1 H, dd, J = 9.6, 5.4 Hz), 2.23-2.17 (1
H, m), 1.15-1.08 (2 H, m), 1.09-1.03 (2 H, m).
Example 15
Reaction Scheme 15
<;;;ON HOH
- O;t: .,,Ph
Ph\( I
N 48
( 1 R* ,2R* ,3R*)-Methylphenyl( 4-(2-phenyloxazol
yl )phenyl )cyclopropanecarboxylate (47)
Compound 40b (75 mg, 0.23 mmol), pivalic acid (14 mg, 0.14
mmol), potassium tert-butoxide (78 mg, 0.69 mmol) and RuPhos (16 mg, 0.034
mmol) were dissolved in dry toluene (5 ml) and the reaction flask was evacuated
and back-filled with nitrogen three times. Pd(OAc)2 (4 mg, 0.017 mmol) and
bromobenzene (54 mg, 0.34 mmol) were then added and the mixture was heated
to 110°C overnight. The reaction mixture was cooled and treated with 0.1 M HCI
(5 ml) and extracted with Et20 (3 x 10 ml). The combined organic layers were
dried (MgS04), filtered and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 50% EtOAc in i-hex) gave the title
compound as a colourless oil (22 mg, 26%). LCMS (ES+) 396 (M+Ht.
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(2-phenyloxazol
yl )phenyl )cyclopropanecarboxam ide ( 48)
Following method A from compound 47 (22 mg, 0.06 mmol).
Purification by preparative HPLC gave the title compound as a white solid (16
mg, 70%). LCMS (ES+) 397 (M+H)+, RT 4.09 min (Analytical method 1 ).
NMR o (ppm)(DMSO-d 6 ): 10.58 (1 H, s), 8.71 (1 H, s), 8.12-8.08 (2 H, m), 7.81 (3
H, d, J = 8.2 Hz), 7.62-7.54 (3 H, m), 7.42 (2 H, d, J = 8.0 Hz), 7.36 (2 H, d, J =
7.6 Hz), 7.31-7.23 (2 H, m), 7.22-7.15 (1 H, m), 3.17 (1 H, dd, J = 6.8, 5.3 Hz),
2.91 (1 H, dd, J = 9.6, 6.8 Hz), 2.27 (1 H, dd, J = 9.6, 5.3 Hz).
Example 16
Reaction Scheme 16
CON HOH
SOa-1
3-Br, R1 = Et, 1 Sb 49a-l
4-Br, R1=Me,15c
Table 3
3 or4 3 or4
R2 Compound R2 Compound
Substitution Substitution
4 50a 4 50g
3 50b 4 50h
4 50c 4 50i
4 4 50j
J:'Y\ 4 50e 4 50k
J:'Y\
4 50f 4 501
)-~H
(1 R*,2R*,3R*)-Methyl 2-(4-(5-fluoropyrimidinyl)phenyl)
phenylcyclopropanecarboxylate (49a)
Following method G from the crude boronate derived from 15c
(250 mg) and 2-chlorofluoropyrimidine (91 mg, 0.69 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex)
gave the title compound as a colourless oil (240 mg, 100%). LCMS (ES+) 349
(M+Ht.
( 1 R* ,2R* ,3R*)-Ethyl(3-( 5-fluoropyrim id inyl )phenyl )
phenylcyclopropanecarboxylate ( 49b)
Following method G from the crude boronate derived from 15b
(300 mg) and 2-chlorofluoropyrimidine (107 mg, 0.81 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex)
gave the title compound as a colourless oil (140 mg, 50%). LCMS (ES+) 363
(M+Ht.
(1 R*,2R*,3R*)-Methyl(4-(5-cyclopropylpyrimidinyl)phenyl)
phenylcyclopropanecarboxylate ( 49c)
Following method G from the crude boronate derived from 15c
(250 mg) and 2-bromocyclopropylpyrimidine (137 mg, 0.69 mmol). Purification
by flash silica column chromatography (gradient elution i-hex to 10% EtOAc in i
hex) gave the title compound as a colourless oil (240 mg, 98%). LCMS (ES+)
371 (M+H(
( 1 R* ,2 R* ,3R*)-Methylphenyl( 4-( 4-(trifl uoromethyl )pyrim id in
yl )phenyl )cyclopropanecarboxylate ( 49d)
Following method G from the crude boronate derived from 15c
(250 mg) and 2-chlorotrifluoromethylpyrimidine (126 mg, 0.69 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 10%
EtOAc in i-hex) gave the title compound as a colourless oil (220 mg, 84%).
LCMS (ES+) 399 (M+H(
( 1 R* ,2 R* ,3R*)-Methylphenyl( 4-( 5-(trifl uoromethyl )pyrim id in
yl )phenyl )cyclopropanecarboxylate ( 49e)
Following method G from the crude boronate derived from 15c
(480 mg) and 2-chlorotrifluoromethylpyrimidine (243 mg, 1.33 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 20%
EtOAc in i-hex) gave the title compound as a white solid (180 mg, 36%). LCMS
(ES+) 399 (M+H(
( 1 R* ,2R* ,3R*)-Methylphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide ( 49f)
Following method G from the crude boronate derived from 15c
(400 mg), and 3-bromopyridazine (160 mg, 1.00 mmol). Purification by flash
silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex) gave
the title compound as a colourless oil (220 mg, 84%). LCMS (ES+) 331 (M+Ht.
( 1 R* ,2R* ,3R*)-Methylphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide (49g)
Following method G from the crude boronate derived from 15c
(400 mg), and 4-bromopyridazine (160 mg, 1.00 mmol). Purification by flash
silica column chromatography (gradient elution i-hex to 10% EtOAc in i-hex) gave
the title compound as a pale yellow solid (210 mg, 61 %). LCMS (ES+) 331
(M+Ht.
( 1R*,2R*,3R*)-Methylphenyl(4-(pyrim id in
yl )phenyl )cyclopropanecarboxylate ( 49h)
Following method G from the crude boronate derived from 15c
(274 mg), and 2-chloropyrimidine (87 mg, 0.76 mmol). Purification by flash silica
column chromatography (gradient elution i-hex to 25% EtOAc in i-hex) gave the
title compound as a pale yellow oil (110 mg, 46%). LCMS (ES+) 331 (M+Ht.
( 1 R* ,2R* ,3R*)-Methylphenyl( 4-(pyrim id in
yl )phenyl )cyclopropanecarboxylate ( 49i)
To a stirred solution of 15c (130 mg, 0.39 mmol) in MeOH:DME
(1 :5, 5 ml), was added Pd(PPh3)4 (45 mg, 0.039 mmol), cesium fluoride (119 mg,
0.78 mmol) and 5-pyrimidine boronic acid (58 mg, 0.47 mmol). The mixture was
degassed with nitrogen for 15 min before heating in the microwave at 120°C for 1
h. The reaction mixture was diluted with H20 (10 ml) and extracted into DCM
(50 ml). The organic layers were dried over MgS04, filtered and concentrated.
Purification by column chromatography (gradient elution i-hex to 5% EtOAc in i
hex) gave the title compound as a colourless oil (120 mg, 93%). lCMS (ES+)
331 (M+H(
( 1 R* ,2 R* ,3R*)-Methyl( 4-( 5-ch loropyrim id inyl )phenyl )
phenylcyclopropanecarboxylate (49j)
Following method G from the crude boronate derived from 15c (1.5
mmol), and 2,5-dichloropyrimidine (298 mg, 2.00 mmol). Purification by flash
silica column chromatography (gradient elution i-hex to 50% EtOAc in i-hex) gave
the title compound as a pale yellow oil (305 mg, 56%). lCMS (ES+) 365 (M+Ht.
( 1 R* ,2 R* ,3R*)-Methyl( 4-( 5-methyl pyrim id inyl )phenyl )
phenylcyclopropanecarboxylate (49k)
Following method G from the crude boronate derived from 15c
(250 mg), and 2-chloromethylpyrimidine (89 mg, 0.69 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 25% EtOAc in i-hex)
gave the title compound as a pale yellow oil (180 mg, 79%). lCMS (ES+) 345
(M+Ht.
( 1 R* ,2R* ,3R*)-Methyl( 4-( 5-methyl-1 H-im idazolyl )phenyl )
phenylcyclopropanecarboxylate (491)
Following method G from crude boronate derived from 15c (1.5
mmol) and 2-bromomethylimidazole (242 mg, 1.5 mmol). The mixture was
stirred at 100°C for 48 h, diluted with H20 (20 ml) and extracted into DCM (50
ml). The layers were passed through a phase separator and concentrated.
Purification Following flash silica column chromatography (gradient elution
DCM/MeOH 0% to 10%) gave the ester intermediate as a yellow oil (285 mg).
The crude material was used in the next step. lCMS (ES+) 335 (M+H(
(1 R*,2R*,3R*)(4-(5-Fluoropyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 50a)
Following method A from compound 49a (220 mg, 0.63 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the title compound as a white solid (81 mg, 37%). lCMS
(ES+) 350 (M+H)+, RT 3.13 min (Analytical method 1). NMR o(ppm)(DMSO
d 6 ): 10.58 (1 H, s), 8.97 (2 H, d, J = 0.8 Hz), 8.70 (1 H, s), 8.30 (2 H, d, J = 8.2
Hz), 7.44 (2 H, d, J = 8.2 Hz), 7.36 (2 H, d, J = 7.6 Hz), 7.27 (2 H, t, J = 7.5 Hz),
7.20 (1 H, d, J = 7.2 Hz), 3.18 (1 H, dd, J = 6.7, 5.6 Hz), 2.93 (1 H, dd, J = 9.6,
6.7 Hz), 2.30 (1 H, dd, J = 9.6, 5.4 Hz)
(1 R*,2R*,3R*)(3-(5-Fluoropyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 50b)
Following method A from compound 49b (140 mg, 0.39 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 7%
MeOH in DCM) and preparative HPLC gave the title compound as a racemic
mixture (12 mg, 9%). LCMS (ES+) 350 (M+H)+, RT 3.61 min (Analytical method
1 ). NMR o (ppm)(DMSO-d 6 ): 10.59 (1 H, s), 9.01 (2 H, s), 8.71 (1 H, s), 8.20
(2 H, t, J = 4.0 Hz), 7.51-7.48 (2 H, m), 7.37 (2 H, d, J = 7.6 Hz), 7.29-7.24 (2 H,
m), 7.20 (1 H, d, J = 7.3 Hz), 3.22 (1 H, dd, J = 6.8, 5.5 Hz), 2.85 (1 H, dd, J =
9.6, 6.8 Hz), 2.32 (1 H, dd, J = 9.6, 5.4 Hz).
(1 R*,2R*,3R*)(4-(5-Cyclopropylpyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 50c)
Following method A from compound 49c (240 mg, 0.65 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the title compound as a white solid (155 mg, 64%). LCMS
(ES+) 372 (M+H)+, RT 3.89 min (Analytical method 1 ). NMR s (ppm)(DMSO
d 6 ): 10.58 (1 H, s), 8.70 (1 H, s), 8.64 (1 H, d, J = 5.2 Hz), 8.30 (2 H, d, J = 8.2
Hz), 7.40 (2 H, d, J = 8.2 Hz), 7.38-7.29 (3 H, m), 7.27 (2 H, t, J = 7.5 Hz), 7.22-
7.15 (1 H, m), 3.17 (1 H, dd, J = 6.8, 5.4 Hz), 2.90 (1 H, dd, J = 9.6, 6.9 Hz), 2.28
(1 H, dd, J = 9.6, 5.4 Hz), 2.21-2.13 (1 H, m), 1.19-1.09 (4 H, m).
( 1 R* ,2R* ,3R*)( 4-( 4-Trifluoromethylpyrim id inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide ( 50d)
Following method A from compound 49d (220 mg, 0.55 mmol).
The carboxylic acid was obtained as the major product. The reaction mixture was
acidified with aqueous 1 M HCI and extracted into EtOAc (3 x 10 ml). The
organic layers were combined, dried (MgS04), filtered and concentrated. The
compound was then subjected to method B. Purification by flash silica column
chromatography (gradient elution DCM to 5% MeOH in DCM) gave the title
compound as a white solid (77 mg, 37%). LCMS (ES+) 400 (M+H)+, 398 (M-H)-,
RT 13.26 min (Analytical method 3). NMR o (ppm)(DMSO-d 6 ): 10.60 (1 H, s),
9.26 (1 H, d, J = 5.0 Hz), 8.71 (1 H, s), 8.38 (2 H, d, J = 8.2 Hz), 7.93 (1 H, d, J =
.0 Hz), 7.50 (2 H, d, J = 8.2 Hz), 7.36 (2 H, d, J = 7.6 Hz), 7.28 (2 H, t, J = 7.5
Hz), 7.22-7.15 (1 H, m), 3.21 (1 H, dd, J = 6.8, 5.4 Hz), 2.94 (1 H, dd, J = 9.7, 6.9
Hz), 2.32 (1 H, dd, J = 9.7, 5.3 Hz).
(1 R,2R,3R)(4-(5-Trifluoromethylpyrimidinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 50e)
Following method A from compound 49e (180 mg, 0.45 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (99 mg, 55%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 10/90 IPNMeOH
(50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 16.2 min). LCMS (ES+) 400
(M+H)+, RT 3.96 min (Analytical method 1). NMR s (ppm)(DMSO-d6): 10.66
(1 H, s), 9.39 (2 H, s), 8.79 (1 H, s), 8.47 (2 H, d, J = 8.2 Hz), 7.55 (2 H, d, J = 8.2
Hz), 7.41 (2 H, d, J = 7.6 Hz), 7.33 (2 H, t, J = 7.5 Hz), 7.24 (1 H, t, J = 7.2 Hz),
3.26 (1 H, dd, J = 6.8, 5.3 Hz), 3.00 (1 H, dd, J = 9.6, 6.8 Hz), 2.38 (1 H, dd, J =
9.6, 5.3 Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide ( 50f)
Following method A from compound 49f (68 mg, 0.21 mmol).
Purification using an lsolute anion exchange SPE (elution DCM-MeOH, 1 :1) gave
the racemic mixture as a white solid (49 mg, 70%). LCMS (ES+) 332 (M+H)+, RT
2.95 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.59 (1 H, s), 9.20
(1 H, dd, J = 4.8, 1.5 Hz), 8.71 (1 H, s), 8.23 (1 H, dd, J = 8.6, 1.5 Hz), 8.14 (2 H,
d, J = 8.1 Hz), 7.78 (1 H, dd, J = 8.6, 4.9 Hz), 7.48 (2 H, d, J = 8.1 Hz), 7.37 (2 H,
d, J = 7.5 Hz), 7.32-7.24 (2 H, m), 7.22-7.16 (1 H, m), 3.19 (1 H, dd, J = 6.8, 5.4
Hz), 2.93 (1 H, dd, J = 9.6, 6.8 Hz), 2.31 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)-N -Hydroxyphenyl( 4-(pyridazin
yl )phenyl )cyclopropanecarboxam ide (50g)
Following method A from compound 49g (190 mg, 0.58 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 10%
MeOH in DCM) gave the racemic mixture as an off-white solid (75 mg, 39%).
LCMS (ES+) 332 (M+H)+, RT 2.77 min (Analytical method 4). 1 H NMR s
(ppm)(DMSO-d 6 ): 10.59 (1 H, s), 9.66 (1 H, dd, J = 2.5, 1.2 Hz), 9.26 (1 H, dd, J
= 5.4, 1.23 Hz), 8.71 (1 H, d, J = 1.7 Hz), 8.02 (1 H, dd, J = 5.5, 2.5 Hz), 7.92 (2
H, d, J = 8.1 Hz), 7.48 (2 H, d, J = 8.1 Hz), 7.36 (2 H, d, J = 7.6 Hz), 7.31-7.23 (2
H, m), 7.22-7.16 (1 H, m), 3.22-3.16 (1 H, m), 2.93 (1 H, dd, J = 9.6, 6.8 Hz), 2.29
(1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyrim id in
yl )phenyl )cyclopropanecarboxam ide ( 50h)
Following method A from compound 49h (110 mg, 0.33 mmol).
Purification by column chromatography (gradient elution DCM to 5% MeOH in
DCM) gave the title compound as a white solid (75 mg, 67%). LCMS (ES+) 332
(M+H)+, (ES-) 330 (M+H)-, RT 2.78 min (Analytical method 1 ). NMR s
(ppm)(DMSO-d 6 ): 10.59 (1 H, s), 8.90 (2 H, d, J = 4.8 Hz), 8.72 (1 H, s), 8.36 (2
H, d, J = 8.2 Hz), 7.48-7.40 (3 H, m), 7.36 (2 H, d, J = 7.6 Hz), 7.27 (2 H, t, J =
7.6 Hz), 7.19 (1 H, t, J = 7.3 Hz), 3.18 (1 H, dd, J = 6.8, 5.4 Hz), 2.93 (1 H, dd, J =
9.6, 6.8 Hz), 2.30 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4-(pyrim id in
yl )phenyl )cyclopropanecarboxam ide (50i)
Following method A from compound 49i (120 mg, 0.36 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) and passage through an lsolute anion exchange SPE (elution
DCM-MeOH, 1 :1) gave the title compound as a white solid (21 mg, 17%). LCMS
(ES+) 332 (M+H)+, RT 3.07 min (Analytical method 1 ). 1 H NMR s (ppm)(DMSO
d6 ): 10.60 (1 H, s), 9.18 (1 H, s), 9.15 (2 H, s), 8.72 (1 H, s), 7.79 (2 H, d, J = 8.1
Hz), 7.45 (2 H, d, J = 8.1 Hz), 7.35 (2 H, d, J = 7.6 Hz), 7.27 (2 H, t, J = 7.6 Hz),
7.19 (1 H, t, J = 7.2 Hz), 3.18 (1 H, dd, J = 6.8, 5.4 Hz), 2.92 (1 H, dd, J = 9.6, 6.8
Hz), 2.27 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R,2R,3R)( 4-(5-Chloropyrim id inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide ( 50j)
Following method A from compound 49j (300 mg, 0.82 mmol). The
racemic mixture (119 mg, 40%) was obtained after purification using flash silica
column chromatography (gradient elution DCM/MeOH 0% to 10%). Preparative
chiral HPLC gave the title compound (Chiralpak IC 30/70 IPNMeOH (50/50/0.1
formic acid)/heptanes, 1.0 ml/min, RT 8.21 min). LCMS (ES+) 366 (M+H), RT
3.90 min (Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.64 (1 H, s), 9.06
(2 H, s), 8.77 (1 H, s), 8.37 (2 H, d, J = 8.2 Hz), 7.50 (2 H, d, J = 8.2 Hz), 7.40 (2
H, d, J = 7.6 Hz), 7.32 (2 H, t, J = 7.5 Hz), 7.26-7.21 (1 H, m), 3.23 (1 H, dd, J =
6.8, 5.4 Hz), 2.98 (1 H, dd, J = 9.7, 6.8 Hz), 2.35 (1 H, dd, J = 9.7, 5.4 Hz).
( 1 R* ,2R* ,3R*)-N-Hydroxy( 4-( 5-methylpyrim id inyl )phenyl )
phenylcyclopropanecarboxam ide (50k)
Following method A from compound 49k (180 mg, 0.52 mmol).
The carboxylic acid was obtained as the major product. The reaction mixture was
acidified with aqueous 1 M HCI and extracted into EtOAc (3 x 10 ml). The
organic layers were combined, dried (MgS04), concentrated and the residue
subjected to method B. Purification by flash silica column chromatography
(gradient elution DCM to 5% MeOH in DCM) and preparative HPLC gave the title
compound as a white solid (16 mg, 7%). LCMS (ES+) 346 (M+H)+, RT 3.50 min
(Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.58 (1 H, s), 8.74 (2 H, d, J
= 0.8 Hz), 8.70 (1 H, s), 8.35-8.28 (2 H, m), 7.45-7.32 (4 H, m), 7.30-7.23 (2 H,
m), 7.22-7.15 (1 H, m), 3.17 (1 H, dd, J = 6.7, 5.4 Hz), 2.91 (1 H, dd, J = 9.6, 6.8
Hz), 2.31 (3 H, s), 2.29 (1 H, dd, J = 9.6, 5.4 Hz).
( 1R*,2R*,3R*)-N-Hydroxy(4-(5-methyl-1 H-imidazolyl )phenyl )
phenylcyclopropanecarboxam ide (501)
Following method A from compound 491 (280 mg, 0.84 mmol).
Purification by preparative HPLC gave the title compound as a white solid (4.8
mg, 1 % yield over 3 steps). LCMS (ES+) 334 (M+H)+, RT 7.93 min (Analytical
method 3). NMR o (ppm)(DMSO-d 6 ): 10.62 (1 H, s), 8.42 (1 H, s), 7.88 (2 H,
d, J = 8.0 Hz), 7.41-7.28 (6 H, m), 7.25-7.20 (1 H, m), 6.84 (1 H, s), 3.16 (1 H, dd,
J = 6.9, 5.5 Hz), 2.92 (1 H, dd, J = 9.4, 6.7 Hz), 2.31-2.20 (4 H, m), OH not
observed.
Example 17
Reaction Scheme 17
-Bromocyclopropyl isoindol ine
To a solution of phthalic anhydride (4.5 g, 20 mmol) in toluene (25
ml) was added cyclopropylamine (1.52 ml) at 0 °C and the reaction mixture was
stirred at 90 °C for 17 h. The solvent was evaporated and THF (20 ml) was
added. To this was added BH3.Me2S THF complex 1 M (80 ml, 80 mmol) and
the mixture was stirred at 50 °C for 48 h. The reaction was cooled to 0°C and
poured onto a solution of 3M HCI (27 ml) and stirred at 60 °C for 1 h. The
mixture was washed with ethyl acetate, the aqueous phase was basified (pH 12)
and extracted with DCM. The organic layer was dried, filtered and concentrated
to afford the title compound as a yellow oil (1.6 g, 34%). lCMS (ES+) 238, 240
(M+Ht.
Example 18
Reaction Scheme 18
<;;:ON HOH
( 1 R* ,2R* ,3R*)-methyl( 4-(2-cyclopropyl isoindolinyl )phenyl )
phenylcyclopropanecarboxylate (51)
Following method G from the boronate derived from 15c (1.5 mmol)
and 5-bromocyclopropylisoindoline (240 mg, 1 mmol). The mixture was stirred
at 90°C for 2 h, diluted with H20 (20 ml) and extracted into DCM (50 ml). The
organic layers were passed through a phase separator and concentrated.
Purification using flash silica column chromatography (gradient elution
DCM/MeOH 1 % to 7%) gave the ester intermediate as a yellow oil (360 mg,
59%). lCMS (ES+) 410 (M+H(
(1 R*,2R*,3R*)(4-(2-cyclopropylisoindolinyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 52)
Following method A from compound 51 (40 mg, 0.098 mmol).
Purification by preparative HPlC gave the title compound as a white solid (6.9
mg, 17%). lCMS (ES+) 411 (M+H)+, RT 7.48 min (Analytical method 3).
NMR o (ppm)(DMSO-d 6 ): 10.63 (1 H, s), 8.75 (1 H, s), 7.65 (2 H, d, J = 8.1 Hz),
7.56 (1 H, s), 7.53 (1 H, d, J = 7.9 Hz), 7.44-7.27 (7 H, m), 7.26-7.20 (1 H, m),
4.05 (4 H, d, J = 9.3 Hz), 3.17 (1 H, dd, J = 6.7, 5.3 Hz), 2.90 (1 H, dd, J = 9.5,
6.8 Hz), 2.29 (1 H, dd, J = 9.5, 5.4 Hz), 2.14-2.08 (1 H, m), 0.56-0.50 (2 H, m),
0.51-0.45 (2 H, m).
Example 19
Reaction Scheme 19
CONHOH
----
15c 53a-c 54a-c
Table 4
R Compound R Compound
(oyy\
54a 54c
Ph v
(1R*,2R*,3R*)-Methyl(3'-(benzyloxy)-[1,1 '-biphenyl]yl)
phenylcyclopropanecarboxylate (53a)
Following method H from compound 15c (660 mg, 2 mmol) and 3-
(benzyloxy)phenyl boronic acid (547 mg, 2.40 mmol). Purification by flash silica
column chromatography (gradient elution i-hex to 10% EtOAc in i-hex) gave the
title compound as a yellow oil (710 mg, 82%). LCMS (ES+) 435 (M+Ht
(1R*,2R*,3R*)-Methyl(4'-(9H-carbazolyl)-[1,1 '-biphenyl]yl)
phenylcyclopropanecarboxylate ( 53b)
Following method H from compound 15c (660 mg, 2.0 mmol) and
4-(9H-carbazolyl)phenyl boronic acid (886 mg, 2.40 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 30% EtOAc in i-hex)
gave the title compound as a yellow oil (310 mg, 31 %). LCMS (ES+) 494 (M+Ht
( 1 R* ,2R* ,3R*)-Methyl( 4-( 4-methyl-3,4-d ihydro-2H-benzo[b][1 ,4 ]oxazin
yl )phenyl )phenylcyclopropanecarboxylate ( 53c)
Following method H from compound 15c (330 mg, 1.0 mmol) and
4-methyl( 4 ,4 ,5,5-tetramethyl-1 ,3,2-d ioxaborolanyl )-3,4-d ihydro-2H-
benzo[b][1,4]oxazine (331 mg, 1.2 mmol). Purification by flash silica column
chromatography (gradient elution i-hex - 5% to 80% EtOAc in i-hex) gave the title
compound as a yellow oil (280 mg, 70%). LCMS (ES+) 400 (M+Ht
(1R,2R,3R)(3'-(Benzyloxy)-[1,1 '-biphenyl]yl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 54a)
Following method A from compound 53a (700 mg, 1.61 mmol).
Purification by flash silica column chromatography (gradient elution EtOAc from
% to 100% in i-hex) followed by PEAX cartridge (elution DCM-MeOH 1 :1) gave
the racemic mixture as a white solid (450 mg, 64%). Purification by chiral
preparative HPLC gave the title compound (Chiralpak IC 20/80 EtOH (0.1 % FA) I
heptane, 1.0 ml/min, RT 13.0 min). LCMS (ES+) 436 (M+H)+, RT 4.47 min
(Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.63 (1 H, s), 8.76 (1 H, s),
7.68 (2 H, d, J = 8.1 Hz), 7.54 (2 H, d, J = 7.5 Hz), 7.50-7.21 (13 H, m), 7.05 (1 H,
dd, J = 8.1, 2.4 Hz), 5.25 (2 H, s), 3.19 (1 H, dd, J = 6.8, 5.4 Hz), 2.93 (1 H, dd, J
= 9.6, 6.8 Hz), 2.30 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 R* ,2R* ,3R*)( 4'-(9H-carbazolyl )-[1 , 1 '-biphenyl]yl )-N-hydroxy
phenylcyclopropanecarboxam ide ( 54b)
Following method A from compound 53b (300 mg, 0.61 mmol).
Purification by preparative HPLC gave the title compound as a white solid (8 mg,
3%). LCMS (ES+) 495 (M+H)+, RT 11.55 min (Analytical method 3). NMR s
(ppm)(DMSO-d 6 ): 10.66 (1 H, s), 8.79 (1 H, s), 8.33 (2 H, d, J = 7.8 Hz), 8.03 (2
H, d, J = 8.2 Hz), 7.83 (2 H, d, J = 8.0 Hz), 7.78 (2 H, d, J = 8.2 Hz), 7.54-7.47 (6
H, m), 7.44-7.30 (6 H, m), 7.25 (1 H, t, J = 7.2 Hz), 3.23 (1 H, dd, J = 6.8, 5.4 Hz),
2.98 (1 H, dd, J = 9.6, 6.9 Hz), 2.34 (1 H, dd, J = 9.6, 5.4 Hz).
( 1R,2R,3R)-N-hydroxy(4-( 4-methyl-3,4-d ihydro-2H-benzo[b] [1 ,4 ]oxazin
yl )phenyl )phenylcyclopropanecarboxamide ( 54c)
Following method A from compound 53c (280 mg, 0.70 mmol).
The carboxylic acid was obtained as the major product. The reaction mixture was
acidified with aqueous 1 M HCI and extracted into EtOAc (3 x 10 ml). The
organic layers were combined, dried (MgS04), filtered and concentrated. The
sample was then subjected to method B. Purification by chiral preparative HPLC
(Chiralpak IC 20/80 EtOH (0.1 % FA) I heptane, 1.0 ml/min, RT 15.9 min) gave
the title compound as a white solid. LCMS (ES+) 401 (M+H)+, RT 4.02 min
(Analytical method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.63 (1 H, s), 8.75 (1 H, s),
7.56 (2 H, d, J = 8.1 Hz), 7.38 (2 H, d, J = 7.6 Hz), 7.35-7.27 (3 H, m), 7.26-7.20
(1 H, m), 7.15 (1 H, dd, J = 8.3, 2.1 Hz), 7.02 (1 H, d, J = 2.1 Hz), 6.81 (1 H, d, J
= 8.4 Hz), 4.33-4.29 (2 H, m), 3.33-3.28 (3 H, m), 3.14 (1 H, dd, J = 6.8, 5.3 Hz),
2.91 (3 H, s), 2.91-2.85 (1 H, m), 2.26 (1 H, dd, J = 9.6, 5.3 Hz).
Example 20
Reaction Scheme 20
CON HOH
3-Br, R1 =Et, 1 Sb
56a-i
55a-i
4-Br, R1 =Me, 15c
Table 5
3 or4 3 or4
R2 Compound R2 Compound
Substitution Substitution
4 56a 3 56f
3 56b 3 56g
4 56c 3 56h
4 4 56i
4 56e
( 1 R* ,2R* ,3R*)-Methyl( 4-( 4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxylate (55a)
Following method I from compound 15c (250 mg, 0.76 mmol) and
iso-propylpiperazine (125 µI, 0.86 mmol). Purification using flash silica column
chromatography (gradient elution i-hex/EtOAc 0% to 100%) gave the title
compound as a yellow oil (187 mg, 65%). LCMS (ES+) 379 (M+Ht
( 1R*,2R*,3R*)-Ethyl(3-(4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxylate ( 55b)
Following method I from compound 15b (250 mg, 0.76 mmol) and
iso-propylpiperazine (125 µI, 0.86 mmol). Purification using flash silica column
chromatography (gradient elution DCM/MeOH 0% to 8%) gave the title
compound as a yellow oil (180 mg, 58%). LCMS (ES+) 393 (M+Ht
( 1R*,2R*,3R*)-Methyl(4-(3,3-d ifl uoropyrrol idinyl )phenyl )
phenylcyclopropanecarboxylate ( 55c)
Following method I from compound 15c (250 mg, 0.76 mmol) and
3,3-difluoropyrrolidine (124 mg, 0.86 mmol). Purification by flash silica column
chromatography (gradient elution i-hex/EtOAc 0% to 100%) gave the title
compound as a clear oil (210 mg, 59%). LCMS (ES+) 358 (M+Ht.
( 1R*,2R*,3R*)-Methyl(4-(3,3-d imethylazetid inyl )phenyl )
phenylcyclopropanecarboxylate ( 55d)
Following method I from compound 15c (250 mg, 0.76 mmol) and
3,3-dimethylazatidine (105 mg, 0.86 mmol). Purification by flash silica column
chromatography (gradient elution i-hex/EtOAc 0% to 100%) gave the title
compound as a clear oil (210 mg, 59%). LCMS (ES+) 336 (M+Ht.
( 1 R*,2R*,3R*)-Methyl( 4-(2-oxaazaspiro[3 .3] heptanyl )phenyl )
phenylcyclopropanecarboxylate ( 55e)
Following method I from compound 15c (250 mg, 0.76 mmol) and
2-oxaazaspiro[3.3]heptane formate salt (160 mg, 0.86 mmol). Purification by
flash silica column chromatography (gradient elution i-hex/EtOAc 0% to 100%)
gave the title compound as a clear oil (210 mg, 59%). LCMS (ES+) 350 (M+H(
( 1 R*,2R*,3R*)-Ethyl(3-(hexahydropyrrolo[1 ,2-a]pyrazin-2( 1 H )-yl )phenyl )
phenylcyclopropanecarboxylate ( 55f)
Following method I from compound 15b (500 mg, 1.56 mmol) and
octahydropyrrolo[1,2-a]pyrazine (195 mg, 1.72 mmol). Purification by flash silica
column chromatography (gradient elution DCM/MeOH 0% to 8%) gave the title
compound as a yellow oil (265 mg, 44%). LCMS (ES+) 391 (M+Ht
( 1R*,2R*,3R*)-Ethylphenyl(3-(4-(pyrrol id inyl )piperid in
yl )phenyl )cyclopropanecarboxylate ( 55g)
Following method I from compound 15b (500 mg, 1.56 mmol) and
4-(pyrrolidinyl)piperidine (241 mg, 1.72 mmol). Purification by flash silica
column chromatography (gradient elution DCM/MeOH 0% to 8%) gave the title
compound as a yellow oil (230 mg, 35%). LCMS (ES+) 491 (M+Ht
( 1R*,2R*,3R*)-Ethyl(3-(6,7-d ihydropyrazolo[1 ,5-a]pyrim id in-4( 5H )-yl )phenyl)
phenylcyclopropanecarboxylate ( 55h)
Following method I from compound 15b (250 mg, 0.78 mmol) and
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (106 mg, 0.86 mmol). Purification by
flash silica column chromatography (gradient elution DCM/MeOH 0% to 8%) gave
the title compound as a yellow oil (165 mg, 42%). LCMS (ES+) 388 (M+Ht
( 1R*,2R*,3R*)-Methyl(4-( 4-methylpiperazinyl )phenyl )
phenylcyclopropanecarboxylate (55i)
Following method I from compound 15c (250 mg, 0.76 mmol) and
N-methylpiperazine (95 µI, 0.86 mmol). Purification using lsolute cation exchange
SCX (elution DCM-MeOH 50% and 5-10% 7N NH3 in MeOH) gave the title
compound as a yellow oil (72 mg, 27%). LCMS (ES+) 351 (M+Ht
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide ( 56a)
Following method A from compound 55a (170 mg, 0.49 mmol).
Purification by preparative HPLC gave the title compound as a white solid (36
mg, 21 %). LCMS (ES+) 380 (M+H)+, RT 2.30 min (Analytical method 1 ).
NMR o (ppm)(DMSO-d 6 ): 10.50 (1 H, d, J = 1.9 Hz), 8.64 (1 H, d, J = 1.7 Hz),
7.31 (2 H, m), 7.25 (2 H, m), 7.20-7.07 (3 H, m), 6.88 (2 H, d, J = 8.4 Hz), 3.08 (4
H, m), 2.99 (1 H, m), 2.75-2.61 (2 H, m), 2.56 (4 H, dd, J = 7.4, 4.1 Hz), 2.12-2.06
(1 H, m), 1.00 (6 H, d, J = 6.5 Hz).
( 1R*,2R*,3R*)-N-Hydroxy(3-(4-isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide ( 56b)
Following method A from compound 55b (180 mg, 0.46 mmol).
Purification by preparative HPLC gave the title compound as a white solid (73
mg, 42%). LCMS (ES+) 380 (M+H)+, RT 7.23 min (Analytical method 3).
NMR o (ppm)(DMSO-d 6 ): 10.56 (1 H, s), 7.37 (2 H, d, J = 7.6 Hz), 7.30 (2 H, t, J
= 7.5 Hz), 7.25-7.17 (2 H, m), 6.88 (1 H, s), 6.84-6.80 (1 H, m), 6.69 (1 H, d, J =
7.5 Hz), 3.18 (5 H, t, J = 4.5 Hz), 3.08 (1 H, dd, J = 6.8, 5.4 Hz), 2.87 (1 H, dd, J =
9.5, 6.9 Hz), 2.73 (1 H, t, J = 6.5 Hz), 2.62 (4 H, t, J = 4.6 Hz), 2.22 (1 H, dd, J =
9.6, 5.4 Hz), 1.06 (6 H, d, J = 6.5 Hz).
( 1R*,2R*,3R*)-N-Hydroxy(4-(3,3-d ifluoropyrrol id inyl )phenyl )
phenylcyclopropanecarboxam ide ( 56c)
Following method A from compound 55c (205 mg, 0.57 mmol).
Purification by preparative HPLC gave the title compound as a white solid (35
mg, 17%). LCMS (ES+) 359 (M+H)+, RT 9.27 min (Analytical method 6).
NMR o (ppm)(DMSO-d 6 ): 10.50 (1 H, s), 8.64 (1 H, d, J = 1.8 Hz), 7.31 (2 H, d, J
= 7.6 Hz), 7.25 (2 H, t, J = 7.4 Hz), 7.19-7.08 (3 H, m), 6.60 (2 H, d, J = 8.2 Hz),
3.66 (2 H, t, J = 13.4 Hz), 3.44 (2 H, m), 2.99 (1 H, m), 2.70-2.65 (2 H, m), 2.33 (1
H, m), 2.08 (1 H, dd, J = 9.5, 5.4 Hz).
( 1 R* ,2R* ,3R *)( 4-(3,3-Dimethylazetid inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide ( 56d)
Following method A from compound 55d (200 mg, 0.59 mmol).
Purification by preparative HPLC gave the title compound as a white solid (23
mg, 14%). LCMS (ES+) 337 (M+H)+, RT 3.42 min (Analytical method 1).
NMR o (ppm)(DMSO-d 6 ): 10.49 (1 H, s), 8.63 (1 H, s), 7.33-7.20 (4 H, m), 7.19-
7.12 (1 H, m), 7.05 (2 H, d, J = 8.2 Hz), 6.37 (2 H, d, J = 8.2 Hz), 3.48 (4 H, s),
2.97 (1 H, dd, J = 6.9, 5.4 Hz), 2.68 (1 H, dd, J = 9.5, 6.9 Hz), 2.06 (1 H, dd, J =
9.5, 5.4 Hz), 1.27 (6 H, s).
( 1 R*,2R*,3R*)( 4-(2-0xaazaspiro[3 .3] heptanyl )phenyl )-N-hyd roxy
phenylcyclopropanecarboxam ide ( 56e)
Following method A from compound 55e (214 mg, 0.61 mmol).
Purification by preparative HPLC gave the title compound as a white solid (23
mg, 14%). LCMS (ES+) 351 (M+H)+, RT 8.07 min (Analytical method 3).
NMR o (ppm)(DMSO-d 6 ): 10.50 (1 H, s), 8.64 (1 H, d, J = 1.8 Hz), 7.31 (2 H, d, J
= 7.6 Hz), 7.28-7.21 (2 H, m), 7.19-7.08 (3 H, m), 6.60 (2 H, d, J = 8.2 Hz), 3.70-
3.61 (4 H, m), 3.48-3.39 (4 H, m), 2.99 (1 H, dd, J = 6.9, 5.4 Hz), 2.70 (1 H, dd, J
= 9.5, 6.9 Hz), 2.08 (1 H, dd, J = 9.5, 5.4 Hz).
( 1 R*,2R*,3R*)(3-(Hexahydropyrrolo[1 ,2-a]pyrazin-2( 1 H )-yl )phenyl )-N-hydroxy-
3-phenylcyclopropanecarboxam ide ( 56f)
Following method A from compound 55f (265 mg, 0.68 mmol).
Purification by preparative HPLC gave the title compound as a white solid (9 mg,
4%). LCMS (ES+) 378 (M+H)+, RT 8.26 min (Analytical method 3). NMR s
(ppm)(DMSO-d 6 ): 10.56 (1 H, s), 7.38 (2 H, d, J = 7.6 Hz), 7.30 (2 H, t, J = 7.5
Hz), 7.24-7.15 (2 H, m), 6.89 (1 H, s), 6.84 (1 H, dd, J = 8.4, 2.4 Hz), 6.69 (1 H, d,
J = 7.6 Hz), 3.87 (1 H, d, J = 11.2 Hz), 3.71 (2 H, d, J = 12.2 Hz), 3.13-3.03 (4 H,
m), 2.87 (1 H, dd, J = 9.6, 6.9 Hz), 2.81-2.71 (1 H, m), 2.30-2.19 (2 H, m), 2.16-
2.04 (2 H, m), 1.91-1.83 (1 H, m), 1.81-1.70 (2 H, m), 1.48-1.39 (1 H, m).
( 1R*,2R*,3R*)-N-Hydroxyphenyl(3-(4-(pyrrol id inyl)piperid in
yl )phenyl )cyclopropanecarboxam ide (56g)
Following method A from compound 55g (230 mg, 0.55 mmol).
Purification by preparative HPLC gave the title compound as a white solid (40
mg, 10%). LCMS (ES+) 406 (M+H)+, RT 2.42 min (Analytical method 1 ).
NMR o (ppm)(DMSO-d 6 ): 10.56 (1 H, s), 8.72 (1 H, s), 7.38 (2 H, d, J = 7.61 Hz),
7.33-7.24 (2 H, m), 7.25-7.14 (2 H, m), 6.90 (1 H, s), 6.90-6.80 (1 H, m), 6.67 (1
H, d, J = 7.59 Hz), 3.84-3.69 (2 H, m), 3.08 (1 H, dd, J = 6.93 5.4 Hz), 2.90-2.82
(1 H, m), 2.82-2.72 (7 H, m), 2.22 (1 H, dd, J = 9.6, 5.4 Hz), 2.00 (2 H, d, J =
12.01 Hz), 1.79 (4 H, s), 1.65-1.51 (2 H, m).
( 1R,2R,3R)(3-(6,7-Dihydropyrazolo[1 ,5-a]pyrim id in-4(5H )-yl )phenyl )-N
hydroxyphenylcyclopropanecarboxam ide ( 56h)
Following method A from compound 55h (180 mg, 0.46 mmol).
The racemic mixture was obtained after purification by preparative HPLC as a
white solid (41.5 mg, 24%). Purification by chiral preparative HPLC (Chiralpak IA
40/60 IPA/MeOH (50/50/0.1 % formic acid) I heptane, 1.0 ml/min, RT 10.1 min)
gave the title compound. LCMS (ES+) 375 (M+H)+, RT 2.90 min (Analytical
method 1 ). NMR o (ppm)(DMSO-d 6 ): 10.59 (1 H, s), 8.74 (1 H, s), 7.39-7.28
(5 H, m), 7.26-7.20 (4 H, m), 7.02 (1 H, d, J = 1.4 Hz), 5.66 (1 H, d, J = 1.9 Hz),
4.15 (2 H, t, J = 6.1 Hz), 3.74 (2 H, t, J = 5.2 Hz), 3.14 (1 H, dd, J = 6.8, 5.4 Hz),
2.88 (1 H, dd, J = 9.5, 6.8 Hz), 2.28-2.22 (3 H, m).
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4-methylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide ( 56i)
Following method A from compound 55i (70 mg, 0.20 mmol).
Purification by preparative HPLC gave the title compound as a white solid (49
mg, 70%). lCMS (ES+) 352 (M+H)+, RT 6.86 min (Analytical method 3).
NMR o (ppm)(DMSO-d 6) 10.50 (1 H, s), 8.64 (1 H, s), 7.31 (2 H, d, J = 7.6 Hz),
7.25 (2 H, t, J = 7.4 Hz), 7.20-7.08 (3 H, m), 6.89 (2 H, d, J = 8.5 Hz), 3.09 (4 H, t,
J = 4.8 Hz), 2.99 (1 H, dd, J = 6.8, 5.4 Hz), 2.71 (1 H, dd, J = 9.5, 6.9 Hz), 2.44 (4
H, t, J = 4.7 Hz), 2.22 (3 H, s), 2.09 (1 H, dd, J = 9.5, 5.4 Hz).
Example 21
Reaction Scheme 21
CON HOH
( 1 R* ,2R* ,3R*)-Methyl( 4-( oxazolyl )phenyl )
phenylcyclopropanecarboxam ide (57)
A mixture of compound 15c (250 mg, 0.75 mmol), 2-(tri-n-
butylstannyl)oxazole (0.230 ml, 1.1 mmol), Pd(PPh3)4 (43 mg, 0.038 mmol) in
1,4-dioxane (4 ml) was heated in the microwave at 150°C for 1 h. The mixture
was concentrated and purified by flash silica column chromatography (gradient
elution DCM to 10% MeOH in DCM) to afford the title compound as a white solid
(175 mg, 73%). lCMS (ES+) 320 (M+Ht.
( 1 R*, 2R*, 3R*J-N-Hyd roxy( 4-( oxazolyl )phenyl )
phenylcyclopropanecarboxam ide ( 58)
Following method A from compound 57 (160 mg, 0.50 mmol).
Crystallization from MeOH gave the title compound as a white solid (71 mg,
45%). lCMS (ES+) 321 (M+H)+, RT 2.80 min (Analytical method 1 ). NMR s
(ppm)(DMSO-d 6 ): 10.58 (1 H, s), 8.70 (1 H, s), 8.21 (1 H, d, J = 0.8 Hz), 7.94 (2
H, d, J = 8.1 Hz), 7.45 (2 H, d, J = 8.1 Hz), 7.39-7.33 (3 H, m), 7.31-7.23 (2 H, m),
7.22-7.15 (1 H, m), 3.20-3.13 (1 H, m), 2.91 (1 H, dd, J = 9.6, 6.8 Hz), 2.28 (1 H,
dd, J = 9.6, 5.3 Hz).
Example 22
Reaction Scheme 22
CON HOH
~-··o
( 1R*,2R*,3R*)-Methyl(4-( 1-methyl-1 H-im idazolyl )phenyl )
phenylcyclopropanecarboxam ide ( 59)
Following the method described for compound 57, from 15c (222
mg, 0.67 mmol) and 1-methyl(tributylstannyl)imidazole (300 mg, 0.81 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 10%
MeOH in DCM) gave the title compound as a yellow solid (187 mg, 84%). LCMS
(ES+) 333 (M+H(
( 1 R* ,2R* ,3R*)-N -Hydroxy( 4-( 1-methyl-1 H-im idazolyl )phenyl )
phenylcyclopropanecarboxam ide (60)
Following method A from compound 59 (187 mg, 0.56 mmol).
Crystallization from DCM and washes with MeOH, gave the title compound as a
white solid (98 mg, 53%). LCMS (ES+) 334 (M+H)+, RT 9.74 min (Analytical
method 3). NMR o (ppm)(DMSO-d 6 ): 10.58 (1 H, s), 8.70 (1 H, s), 7.65 (2 H,
d, J = 8.1 Hz), 7.44-7.31 (4 H, m), 7.30-7.24 (3 H, m), 7.23-7.15 (1 H, m), 6.99 (1
H, d, J = 1.1 Hz), 3.75 (3 H, s), 3.19-3.13 (1 H, dd, J = 6.8, 5.4 Hz), 2.90 (1 H, dd,
J = 9.6, 6.8 Hz), 2.26 (1 H, dd, J = 9.6, 5.4 Hz).
Example 23
Reaction Scheme 23
~~2Me ~~~2Me ~CONHOH
- 'Ph - .,,
,,,;:;.
Br r( N'- r( N.:::
61 F~N 62 F~N 63
( 1R*,2S*,3S*)-Methyl(4-bromophenyl )methyl
phenylcyclopropanecarboxylate (61)
To a solution of 15c (331 mg, 1 mmol) in dry THF at -78 °C, was
added LOA (2 Min THF, 0.5 ml) dropwise and the reaction mixture was stirred at
-78 °C for 30 min. Methyl iodide (0.065 ml, 1 mmol) was added and the reaction
mixture was allowed to warm up to r.t. and stirred for 1 h. The reaction mixture
was quenched with water and the compound was extracted into DCM. The
organic phase was dried (MgS04), filtered and concentrated. Purification by flash
silica column chromatography (gradient elution i-hex to 50% EtOAc in i-hex) gave
the title compound as a colourless oil (346 mg, 100%). lCMS (ES+) 346 (M+H(
( 1R*,2S*,3S*)-Methyl(4-(5-fluoropyrim id inyl )phenyl )methyl
phenylcyclopropanecarboxylate (62)
Following method G from 61 (346 mg, 1.0 mmol) and 2-chloro
fluoropyrimidine (170 µI, 1.1 mmol). Purification by flash silica column
chromatography (gradient elution i-hex to 10% EtOAc in i-hex) gave the title
compound as a colourless oil (160 mg, 44%). lCMS (ES+) 363 (M+H(
( 1R*,2S*,3S*)(4-( 5-Fluoropyrim id inyl )phenyl )-N-hydroxymethyl
phenylcyclopropanecarboxam ide (63)
Following method A from 62 (350 mg, 0.97 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 10% MeOH in DCM)
followed by preparative HPlC gave the title compound as a white solid (2 mg,
2%). lCMS (ES+) 364 (M+H)+, RT 10.83 min (Analytical method 3). NMR s
(ppm)(DMSO-d 6 ): 10.62 (1 H, s), 8.98 (2 H, d, J = 0.7 Hz), 8.64 (1 H, s), 8.31 (2
H, d, J = 8.1 Hz), 7.51 (2 H, d, J = 8.1 Hz), 7.31-7.23 (4 H, m), 7.22-7.15 (1 H, m),
3.46 (1 H, d, J = 7.2 Hz), 2.78 (1 H, d, J = 7.2 Hz), 1.12 (3 H, s).
Example 24
Reaction Scheme 24
CONHOH
( 1R*,2R*,3R*)-Methyl(4-( 1 H-pyrazolyl )phenyl )
phenylcyclopropanecarboxylate (64)
To a stirred solution of compound 15c (1.0 g, 3.02 mmol) in dioxane
(5 ml) was added bis-pinacolato diboron (844 mg, 3.32 mmol), Pd(dppf)Cl2 (246
mg, 0.30 mmol) and potassium acetate (1.48 g, 15.1 mmol). The mixture was
degassed with nitrogen, heated to 100°C for 2 h, diluted with H20 (20 ml) and
extracted into DCM (2 x 20 ml). The organic layers were passed through a
phase separator and concentrated. Part of this crude residue (400 mg, 1.00
mmol) was dissolved in a mixture of MeOH (4 ml) and THF (2 ml) and to this
was added pyrazole (82 mg, 1.2 mmol) and Cu20 (8 mg, 0.056 mmol). The
mixture was stirred at 100°C for 16 h, diluted with H20 (10 ml) and extracted into
DCM (20 ml). The organic layers were passed through a phase separator and
concentrated. Purification by flash silica column chromatography (gradient
elution DCM to 5% MeOH in DCM) afforded the title compound as a cream solid
(161 mg, 51%). lCMS (ES+) 319 (M+Ht.
(1 R*,2R*,3R*)(4-(1 H-pyrazolyl)phenyl)-N-hydroxy
phenylcyclopropanecarboxamide (65)
Following method A from compound 64 (121 mg, 0.38 mmol) The
carboxylic acid was obtained as the major product. The acid (43 mg, 0.14 mmol)
was subjected to method B. Purification by preparative HPlC gave the title
compound as a cream solid (9 mg, 21 %). lCMS (ES+) 320 (M+H)+ , RT 8.49
min (Analytical method 3). NMR o (ppm)(DMSO-d 6) 10.56 (1 H, s), 8.69 (1 H,
s), 8.48 (1 H, d, J = 2.5 Hz), 7.80 (2 H, d, J = 8.4 Hz), 7.73 (1 H, d, J = 1.7 Hz),
7.40 (2 H, d, J = 8.3 Hz), 7.35 (2 H, d, J = 7.6 Hz), 7.27 (2 H, m), 7.19 (1 H, m),
6.54 (1 H, dd, J = 2.4, 1.7 Hz), 3.19-3.13 (1 H, dd, J = 6.8, 5.3 Hz), 2.89 (1 H, dd,
J = 9.6, 6.8 Hz), 2.24 (1 H, dd, J = 9.6, 5.3 Hz).
Example 25
Reaction Scheme 25
CON HOH
~~C02Me
CF3 66
( E)-Methyl( 5-(trifl uoromethyl )pyrid inyl )acrylate ( 66)
A stirred solution of 5-bromo(trifluoromethyl)pyridine (1.0 g, 4.42
mmol), (E)-ethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)acrylate (1.0 g,
4.43 mmol), Pd(PPh3)4 (511 mg, 0.44 mmol) and Na2C03 (13.3 ml, 1 M solution,
13.3 mmol) was degassed with nitrogen for 10 min and then heated to 100°C for
17 h. The mixture was allowed to cool, diluted with water (20 ml), and extracted
into DCM (3 x 20 ml). The product was extracted from the organic layers with
sat. NaHC03 (20 ml). The pH was adjusted to 5.5 and the resulting white
precipitate collected by vacuum filtration (431 mg, 45%). lCMS indicated that the
corresponding carboxylic acid had formed. In a separate flask, thionyl chloride
(0.19 ml, 1.99 mmol) was added slowly to MeOH (5 ml) at -78°C, and the acid
(431 mg, 1.99 mmol) was added. The mixture was refluxed for 1.5 h, cooled to
r.t. and concentrated. The residue was dissolved in sat. NaHC03 (20 ml) and
extracted into DCM (3 x 20 ml), and the combined organic layers passed through
a phase separator and concentrated to give the title compound as a colourless oil
(403 mg, 88%). lCMS (ES+) 232 (M+Ht_
( 1 R*,2R*,3R*)-Ethylphenyl( 5-(trifl uoromethyl )pyrid in
yl )cyclopropanecarboxylate (67)
Following method F from compound 66 (403 mg, 1.74 mmol) and
6a (678 mg, 2.62 mmol). After stirring at 0°C for 2 h an additional 1.5 equivalents
of LiHMDS were added. Purification by flash silica column chromatography
(gradient elution i-hex to 10% EtOAc in i-hex) gave the title compound as a
colourless oil (250 mg, 2:1 trans: cis, 45%). lCMS (ES+) 322 (M+Ht
(1 R,2R,3R)-N-Hydroxyphenyl(5-(trifluoromethyl)pyridin
yl)cyclopropanecarboxamide (68)
Following method A from compound 67 (250 mg, 0.78 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) followed by preparative HPlC gave the racemic mixture as a
white solid (83 mg, 11 % ). Preparative chiral HPlC gave the title compound
(Chiralpak IC 20/80 EtOH (0.1 % formic acid)/heptane, 1.0 ml/min, RT 11.3 min).
lCMS (ES+) 323 (M+H)+, RT 3.30 min (Analytical method 1 ). NMR s
(ppm)(DMSO-d 6 ): 10.64 (1 H, s), 8.96 (1 H, s), 8.88 (1 H, s), 8.79 (1 H, s), 8.15 (1
H, s), 7.41 (2 H, d, J = 7.6 Hz), 7.32 (2 H, t, J = 7.4 Hz), 7.24 (1 H, t, J = 7.2 Hz),
3.41 (1 H, obscured by water), 3.15 (1 H, dd, J = 9.8, 6.9 Hz), 2.44 (1 H, dd, J =
9.8, 5.4 Hz).
Example 26
Reaction Scheme 26
tert-Butyl( 4-( ( 1 R* ,2R* ,3R*)( methoxycarbonyl )phenylcyclopropyl )phenyl)-
,6-d ihyd ropyrid ine-1 (2H)-carboxylate (69)
Following method H from compound 15c (660 mg, 2 mmol) and (1-
(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridinyl)boronic acid (750 mg, 2.4
mmol). The crude compound was used in the next step without further
purification.
( 1 R* ,2R* ,3R*)-Methylphenyl( 4-( 1 ,2,3,6-tetrahydropyrid in
yl )phenyl )cyclopropanecarboxylate (70)
A solution of 69 (2 mmol) in a mixture of TFA (6 ml) and DCM (14
ml) was stirred at r.t. for 3 h. The reaction mixture was concentrated and the
residue dissolved in DCM-MeOH 1 :1 (2 ml) and passed through a SCX cartridge
(elution 7 M NH3 in MeOH). The free amine was isolated as a yellow oil (655 mg,
96%). This was dissolved in CH3CN (20 ml) and Cs2C03 (1.2 g, 3.9 mmol) and
benzyl bromide (255 µl, 2.15 mmol) were added. The reaction mixture was
stirred for 17 hand concentrated. The residue was dissolved in DCM and
washed with water and brine. The organic layer was passed through a phase
separator and concentrated. Purification by flash silica column chromatography
(gradient elution i-hex to 15% EtOAc in i-hex) gave the title compound as a yellow
oil (305 mg, 36%). lCMS (ES+) 424 (M+H)+.
( 1R,2R,3R)(4-( 1-Benzyl-1 ,2,3,6-tetrahydropyrid inyl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide (71)
Following method A from compound 70 (300 mg, 0.71 mmol).
Purification by PEAX cartridge (elution DCM-MeOH 1 :1) gave the racemic
mixture as a yellow solid (230 mg, 94%). Purification by chiral preparative HPlC
(Chiralpak IC 40/60 EtOH (0.1 % FA) I heptane, 1.0 ml/min, RT 14.2 min) gave
the title compound as a yellow solid. lCMS (ES+) 425 (M+H)+, RT 7.59 min
(Analytical method 3). NMR o (ppm)(DMSO-d 6 ): 10.61 (1 H, s), 8.75 (1 H, s),
7.45-7.20 (14 H, m), 6.18 (1 H, s), 3.63 (2 H, s), 3.15-3.08 (3 H, m), 2.86 (1 H, dd,
J = 9.4, 6.7 Hz), 2.69 (2 H, t, J = 5.6 Hz), 2.55-2.46 (2 H, m), 2.23 (1 H, dd, J =
9.6, 5.3 Hz).
Example 27
Reaction Scheme 27
(:ON HOH
- -(fJ"' -yell I co,"__ ~~~.~~
-----~= -, ,,()
N 0 ~ o lb ~
---./0 R~
~ I ~ I R
\\ I
N R = H, 75a
72 73 R = H, 74a
R-F,75b
R-F, 74b
-( 4-Bromophenyl )methyloxazole (72)
Triflic acid (37 ml, 0.22 mol) was added dropwise to a solution of
thallium acetate (28.7 g, 0.07 mol) in acetonitrile (400 ml) at r.t under nitrogen.
The solution was stirred for 15 min before a solution of 4-bromobenzaldehyde in
acetonitrile (200 ml) was added and the solution heated to 90°C for 2.5 h. The
reaction mixture was concentrated and the red residue was taken up in DCM
(600 ml), washed with saturated NaHC03, water, dried (MgS04) and
concentrated to give a brown gum (12.7 g). Purification by flash silica column
chromatography (gradient elution i-hex to 70% EtOAc in i-hex) gave the title
compound as an orange solid (8.68 g, 72%). lCMS (ES+) 238,240 (M+Ht
E thyl( 4-(2-methyloxazolyl )phenyl )acrylate (73)
Following method E from compound 72 (8.68 g, 36
mmol).mlmlml The reaction solution was decanted from the palladium residues
and salts and then concentrated to give an orange solid. This was taken up in
DCM (150 ml), washed with water, dried (MgS04) and concentrated to give an
orange solid. This was triturated with diethyl ether to give the title compound as a
beige solid (6.18 mg, 66%). lCMS (ES+) 258 (M+H(
( 1R*,2R*,3R*)-Ethyl(4-(2-methyloxazolyl )phenyl )
phenylcyclopropanecarboxylate (7 4a)
Following method F from compound 73 (500 mg, 1.95 mmol) and
6a (756 mg, 2.92 mmol). The reaction was incomplete after 2 h. The reaction
was cooled to -20°C and an additional 1.5 equivalents of sulfonium salt, 12-
crown-4 and LiHMDS were added and the mixture stirred at r.t. overnight.
Purification by flash silica column chromatography (gradient elution i-hex to 30%
EtOAc in i-hex) gave the title compound as an orange oil (460 mg, 12:2:1
cinnammate:trans:cis). lCMS (ES+) 348 (M+H(
( 1 S*,2R*,3R*)-Ethyl(2-fl uorophenyl )( 4-(2-methyloxazol
yl )phenyl )cyclopropanecarboxylate (7 4b)
Following method F from compound 73 (500 mg, 1.95 mmol) and
1-(2-fluorobenzyl)tetrahydrothiophenium bromide (811 mg, 2.93 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 25%
EtOAc in i-hex) gave the title compound as an orange oil (888 mg, >100%, 3:1,
trans:cis). LCMS (ES+) 366 (M+Ht.
( 1 R,2R,3R)-N-Hyd roxy( 4-(2-methyloxazolyl )phenyl )
phenylcyclopropanecarboxam ide (75a)
Following method A from compound 74a (460 mg, 13% pure).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) and then preparative HPLC gave the racemic mixture as a white
solid (35 mg, 59%). Preparative chiral HPLC gave the title compound (Chiralpak
IC 40/60 EtOH (0.1% formic acid)/Heptane, 1.0 ml/min, RT 12.0 min). LCMS
(ES+) 335 (M+H( RT 3.28 min (Analytical method 1). NMR s (ppm)(DMSO
d5): 10.50 (1 H, s), 8.63 (1 H, s), 7.55 (2 H, d, J = 8.1 Hz), 7.43 (1 H, s), 7.34-7.23
(4 H, m), 7.23-7.15 (2 H, m), 7.14-7.07 (1 H, m), 3.05 (1 H, dd, J = 6.8, 5.4 Hz),
2.81 (1 H, dd, J = 9.6, 6.8 Hz), 2.40 (3 H, s), 2.16 (1 H, dd, J = 9.6, 5.4 Hz).
( 1 S,2R,3R)(2-FI uorophenyl )-N-hyd roxy( 4-(2-methyloxazol
yl )phenyl )cyclopropanecarboxam ide (75b)
Following method A from compound 74b (200 mg, 0.55 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) and then preparative HPLC gave the racemic mixture as a white
solid (99 mg, 54%). Preparative chiral HPLC gave the title compound (Chiralpak
IC 20/80 IPA/MeOH (50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 17.4 min).
LCMS (ES+) 353 (M+H( RT 3.41 min (Analytical method 1). NMR s
(ppm)(DMSO-d5): 10.67 (1 H, s), 8.80 (1 H, s), 7.68 (2 H, d, J = 8.1 Hz), 7.56 (1
H, s), 7.45 (3 H, dd, J = 12.1, 7.7 Hz), 7.33-7.26 (1 H, m), 7.21-7.11 (2 H, m),
3.12 (1 H, dd, J = 6.9, 5.3 Hz), 2.88 (1 H, dd, J = 9.3, 6.9 Hz), 2.53 (3 H, s ), 2.32
(1 H, dd, J = 9.3, 5.3 Hz).
Example 28
Reaction Scheme 28
( 1 R*,2R*,3R*)-Ethyl(3-( 5-methyl pyrim id inyl )phenyl )
phenylcyclopropanecarboxylate (76)
Following method G from the crude boronate derived from 15b
(565 mg) and 2-chloromethyl pyrimidine (194 mg, 1.51 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 25% EtOAc in i-hex)
gave the title compound as a colourless oil (260 mg, 50% ). LCMS (ES+) 359
(M+Ht.
( 1 R,2R,3R)-N-Hyd roxy(3-( 5-methyl pyrim id inyl )phenyl )
phenylcyclopropanecarboxam ide (77)
Following method A from compound 76 (260 mg, 0.73 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (220 mg, 88%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 40/60 EtOH (0.1 %
formic acid)/Heptane, 1.0 ml/min, RT 18.0 min). LCMS (ES+) 346 (M+Ht. RT
3.47 min (Analytical method 1). NMR o (ppm)(DMSO-d6): 10.52 (1 H, s), 8.70
(2 H, s), 8.65 (1 H, s), 8.19-8.13 (2 H, m), 7.40 (2 H, d, J = 5.2 Hz), 7.30 (2 H, d, J
= 7.6 Hz), 7.20 (2 H, t, J = 7.5 Hz), 7.12 (1 H, t, J = 7.2 Hz), 3.15 (1 H, dd, J = 6.8,
.4 Hz), 2.78 (1 H, dd, J = 9.6, 6.8 Hz), 2.30-2.20 (4 H, m).
Example 29
Reaction Scheme 29
( 1 R* ,2R* ,3R*)-Methyl 2-( 4-(3-methyl-1 H-pyrazolyl )phenyl )
phenylcyclopropanecarboxylate (78)
To a stirred solution of 15c (1.0 g, 3.02 mmol) in dioxane (5 ml)
was added bis-pinacolato diboron (844 mg, 3.32 mmol), Pd(dppf)Cl2 (246 mg,
0.30 mmol) and potassium acetate (1.48 g, 15.1 mmol). The mixture was
degassed with nitrogen, heated to 100°C for 2 h, diluted with H20 (20 ml) and
extracted into DCM (2 x 20 ml). The organic layers were passed through a
phase separator and concentrated. Part of this crude residue (600 mg, 1.5 mmol)
was dissolved in a mixture of MeOH (6 ml) and THF (4 ml) and to this was
added 3-methylpyrazole (145 µl, 1.8 mmol) and Cu20 (15 mg, 0.11 mmol). The
mixture was stirred at 100°C for 48 h, diluted with H20 (20 ml) and extracted into
DCM (50 ml). The organic layers were passed through a phase separator and
concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 60% EtOAc in i-hex) afforded the title compound as a cream solid
(150 mg, 30%). lCMS (ES+) 333 (M+Ht.
( 1R,2R,3R)-N-Hydroxy(4-(3-methyl-1 H-pyrazolyl )phenyl )
phenylcyclopropanecarboxam ide (79)
Following method A from compound 78 (148 mg, 0.45 mmol).
Purification by preparative HPlC gave the racemic mixture as a cream solid (69.8
mg, 47%). Preparative chiral HPlC gave the title compound (Chiralpak IC 40/60
IPA/MeOH (50/50/0.1 formic acid)/heptane, 1.0 ml/min, RT 9.0 min). RT 3.56
min (Analytical method 1). lCMS (ES+) 334 (M+Ht, RT 8.67 min. NMR s
(ppm)(DMSO-d6) 10.62 (1 H, s), 8.75 (1 H, s), 8.40 (1 H, d, J = 2.4 Hz), 7.79 (2 H,
d, J = 8.4 Hz), 7.47-7.37 (4 H, m), 7.32 (2 H, t, J = 7.5 Hz), 7.27-7.19 (1 H, m),
6.37 (1 H, d, J = 2.4 Hz), 3.18 (1 H, dd, J = 6.8, 5.4 Hz), 2.91 (1 H, dd, J = 9.6,
6.8 Hz), 2.32 (3 H, s), 2.27 (1 H, dd, J = 9.6, 5.4 Hz).
Example 30
Reaction Scheme 30
C02Et
Q _,,N
_,,N
ff''o
Cl N
CON HOH
(E)-Ethyl(6-chloropyrid inyl )acrylate (80)
NaH (792 mg, 20.0 mmol) was added portion wise to stirred
anhydrous DMSO (18 ml). The mixture was heated to 80°C until evolution of
gas ceased and then cooled to 0°C. A solution of (carbethoxymethyl)
triphenylphosphonium bromide (4.3 g, 10.0 mmol) in DMSO (36 ml) was then
added and the mixture stirred at r.t for 30 min. The mixture was cooled to 0°C
and a solution of 6-chloroisonicotinaldehyde (1.4 g, 10.0 mmol) in DMSO (36 ml)
was added and the mixture was stirred at r.t for 1 h. The mixture was then
poured into aqueous 1 M HCI and extracted into DCM (3 x 70 ml). The organics
were combined and washed with H20 (3 x 100 ml) and brine (3 x 100 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 80% EtOAc in i-hex) gave the title
compound as a yellow solid (0.95 g, 45%). lCMS (ES+) 212 (M+H(
( 1 S*,2R*,3R*)-E thyl(6-ch loropyrid inyl )(2-
fluorophenyl )cyclopropanecarboxylate (81)
Following method F from compound 80 (730 mg, 3.45 mmol) and
6b (1.43 g, 5.18 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 40% EtOAc in i-hex) gave the title compound (810 mg,
73%). lCMS (ES+) 320 (M+H(
( 1 S* ,2R* ,3R*)-Ethyl(2-fluorophenyl )(6-( 4-isopropylpiperazinyl )pyrid in
yl )cyclopropanecarboxylate (82)
A mixture of compound 81 (200 mg, 0.63 mmol) and
isopropylpiperazine (0.75 ml) was heated in the microwave at 180°C for 1 h. The
reaction mixture was dissolved in DCM (30 ml) and washed with water (2 x 20
ml). The organic layer was passed through a phase separator and concentrated
to afford a crude compound used in the next step (205 mg). lCMS (ES+) 412
(M+Ht.
(1 S, 2R, 3R)(2-Fluorophenyl)-N-hydroxy(6-(4-isopropylpiperazin
yl )pyrid inyl )cyclopropanecarboxam ide (83)
Following method A from compound 82 (200 mg, 0.45 mmol).
Purification by preparative HPlC gave the racemic mixture as a white solid (49.8
mg, 26%). Preparative chiral HPlC gave the title compound (Chiralpak IC 50/50
IPA/MeOH (50/50/0.1 formic acid)/heptane, 1.0 ml/min, RT 13.2 min). RT 2.18
min (Analytical method 1). lCMS (ES+) 399. NMR s (ppm)(DMSO-d5) 10.63
(1 H, s), 8.77 (1 H, s), 8.17 (1 H, s), 7.46-7.41 (2 H, m), 7.30-7.27 (1 H, m), 7.17-
7.14 (2 H, m), 6.86 (1 H, d, J = 8.8 Hz), 3.55-3.42 (5 H, m), 2.99-2.95 (1 H, m),
2.78-2.74 (2 H, m), 2.67-2.57 (3 H, m), 2.19 (1 H, dd, J = 9.0, 5.2 Hz), 1.06 (6 H,
d, J = 6.4 Hz).
Example 31
Reaction Scheme 31
CIYN Cl
....:::-
··.,,~
(E)-Ethyl(2,6-dichloropyridinyl)acrylate (84)
NaH (613 mg, 15.4 mmol) was added portion wise to stirred
anhydrous DMSO (10 ml). The mixture was heated to 80°C until evolution of
gas ceased and then cooled to 0°C. A solution of (carbethoxymethyl)
triphenylphosphonium bromide (3.29 g, 7.74 mmol) in DMSO (5 ml) was then
added and the mixture stirred at r.t for 30 min. The mixture was cooled to 0°C
and a solution of 2,6-dichloroisonicotinaldehyde (1.35 g, 7.74 mmol) in DMSO (5
ml) was added and the mixture was stirred at r.t for 1 h. The mixture was then
poured into aqueous 1 M HCI and extracted into DCM (3 x 50 ml). The organics
were combined and washed with H20 (3 x 100 ml) and brine (2 x 100 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 20% EtOAc in i-hex) gave the title
compound as a yellow solid (1.25 g, 66%). lCMS (ES+) 247 (M+H(
(E)-Ethyl(2-chlorocyclopropylpyridinyl)acrylate (85)
A stirred solution of compound 84 (1.29 g, 5.24 mmol), cyclopropyl
boronic acid (496 mg, 5.77 mmol), potassium phosphate (tribasic) (3.88 g, 18.3
mmol), Pd(OAc)2 (117 mg, 0.52 mmol) and tricyclohexylphosphine (1.05 ml, 1 M
in toluene, 1.05 mmol) in toluene/l-l-O (30ml/1.5 ml) was degassed using
nitrogen for 15 min and then heated at 100°C for 17 h. The reaction mixture was
allowed to cool, diluted with H20 (50 ml) and extracted into DCM (3 x 50 ml).
The combined organics were washed with H20 (2 x 50 ml) and brine (50 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 5% EtOAc in i-hex) gave the title
compound as a yellow solid (561 mg, 43%). lCMS (ES+) 252.5 (M+Ht.
( 1 S*,2R*,3R*)-E thyl(2-ch lorocyclopropyl pyrid inyl )(2-
fluorophenyl )cyclopropanecarboxylate (86)
Following method F from compound 85 and 6b (894 mg, 3.23
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 4% EtOAc in i-hex) gave the title compound (790 mg, 99%, 5:1 trans:cis).
lCMS (ES+) 360.5 (M+Ht.
(1 S*,2R*,3R*)-Ethyl(2,6-dicyclopropylpyridinyl)(2-
fluorophenyl)cyclopropanecarboxylate (87)
A stirred solution of compound 86 (162 mg, 0.45 mmol), cyclopropyl
boronic acid (62 mg, 0.72 mmol), potassium phosphate (tribasic) (0.49 g, 2.30
mmol), Pd(OAc)2 (14 mg, 0.065 mmol) and tricyclohexylphosphine (0.13 ml, 1 M
in toluene, 0.13 mmol) in toluene/l-l.O (5 ml/0.25 ml) was degassed using
nitrogen for 15 min and then heated at 100°C for 17 h. The mixture was allowed
to cool, diluted with H20 (10 ml) and extracted into DCM (3 x 10 ml). The
combined organics were washed with H20 (2 x 10 ml) and brine (10 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 5% EtOAc in i-hex) gave the title
compound (164 mg, 100%). LCMS (ES+) 366 (M+Ht.
( 1 S,2R,3R)(2 ,6-Dicyclopropyl pyrid inyl )(2-fl uorophenyl )-N
hyd roxycyclopropanecarboxam ide (88)
Following method A from compound 87 (164 mg, 0.45 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 3%
MeOH in DCM) gave the racemic mixture as a white solid (85 mg, 53%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 15/85 IPNMeOH
(50/50)/heptane, 1.0 ml/min, RT 9.3 min). RT 2.48 min (Analytical method 1).
LCMS (ES+) 353 (M+H( NMR s (ppm)(DMSO-d5): 10.86 (1 H, s), 9.01 (1 H,
s), 7.64-7.59 (1 H, m), 7.53-7.46 (1 H, m), 7.38-7.31 (2 H, m), 7.24 (0.2 H, s),
7.20 (1.8 H, s), 3.20-3.10 (2 H, m), 2.54 (1 H, dd, J = 9.3, 5.3 Hz), 2.26-2.17 (2 H,
m), 1.12-1.07 (8 H, m).
Example 32
Reaction Scheme 32
OYOEt
?OEt
N,N -
- N,N - N:ir""O
89a-b 90a-b 91a-b
R= t>->- 92a OYNHOH
N:ir""O
1-(Cyclopropylmethyl)iodo-1 H-pyrazole (89a)
To a solution of 4-iodopyrazole (960 mg, 5 mmol) in DMF (6 ml) at
0 °C was added NaH (227 mg, 5.9 mmol) and the mixture was stirred for 1 h.
Then cyclopropyl bromide (755 mg, 5.9 mmol) was added and the reaction
mixture was stirred at r.t. overnight. The reaction mixture was quenched with sat
NaHC03 and extracted with EtOAc. The organic layer was dried (MgS04),
filtered and concentrated to afford a crude used in the next step without further
purification (905 mg, 73%). lCMS (ES+) 249 (M+Ht.
2-(4-lodo-1 H-pyrazolyl)(trifluoromethyl)pyridine (89b)
To a solution of 4-iodopyrazole (960 mg, 5 mmol) in DMF (10 ml) at
0 °C was added Cs2C03 (2.4 g, 7.4 mmol) and 5-trifluoromethylchloropyridine
(1.5 g, 8.3 mmol). The reaction mixture was stirred at 60°C overnight. The
reaction mixture was quenched with H20 and extracted with EtOAc. The organic
layer was dried (MgS04), filtered and concentrated to afford a crude used in the
next step without further purification (1.29 g, 76%). lCMS (ES+) 340 (M+Ht.
(E)-Ethyl(1-(cyclopropylmethyl)-1 H-pyrazolyl)acrylate (90a)
A mixture of compound 89a (900 mg, 3.6 mmol), palladium acetate
(10 mg, 0.04 mmol), P(OEt)3 (27 µl, 0.16 mmol), EbN (1 ml, 7.2mmol) and ethyl
acrylate in DMF (10 ml) was stirred at 80°C for 17 h. The reaction mixture was
partitioned between water and EtOAc, the organic layer was washed with water
and 4% aq. LiCI, dried (MgS04), filtered and concentrated. Purification by flash
silica column chromatography (gradient elution i-hex to 40% EtOAc in i-hex) gave
the title compound as a yellow oil (489 mg, 62%). lCMS (ES+) 221 (M+Ht.
(E)-Ethyl 3-(1-(5-(trifluoromethyl)pyridinyl)-1 H-pyrazolyl)acrylate (90b)
To a solution of compound 89b (960 mg, 5 mmol) in DMF (10 ml)
at 0°C was added Cs2C03 (2.4 g, 7.4 mmol) and 5-trifluoromethyl
chloropyridine (1.5 g, 8.3 mmol). The reaction mixture was stirred at 60°C
overnight. The reaction mixture was quenched with H20 and extracted with
EtOAc. The organic layer was dried (MgS04), filtered and concentrated to afford
a crude used in the next step without further purification (1.29 g, 76%). lCMS
(ES+) 340 (M+H(
(1 R*,2R*,3R*)-Ethyl(1-(cyclopropylmethyl)-1 H-pyrazolyl)
phenylcyclopropanecarboxylate (91 a)
Following method F from compound 90a (195 mg, 0.89 mmol) and
1-benzyltetrahydrothiophenium triflate (436 mg, 1.33 mmol). The reaction was
incomplete after 1 h. The reaction was cooled to -20°C and an additional 1.5
equivalents of sulfonium salt, 12-crown-4 and LiHMDS were added and the
mixture stirred at r.t. overnight. Purification by flash silica column chromatography
(gradient elution i-hex to 25% EtOAc in i-hex) gave the title compound as a yellow
oil (250 mg, 93%, 1 :1 trans:cis). LCMS (ES+) 311 (M+H(
( 1R*,2R*,3R*)-Ethylphenyl(1-(5-(trifluoromethyl )pyrid inyl )-1 H-pyrazol
yl )cyclopropanecarboxylate (91 b)
Following method F from compound 90b (263 mg, 0.85 mmol) and
1-benzyltetrahydrothiophenium triflate (416 mg, 1.27 mmol). The reaction was
incomplete after 1 h. The reaction was cooled to -20°C and an additional 1.5
equivalents of sulfonium salt, 12-crown-4 and LiHMDS were added and the
mixture stirred at r.t. overnight. Purification by flash silica column chromatography
(gradient elution i-hex to 10% EtOAc in i-hex) gave the title compound as a yellow
oil (207 mg, 61 %, 5:4 trans:cis). LCMS (ES+) 402 (M+H(
( 1R,2R,3R)(1-(Cyclopropylmethyl )-1 H-pyrazolyl )-N-hydroxy
phenylcyclopropanecarboxam ide (92a)
Following method A from compound 91a (250 mg, 0.81 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (65 mg, 27%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 20/80 IPNMeOH
(50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 12.0 min). RT 3.12 min
(Analytical method 1). LCMS (ES+) 298 (M+H( NMR s (ppm)(DMSO-d6):
.42 (1 H, s), 8.57 (1 H, s), 7.65 (0.1 H, s), 7.63 (0.9 H, s), 7.31 (0.1 H, s), 7.28
(0.9 H, s), 7.24-7.13 (4 H, m), 7.11-7.06 (1 H, m), 3.82 (2 H, d, J = 7.1 Hz), 2.80
(1 H, dd, J = 6.8, 5.3 Hz), 2.59 (1 H, dd, J = 9.4, 6.8 Hz), 1.91 (1 H, dd, J = 9.4,
.3 Hz), 1.17-1.07 (1 H, m), 0.46-0.39 (2 H, m), 0.29-0.24 (2 H, m)
( 1R,2R,3R)-N-Hydroxyphenyl(1-( 5-(trifluoromethyl )pyrid inyl )-1 H-pyrazol-
4-yl )cyclopropanecarboxam ide (92b)
Following method A from compound 91 b (263 mg, 0.85 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM), then preparative chiral HPLC (Chiralpak IC 20/80 IPA/MeOH
(50/50/0.1 % formic acid)/Heptane, 1.0 ml/min, RT 10.2 min) and preparative
achiral HPLC gave the title compound (15 mg, 20%). RT 3.12 min (Analytical
method 4). LCMS (ES+) 389 (M+Ht. NMR s (ppm)(DMSO-d6): 10.51 (1 H,
s), 8.84 (1 H, s), 8.64 (1 H, s), 8.61 (1 H, s), 8.33 (1 H, dd, J = 8.7, 2.4 Hz), 8.03
(1 H, d, J = 8.7 Hz), 7.89 (1 H, s), 7.27 (2 H, d, J = 7.5 Hz), 7.22 (2 H, t, J = 7.5
Hz), 7.14 (1 H, d, J = 7.2 Hz), 2.99 (1 H, dd, J = 6.9, 5.3 Hz), 2.84 (1 H, dd, J =
9.4, 6.9 Hz), 2.12 (1 H, dd, J = 9.4, 5.3 Hz)
Example 33
Reaction Scheme 33
Boe~
t~JJ ~.Ph
S:,_ 02Me
CONHOH CO Me
F,C(~'Ph ~ t)crl~Ph ~ "(~'Ph
0 98 0 97 96
(E)( 4-( tert-Butoxycarbonyl )-2,3,4 ,5-tetrahydrobenzo[~ [1 ,4 ]oxazepinyl )acrylic
acid (93)
To a stirred solution of tert-butylbromo-2,3-
dihydrobenzojjjj l ,4]oxazepine-4(5H)-carboxylate (480 mg, 1.46 mmol) in dioxane
(20 ml) was added (E)-ethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)acrylate (360 mg, 1.61 mmol), aqueous Na2C03 (1.44 ml, 2 M, 2.92 mmol)
and Pd(dppf)Cl2 (33 mg, 0.04 mmol). The mixture was degassed with nitrogen
and then heated at 90°C for 17 h. The reaction mixture was diluted with H20 and
extracted into DCM. The organic layer was passed through a phase separator
and concentrated. Purification by flash silica column chromatography (gradient
elution i-hex to 25% EtOAc in i-hex) gave the title compound as a yellow oil (267
mg, 57%). lCMS (ES+) 320 (M+Ht.
(E)-tert-Butyl(3-methoxyoxopropenyl)-2,3-
d ihydrobenzojr] [1 ,4 ]oxazepine-4(5H )-carboxylate (94)
To a stirred solution of compound 93 (267 mg, 0.84 mmol) in MeOH
(30 ml) was added H2S04 (3 drops) and the mixture heated to 80°C for 17 h.
The reaction mixture was concentrated and purified by flash silica column
chromatography (gradient elution DCM to 25% MeOH in DCM) to give the
deprotected amine (270 mg, 1.16 mmol). This was dissolved in DCM (10 ml)
and di-tert-butyl dicarbonate (304 mg, 1.39 mmol) and DIPEA (0.4 ml, 2.32
mmol) added. The solution was stirred at r.t for 2 hand then diluted with H20 (50
ml) and DCM (40 ml). The biphasic mixture was shaken and the organics
collected. The aqueous layer was re-extracted with DCM (50 ml) and the
combined organics passed through a phase separator and concentrated.
Purification by flash silica column chromatography (gradient elution i-hex to 25%
EtOAc in i-hex) gave the title compound as a yellow oil (230 mg, 60%). lCMS
(ES+) 333 (M+H(
terl-Butyl( ( 1 R* ,2R* ,3R*)(methoxycarbonyl )phenylcyclopropyl )-2,3-
d ihydrobenzo[f] [1 ,4 ]oxazepine-4(5H )-carboxylate (95)
Following method F from compound 94 (200 mg, 0.60 mmol) and
1-benzyltetrahydrothiophenium triflate (296 mg, 0.90 mmol). Purification by flash
silica column chromatography (gradient elution i-hex to 20% EtOAc in i-hex) gave
the title compound as a colourless oil (206 mg, 84%, 5:4 trans:cis). lCMS (ES+)
424 (M+H(
( 1 R*,2R*,3R*)-Methylphenyl(2,3,4 ,5-tetrahydrobenzo[~ [1,4 ]oxazepin
yl )cyclopropanecarboxylate (96)
To a stirred solution of compound 95 (206 mg, 0.50 mmol) in MeOH
(10 ml) was added H2S04 (3 drops) and the mixture heated to 80°C for 1 h. The
reaction mixture was concentrated, dissolved in a minimum quantity of
DCM:MeOH (1 :1) and loaded onto an sex-cartridge (elution with 5% (7 M NH3 in
MeOH) in DCM:MeOH (1 :1 )). The sample was concentrated to give a colourless
oil (137 mg, 88%).
(1 R*,2R*,3R*)-Methylphenyl(4-(2,2,2-trifluoroethyl)-2,3,4,5-
tetrahydrobenzojr] [1,4 ]oxazepinyl )cyclopropanecarboxylate (97)
To a stirred solution of compound 96 (137 mg, 0.45 mmol) in DMF
(5 ml) was added DIPEA (0.23 ml, 1.35 mmol) and 2,2,2-trifluoroethyl
methylbenzenesulfonate (172 mg, 0.68 mmol) and the mixture heated to 80°C for
2 h. The reaction was partitioned between DCM (50 ml) and H20 (50 ml), and
the organics collected. The aqueous portion was extracted with DCM (50 ml),
and the combined organics washed with H20 (5 x 50 ml) and 4 % aqueous LiCI
(100 ml). The organics were collected, dried (MgS04), filtered and concentrated.
Purification by flash silica column chromatography (gradient elution i-hex to 10%
EtOAc in i-hex) gave the title compound as a colourless oil (126 mg, 72%).
LCMS (ES+) 390 (M+H(
(1 R*,2R*,3R*)-N-Hydroxyphenyl(4-(2,2,2-trifluoroethyl)-2,3,4,5-
tetrahydrobenzojr] [1,4 ]oxazepinyl )cyclopropanecarboxam ide (98)
Following method A from compound 97 (126 mg, 0.32 mmol).
Purification by preparative HPLC gave the racemic mixture as a white solid (33
mg, 25%). Preparative chiral HPLC gave the title compound (Chiralpak IC 10/90
EtOH (0.1 % formic acid)/heptane, 1.0 ml/min, RT 12.9 min). RT 3.70 min
(Analytical method 1). LCMS (ES+) 407 (M+Ht. NMR s (ppm)(DMSO-d5):
.46 (1 H, s), 8.60 (1 H, s), 7.24 (2 H, d, J = 7.6 Hz), 7.21-7.15 (2 H, m), 7.13-
7.07 (1 H, m), 7.05-7.01 (2 H, m), 6.87 (1 H, d, J = 7.9 Hz), 3.92-3.88 (2 H, m),
3.84 (2 H, s), 3.19-3.03 (4 H, m), 2.97 (1 H, dd, J = 6.8, 5.4 Hz), 2.72 (1 H, dd, J =
9.5, 6.8 Hz), 2.07 (1 H, dd, J = 9.5, 5.4 Hz).
Example 34
Reaction Scheme 34
CON HOH
( 1 S*,2R*,3R*)-E thyl(3-ch lorophenyl )(2-cyclopropyl pyrid in
yl )cyclopropanecarboxylate (99a)
1-(3-Chlorobenzyl)tetrahydro-1 H-thiophenium bromide was
synthesized using the same preparation as compound 6b, from 1-(bromomethyl)-
3-chlorobenzene. Following method F from compound 26b (190 mg, 0.88 mmol)
and 1-(3-chlorobenzyl)tetrahydro-1 H-thiophenium bromide (385 mg, 1.31
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 25% EtOAc in i-hex) gave the title compound as a colourless oil (299 mg,
>99%, 3:2 trans:cis). LCMS (ES+) 342.5 (M+Ht.
( 1 S*,2R*,3R*)-E thyl(3-fl uorophenyl )(2-cyclopropyl pyrid in
yl )cyclopropanecarboxylate (99b)
1-(3-Fluorobenzyl)tetrahydro-1 H-thiophenium bromide was
synthesized using the same preparation as compound 6b, from 1-(bromomethyl)-
3-fluorobenzene. Following method F from compound 26b (190 mg, 0.88 mmol)
and 1-(3-chlorobenzyl)tetrahydro-1 H-thiophenium bromide (363 mg, 1.31
mmol). Purification by flash silica column chromatography (gradient elution i-hex
to 25% EtOAc in i-hex) gave the title compound as a colourless oil (243 mg, 85%,
3:2 trans:cis). LCMS (ES+) 326 (M+H(
(1 S,2R,3R)(3-Chlorophenyl)(2-cyclopropylpyridinyl)-N
hydroxycyclopropanecarboxamide (100a)
Following method A from compound 99a (299 mg, 0.88 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) and preparative HPLC gave the racemic mixture as a white solid
(100 mg, 35%). Preparative chiral HPLC gave the title compound (Chiralpak IC
30170 EtOH (0.1 % formic acid) /heptane, 1.0 ml/min, RT 8.6 min). RT 2.36 min
(Analytical method 1). LCMS (ES+) 329 (M+Ht. NMR s (ppm)(DMSO-d6):
.56 (1 H, s), 8.72 (1 H, s), 8.21 (1 H, d, J = 5.1 Hz), 7.32 (1 H, s), 7.27-7.13 (4
H, m), 6.96 (1 H, dd, J = 5.2, 1.7 Hz), 3.03 (1 H, dd, J = 6.7, 5.3 Hz), 2.92 (1 H,
dd, J = 9.6, 6.8 Hz), 2.23 (1 H, dd, J = 9.6, 5.4 Hz), 2.02-1.94 (1 H, m), 0.88-0.80
(4 H, m).
(1 S,2R,3R)(2-Cyclopropylpyridinyl)(3-fluorophenyl)-N
hydroxycyclopropanecarboxam ide ( 1 OOb)
Following method A from compound 99b (243 mg, 0.75 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) and preparative HPLC gave the racemic mixture as a white solid
(95 mg, 41 % ). Preparative chiral HPLC gave the title compound (Chiralpak IC
/80 IPA/MeOH (50/50/0.1 % formic acid) /heptane, 1.0 ml/min, RT 12.1 min).
RT 2.21 min (Analytical method 1). LCMS (ES+) 313 (M+Ht. NMR s
(ppm)(DMSO-d5): 10.55 (1 H, s), 8.70 (1 H, s), 8.21 (1 H, d, J = 5.1 Hz), 7.27-
7.18 (1 H, m), 7.16-7.04 (3 H, m), 6.97-6.90 (2 H, m), 3.02 (1 H, dd, J = 6.6, 5.2
Hz), 2.91 (1 H, dd, J = 9.6, 6.7 Hz), 2.24 (1 H, dd, J = 9.7, 5.4 Hz), 2.01-1.94 (1
H, m), 0.88-0.80 (4 H, m).
Example 35
Reaction Scheme 35
OYOMe
~ ~;;r .. ,o
15c r 101
( 1 S*,2R*,3R*)(2 ,6-Dicyclopropyl pyrid inyl )(2-fl uorophenyl )-N
hyd roxycyclopropanecarboxam ide (101)
A mixture of 15c (250 mg, 0.75 mmol), 5-methyl
(tributylstannyl)thiazole (350 mg, 0.90 mmol) and Pd(PPh3)4 (43 mg, 0.037 mmol)
in dioxane (4 ml) was heated under microwave irradiation at 150 °C for 1 h. The
reaction mixture was concentrated and purified by flash silica column
chromatography (gradient elution i-hex to 20% EtOAc in i-hex) to give the title
compound (180 mg, 69%). LCMS (ES+) 350 (M+Ht.
( 1 R,2 R,3R )-N-hyd roxy( 4-( 5-methylth iazolyl )phenyl )
phenylcyclopropanecarboxam ide ( 102)
Following method A from compound 101 (160 mg, 0.46 mmol).
Purification by flash silica column chromatography (gradient elution DCM to 5%
MeOH in DCM) gave the racemic mixture as a white solid (150 mg, 93%).
Preparative chiral HPLC gave the title compound (Chiralpak IC 40/60 IPNMeOH
(50/50/0.1 % formic acid)/heptane, 1.0 ml/min, RT 11.8 min). RT 3.72 min
(Analytical method 1). LCMS (ES+) 351 (M+Ht. NMR s (ppm)(DMSO-d6):
.53 (1 H, s), 8.65 (1 H, s), 7.75 (2 H, d, J = 8.1 Hz), 7.51 (1 H, d, J = 1.4 Hz),
7.34-7.23 (4 H, m), 7.19 (2 H, t, J = 7.5 Hz), 7.11 (1 H, t, J = 7.2 Hz), 3.07 (1 H,
dd, J = 6.8, 5.4 Hz), 2.82 (1 H, dd, J = 9.6, 6.8 Hz), 2.42 (3 H, under DMSO), 2.19
(1 H, dd, J = 9.6, 5.4 Hz).
Example 36
Reaction Scheme 36
OYNHOH
I '<::::
I '<::::
---- ----
---- ~·····6'<::::
F C/'.NJLNJ _.;:;;
Cl 3 H
103 104 105
(E)-Ethyl(6-chloropyrid inyl )acrylate ( 103)
NaH (792 mg, 20.0 mmol) was added portion wise to stirred
anhydrous DMSO (18 ml). The mixture was heated to 80°C until evolution of
gas ceased and then cooled to 0°C. A solution of (carbethoxymethyl)
triphenylphosphonium bromide (4.3 g, 10.0 mmol) in DMSO (36 ml) was then
added and the mixture stirred at r.t for 30 min. The mixture was cooled to 0°C
and a solution of 6-chloroisonicotinaldehyde (1.4 g, 10 mmol) in DMSO (36 ml)
was added and the mixture was stirred at r.t for 1 h. The mixture was then
poured into aqueous 1 M HCI and extracted into DCM (3 x 70 ml). The organics
were combined and washed with H20 (3 x 100 ml) and brine (3 x 100 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 80% EtOAc in i-hex) gave the title
compound as a yellow solid (0.95 g, 45%). lCMS (ES+) 212 (M+H(
( 1 S*,2R*,3R*)-E thyl(6-ch loropyrid inyl )(2-
fluorophenyl )cyclopropanecarboxylate ( 104)
Following method F from compound 103 (730 mg, 3.45 mmol) and
6b (1.43 g, 5.18 mmol). Purification by flash silica column chromatography
(gradient elution i-hex to 40% EtOAc in i-hex) gave the title compound (810 mg,
73%). lCMS (ES+) 320 (M+H(
( 1 S* ,2R* ,3R*)-Ethyl(2-fluorophenyl )(6-( (2,2,2-trifluoroethyl )amino )pyridin
yl )cyclopropanecarboxylate (105)
A mixture of compound 104 (65 mg, 0.203 mmol),
trifluoroethylamine (1.0 ml) and NMP (1.0 ml) was heated in the microwave at
225°C for 1.30 h. The reaction mixture was concentrated and the crude
compound purified by flash silica column chromatography (gradient elution DCM
to 10% MeOH in DCM) gave the title compound as a yellow solid (42 mg, 54%).
lCMS (ES+) 383 (M+H(
(1 S, 2R, 3R)(2-Fluorophenyl)-N-hydroxy(6-((2,2,2-
trifluoroethyl)amino )pyridinyl)cyclopropanecarboxamide (106)
Following method A from compound 105 (40 mg, 0.105 mmol).
Post work-up the racemic compound was obtained as a white solid (38 mg,
98% ). Preparative chiral HPlC gave the title compound (Chiralpak IC 15/85
EtOH/heptane, 1.0 ml/min, RT 9.2 min). RT 2.60 min (Analytical method 1)
lCMS (ES+) 370. NMR s (ppm)(DMSO-d5): 10.52 (1 H, s), 8.65 (1 H, s), 7.96
(1 H, t, J = 2.4 Hz), 7.33-7.25 (2 H, m), 7.20-7.13 (1 H, m), 7.07-6.93 (3 H, m),
6.53 (1 H, d, J = 8.6 Hz), 4.14-4.01 (2 H, m), 2.83 (1 H, dd, J = 6.9, 5.3 Hz), 2.63
(1 H, dd, J = 9.2, 7.0 Hz), 2.05 (1 H, dd, J = 9.2, 5.3 Hz).
Example 37
Reaction Scheme 37
C02Et CON HOH
F,c-{d-o ~ F,c-{~·-o
(E)-Ethyl(2-(trifluoromethyl)imidazo[1,2-a]pyridinyl )acrylate (107)
A stirred mixture of 7-bromo(trifluoromethyl)imidazo[1,2-
a]pyridine (1.00 g, 3.77 mmol), ethyl acrylate (0.53 ml, 4.91 mmol), palladium
acetate (84.6 mg, 0.38 mmol), P(o-tol)3 (33 mg, 0.76 mmol) and triethylamine
(1.05 ml, 7.55 mmol) in MeCN (1 Oml) was degassed under nitrogen for 15 min
and heated to 80°C for 18 h. The reaction mixture was cooled and the MeCN
was removed in vacuo. The residue was partitioned between DCM and H20 and
the organic layers were passed through a phase separator and concentrated.
Purification by flash silica column chromatography (gradient elution i-hex to 100%
EtOAc) gave the title compound as a pale yellow solid (1.09 g, 100%). lCMS
(ES+) 285 (M+H(
( 1 R*,2R*,3R*)-Ethylphenyl(2-(trifluoromethyl )im idazo[1 ,2-a]pyrid in
yl )cyclopropanecarboxylate (108)
Following method F from compound 107 (0.83 mg, 2.92 mmol) and
1-(2-fluorobenzyl)tetrahydro-1 H-thiophenium triflate (1.44 mg, 4.38 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 30%
EtOAc in i-hex) gave the title compound as a pale yellow oil (540mg, 49%, 2:1
trans:cis). lCMS (ES+) 375 (M+Ht.
( 1 R,2R,3R)-N-Hydroxyphenyl(2-(trifluoromethyl )im idazo[1 ,2-a]pyrid in
yl )cyclopropanecarboxam ide (109)
Following method A from compound 108 (540 mg, 1.44 mmol).
Purification by preparative-HPlC gave the racemic product as a pale yellow solid
(215 mg, 41 %). Preparative chiral purification afforded the title compound
(Chiralpak IC 40/60 IPA/MeOH(50/50)/Heptane 5.0 ml/min, RT 7.46 min.) lCMS
(ES+) 362 (M+Ht, RT 3.35 min. (Analytical method 1); NMR s (ppm)(DMSO
d6): 10.62 (1 H, s), 8.72 (1 H, s), 8.64 (1 H, s), 8.43 (1 H, s), 7.66 (1 H, d, J = 9.4
Hz), 7.39-7.33 (3 H, m), 7.32-7.24 (2 H, m), 7.23-7.16 (1 H, m), 3.19 (1 H, dd, J =
6.8, 5.4 Hz), 2.91 (1 H, dd, J = 9.6, 6.9 Hz), 2.26 (1 H, dd, J = 9.6, 5.4 Hz).
Example 38
Reaction Scheme 38
(E)-Ethyl(2-methylthiazolyl)acrylate (110)
Following method C to a stirred solution of 2-methyl-1,3 thiazole-50
carboxaldehyde (1.00 g, 7.86 mmol) in anhydrous THF (10 ml) at -10°C was
added sodium hydride (0.63 g, 16.0 mmol) portionwise over 10 min. This was
stirred for a further 30 min at -10°C then triethylphoshonoacetate (3.12 ml, 16.0
mmol) in THF (10 ml) was added dropwise at -10°C. The solution was warmed to
RT and stirred for 18 h. The reaction mixture was poured into iced water and
extracted with ethyl acetate. The organic layer was washed with brine, dried
(MgS04), filtered and concentrated to give a dark brown gum (1.97 g).
Purification by flash silica column chromatography (gradient elution i-hex to 100%
EtOAc in i-hex) gave the title compound as a pale yellow solid (1.39 g, 89%).
lCMS (ES+) 198 (M+H(
(1 R*,2R*,3S*)-Ethyl(2-methylthiazolyl)phenylcyclopropanecarboxy (111)
Following method F from compound 110 (0.72 g, 3.65 mmol) and
1-(2-fluorobenzyl)tetrahydro-1 H-thiophenium triflate (1.80 g, 5.48 mmol).
Purification by flash silica column chromatography (gradient elution i-hex to 30%
EtOAc in i-hex) gave the title compound as a pale yellow oil (392 mg, 37%, 4:1
trans:cis). LCMS (ES+) 287 (M+Ht.
( 1 R,2R,3S)-N-Hyd roxy(2-methylth iazolyl )
phenylcyclopropanecarboxam ide ( 112)
Following method A from 111 (390 mg, 1.36 mmol). Purification by
preparative-HPLC gave the the racemic product as a pale yellow solid (240 mg,
64 %). Preparative chiral purification gave the title compound (Chiralpak IC 40/60
IPNMeOH(50/50)/Heptane 5.0 ml/min, RT 6.05 min). LCMS (ES+) 275 (M+Ht,
RT 2.86 min. (Analytical method 1); NMR s (ppm)(DMSO-d6): 10.59 (1 H, s),
8.72 (1 H, s), 7.53 (1 H, s), 7.33-7.21 (4 H, m), 7.22-7.15 (1 H, m), 3.26-3.20 (1 H,
m), 2.81 (1 H, dd, J = 9.6, 6.8 Hz), 2.60 (3 H, s), 2.16 (1 H, dd, J = 9.6, 5.3 Hz).
Example 39
Reaction Scheme 39
114 115
(E)-Ethyl(imidazo[1,2-a]pyridinyl)acrylate (113)
Following method C from imidazo[1,2-a]pyridinecarbaldehyde (1
g, 6.85 mmol). Purification by flash silica column chromatography (gradient
elution i-hex to 75% EtOAc in i-hex) gave the title compound (800 mg, 54%).
LCMS (ES+) 217 (M+H(
(1 R*,2R*,3R*)-Ethyl(imidazo[1,2-a]pyridinyl)
phenylcyclopropanecarboxylate ( 114)
Following method F from 113 (800 mg, 3.70 mmol) and 1-(2-
fluorobenzyl)tetrahydro-1 H-thiophenium triflate (1.82 mg, 5.56 mmol). Purification
by flash silica column chromatography (gradient elution i-hex to 100% EtOAc in i
hex) gave the title compound (813 mg, 72%). LCMS (ES+) 307 (M+H(
( 1 R,2R,3R)-N-hydroxy(im idazo[1 ,2-a]pyrid inyl )
phenylcyclopropanecarboxam ide ( 115)
Following method A from 114 (813 mg, 2.66 mmol). Precipitation
from DCM gave the title compound as a white solid (400 mg, 51 %). Preparative
chiral purification gave 8 (Chiralpak IC 40/60 IPA/MeOH(50/50)/Heptane 5.0
ml/min, RT 10.4 min). lCMS (ES+) 294 (M+Ht, RT 2.05 min. (Analytical method
1); NMR o (ppm)(DMSO-d6): 10.56 (1 H, s), 8.72 (1 H, s), 8.14 (1 H, d, J = 6.7
Hz), 7.52 (1 H, d, J = 9.0 Hz), 7.43 (0.1 H, s), 7.41 (1 H, s), 7.35 (2 H, d, J = 7.5
Hz), 7.26-7.13 (4 H, m), 6.97-6.93 (1 H, m), 3.20 (1 H, dd, J = 6.8, 5.4 Hz), 2.84
(1 H, dd, J = 9.5, 6.8 Hz), 2.09 (1 H, dd, J = 9.5, 5.4 Hz).
Example 40
Reaction Scheme 40
117 118
(E)-Ethyl(5-chloropyridinyl)acrylate (116)
NaH (570 mg, 14.24 mmol) was added portion wise to stirred
anhydrous DMSO (10 ml). The mixture was heated to 80°C until evolution of
gas ceased and then cooled to 0°C. A solution of (carbethoxymethyl)
triphenylphosphonium bromide (3.05 g, 7.12 mmol) in DMSO (10 ml) was then
added and the mixture stirred at r.t for 30 min. The mixture was cooled to 0°C
and a solution of 5-chloronicotinaldehyde (1.0 g, 7.12 mmol) in DMSO (10 ml)
was added and the mixture was stirred at r.t for 1 h. The mixture was then
poured into aqueous 1 M HCI and extracted into DCM (3 x 50 ml). The organics
were combined and washed with H20 (3 x 100 ml) and brine (3 x 100 ml),
separated, dried (MgS04) and concentrated. Purification by flash silica column
chromatography (gradient elution i-hex to 25% EtOAc in i-hex) gave the title
compound as a yellow solid (1.1g,57%). lCMS (ES+) 271 (M+H(
( 1 R*,2R*,3R*)-Ethyl( 5-ch loropyrid inyl )phenylcyclopropanecarboxylate
(117)
Following method F from 116 (1.1 g, 4.07 mmol) and 1-(2-
fluorobenzyl)tetrahydro-1 H-thiophenium triflate (2.0 g, 6.10 mmol). Purification by
flash silica column chromatography (gradient elution i-hex to 15% EtOAc in i-hex)
gave the title compound (396 mg, 54%). lCMS (ES+) 361 (M+Ht.
(1 R,2R,3R)(5-Chloropyridinyl)-N-hydroxy
phenylcyclopropanecarboxam ide ( 118)
Following method A from 117 (396 mg, 1.10 mmol). Purification by
flash silica column chromatography (gradient elution DCM to 5% MeOH in DCM)
and preparative HPLC purification gave the racemic compound (161 mg, 51%).
Preparative chiral purification gave the title compound (Chiralpak IC 40/60
IPNMeOH(50/50/0.1 % formic acid)/heptane 5.0 ml/min, RT 7.74 min). LCMS
(ES+) 289 (M+Ht, RT 3.10 min. (Analytical method 1); NMR s (ppm)(DMSO
d6): 10.47 (1 H, s), 8.61 (1 H, s), 8.49 (1 H, d, J = 1.9 Hz), 8.40 (1 H, d, J = 2.3
Hz), 7.78-7.73 (1 H, m), 7.26 (2 H, d, J = 7.6 Hz), 7.19 (2 H, t, J = 7.5 Hz), 7.11 (1
H, t, J = 7.2 Hz), 3.10 (1 H, dd, J = 6.8, 5.4 Hz), 2.93 (1 H, dd, J = 9.6, 6.9 Hz),
2.26 (1 H, dd, J = 9.6, 5.4 Hz).
Example 41
The following examples may be prepared according to methods
substantially as described above.
Table 6
Structure IUPAC Name
O<:::rNHOH
( 1 S,2R,3S)(2-fluorophenyl )-N-hydroxymethyl( 4-
N~"o
(2-methyloxazolyl )phenyl )cyclopropanecarboxam ide
O<:::rNHOH
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-(3-methyl-
ff"'6
1 H-pyrazolyl )phenyl )cyclopropanecarboxam ide
O<:::rNHOH
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-(3-
(trifluoromethyl)-1 H-pyrazol
~~ N
yl )phenyl )cyclopropanecarboxam ide
O~NHOH
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(4-
(isopropyl(2-
~N I b I b
d··O
morphol inoethyl )amino )phenyl )cyclopropanecarboxam id
-..../'N
,)_.__
O";rNH
( 1 R,2R,3R)(2-cyclopropyl pyrim id inyl )-N-hyd roxy
phenylcyclopropanecarboxam ide
v>::r"o
O";rNH
(1 R,2R,3R)(benzo[d]isoxazolyl)-N-hydroxy
phenylcyclopropanecarboxam ide
q,r.o
o-N fi
O~NHOH
~-- .. ,o
(1 R,2R,3R)(6-cyclopropylpyridazinyl)-N-hydroxy
phenylcyclopropanecarboxam ide
O";rNHOH
ff··O
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(6-(3-methyl-
~~ N
N 1 H-pyrazolyl )pyrid inyl )cyclopropanecarboxam ide
O";rNHOH
( 1 S ,2R,3R)( 6-( 5-ch loropyrim id inyl )pyrid inyl )
,~··O
(2-fluorophenyl)-N-hydroxycyclopropanecarboxamide
Cl N
OYN'OH
(1 R,2R,3R)(5-chloro(4-isopropylpiperazin
yl )pyrid inyl )-N-hyd roxy
r,q4~c
phenylcyclopropanecarboxam ide
IN-..) Cl
(1 S,2R,3R)(2-fluorophenyl)(6-(5-fluoropyrimidin
yl)pyridinyl)-N-hydroxycyclopropanecarboxamide
OyNHOH
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(6-(5-
methyl pyrim id inyl )pyrid in
J:~·-6 yl )cyclopropanecarboxam ide
OYNHOH
( 1 R,2R,3R)-N-hyd roxy(6-(2-methyloxazolyl )pyrid in-
o ~1Y .. ·o
3-yl )phenylcyclopropanecarboxam ide
(1 R,2R,3R)(5-chloro(2-methyloxazolyl)pyridin
yl )-N-hyd roxyphenylcyclopropanecarboxam ide
(1 S,2R,3R)(2-fluorophenyl)-N-hydroxy(2-(2,2,2-
trifluoroethylam ino )pyrid in
yl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxyphenyl(1-(2,2,2-
trifluoroethyl )-1 H-pyrazolyl )cyclopropanecarboxam ide
OyN'OH
(1 R,2R,3R)(1-cyclopropyl-1 H-pyrazolyl)-N-hydroxy-
No('···o 3-phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxyphenyl(1-(1-(2,2,2-
trifluoroethyl )pipe rid inyl )-1 H-pyrazol
yl )cyclopropanecarboxam ide
OYN'OH
(1 R,2R,3R)(1,3-dimethyl-1 H-pyrazolyl)-N-hydroxy-
3-phenylcyclopropanecarboxam ide
NY""O
OYN'OH
( 1 R,2R,3S)-N-hydroxy(2-methylth iazolyl )
phenylcyclopropanecarboxam ide
-<r· .. o
(1 R,2R,3R)(8-chloro-1,2,3,4-tetrahydroquinolinyl)
N-hyd roxyphenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxyphenyl(4-(2,2,2-
trifluoroethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin
yl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxy(1-methyl(2,2,2-
trifluoroethyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin
yl )phenylcyclopropanecarboxam ide
(1 R,2R,3R)(1-fluoro(2,2,2-trifluoroethyl)-1,2,3,4-
tetrahydropyrrolo[1,2-a]pyrazinyl)-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxyphenyl(2-(2,2,2-
trifluoroethyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin
yl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxyphenyl(7-(2,2,2-
trifluoroethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin
yl )cyclopropanecarboxam ide
O~NHOH
(1 R,2R,3R)-N-hydroxyphenyl(2-
(trifluoromethyl )im idazo[1 ,2-a]pyrid in
yl )cyclopropanecarboxam ide
F,C~u6···o
( 1 R,2R,3R)-N-hydroxy(im idazo[1 ,2-a]pyrid inyl )
phenylcyclopropanecarboxam ide
O~NHOH
(1 R,2R,3R)-N-hydroxyphenyl(pyrrolo[1,2-
a] pyrim id inyl )cyclopropanecarboxam ide
~)~···o
NJ I~
( 1R,2R,3R)-N-hydroxy(1 ,5-naphthyrid inyl )
phenylcyclopropanecarboxam ide
(1 S,2S,3R)(2-cyclopropylpyridinyl)-N-hydroxy(2-
I "::::
methylth iazolyl )cyclopropanecarboxam ide
N .o
Oo/N,
- OH
(1 S,2S,3R)(2-cyclopropylpyridinyl)-N-hydroxy(5-
(trifl uoromethyl )th iophenyl )cyclopropanecarboxam ide
''r(
O~NHOH
(1 R,2R,3R)(1-((5-fluoropyridinyl)methyl)-1 H-
N.:.Y·,,,o
pyrazolyl)-N-hydroxy
phenylcyclopropanecarboxam ide
O~N'OH
(1 S,2R,3S)(3-fluoromethylthiophenyl)-N-
hydroxy(1-methyl-1 H-pyrazol
N:r·,,,~
yl )cyclopropanecarboxam ide
'N I s ,1
O~N'OH
(1 S,2S,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)(5-
~ CF3
methyl(trifl uoromethyl )th iophen
yl )cyclopropanecarboxam ide
} ''r?
O~N'OH
(1 S,2S,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)(5-
methyl th iophenyl )cyclopropanecarboxam ide
Npr·,,~~
O~N'OH
(1 R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)o-
tolylcyclopropanecarboxam ide
N~''()
(1 R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)(2-
(trifl uoromethyl )phenyl )cyclopropanecarboxam ide
(1 S,2R,3R)(2-chlorophenyl)-N-hydroxy(1-methyl-
1 H-pyrazolyl )cyclopropanecarboxam ide
(1 R,2R,3R)(3-fluorophenyl)-N-hydroxy(1-methyl-
N /:--._ fa.,,,r(YF
1 H-pyrazolyl )cyclopropanecarboxam ide
~_J v
(1 R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)m
tolylcyclopropanecarboxam ide
O~N'OH
(1 R,2R,3R)-N-hydroxy(1-methyl-1 H-pyrazolyl)(3-
(trifl uoromethyl )phenyl )cyclopropanecarboxam ide
Nor··,,vCF3
O~N'OH
( 1 R,2R,3R)(3-chlorophenyl )-N-hydroxy( 1-methyl-
1 H-pyrazolyl )cyclopropanecarboxam ide
Nor·,,vCI
(1 S,2S,3R)(2-cyclopropylpyridinyl)(3-fluoro
I~ methylth iophenyl )-N
N ,,,,::;
hydroxycyclopropanecarboxam ide
0vN'OH
(1 S,2S,3R)(2-cyclopropylpyridinyl)-N-hydroxy(5-
methyl(trifl uoromethyl )th iophen
':-~
yl )cyclopropanecarboxam ide
0vN'OH
(1 S,2S,3R)(2-cyclopropylpyridinyl)-N-hydroxy(5-
methyl th iophenyl )cyclopropanecarboxam ide
OyNHOH
( 1 R,2R,3R)-N-hyd roxyphenyl( 4-( 5-(trifl uoromethyl )-
N....._ I I h-
1 H-im idazolyl )phenyl )cyclopropanecarboxam ide
.c.c
OyNHOH
( 1 R,2R,3R)(3-chloro(5-methyl-1 H-im idazol
N....._ I I h-
ff··o
yl )phenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
~NH Cl
OyNHOH
( 1 R,2R,3R)(3-fluoro(5-methyl-1 H-im idazol
yl )phenyl )-N-hyd roxyphenylcyclopropanecarboxam ide
Nff···o
~NH F
Example 42: Analysis of inhibition of HDAC4 with Class Ila Histone
Deacetylase (HDAC) inhibitors.
The potency of Class Ila Histone Deacetylase (HDAC) inhibitors is
quantified by measuring the Histone Deacetylase 4 (HDAC4) catalytic domain
enzymatic activity using the Class Ila selective substrate, Boc-Lys(Tfa)-AMC.
The substrate is deacetylated to Boc-Lys-AMC by HDAC4. Cleavage by trypsin
results in the release of the fluorophore AMC from the deacetylated substrate.
The fluorescence of the sample is directly related to the histone deacetylase
activity in the sample.
Serially dilute HDAC inhibitor compounds. Serial dilutions of the
HDAC inhibitors and control reference compound (1-(5-(3-((4-(1,3,4-oxadiazol
yl )phenoxy)methyl )-1 ,2,4-oxad iazolyl )th iophenyl )-2,2,2-trifluoroethanone)
are made by first resuspending the lyophilized compound to a final concentration
of 10 mM in 100% dimethyl sulfoxide (DMSO). Stocks of 60 µI aliquots of the 10
mM compound in DMSO are prepared and stored at -20°C. From one stock
aliquot of each compound to be tested and the reference compound, a 16-point
serial dilution is prepared according to Table 7 using a 125 µI 16-channel Matrix
multi-channel pipette (Matrix Technologies Ltd).
Table 7: Serial Dilution of Compounds
Diluted Concentration Dilution
Well Volumes
Solutions (µM) ratio
60 µ11 OmM Test
Concentration 1 A 10000 - compound/
reference control
Concentration 2 B 5000 1 :2 30 µI A+ 30 µI DMSO
Concentration 3 c 2500 1 :2 30 µI B + 30 µI DMSO
Concentration 4 D 1000 1 :2.5 30 µIC+ 45 µI DMSO
Concentration 5 E 500 1 :2 30 µID+ 30 µI DMSO
Concentration 6 F 250 1 :2 30 µIE+ 30 µI DMSO
Concentration 7 G 125 1 :2 30 µI F + 30 µI DMSO
Concentration 8 H 62.5 1 :2 30 µI G + 30 µI DMSO
Concentration 9 I 31.25 1 :2 30 µI H + 30 µI DMSO
Concentration
J 15.63 1 :2 30 µI I+ 30 µI DMSO
Concentration
K 7.81 1 :2 30 µI J + 30 µI DMSO
Concentration
L 3.91 1 :2 30 µI K + 30 µI DMSO
Concentration M 1.95 1 :2 30 µIL+ 30 µI DMSO
Concentration
N 0.98 1 :2 30 µI M + 30 µI DMSO
Concentration
0.49 1 :2 30 µIN+ 30 µI DMSO
Concentration
0.24 1 :2 30 µI 0 + 30 µI DMSO
2 µI (200x) of each diluted solution and each control (full activity:
100% DMSO alone or full inhibition 1 mM) is stamped into V-bottomed
polypropylene 384-well compound plates using either the Bravo (384-well head
from Agilent) or 12.5 µI 16-channel Matrix multi-channel pipette (Matrix
Technologies Ltd). Each well with the 200x compound solution is diluted 1 :20 by
the addition of 38 µI assay buffer+ DMSO (10.5 % DMSO, 45 mM Tris-HCI, 123
mM NaCl, 2.4 mM KCI, and 0.9 mM MgCl2 at pH 8.0 and equilibrated to room
temperature).
Prepare HDAC4 catalytic domain enzyme (0.86 µg/ml). The
HDAC4 catalytic domain enzyme is human catalytic domain HDAC4 protein
(amino acids 648-1057, but with a replacement of amino acids 730-744 with 4
amino acid GSGS linker) made from VCID 3428 and provided by Emerald
Biostructures at 1 .2 mg/ml. A working solution of enzyme is prepared from a 1.2
mg/ml stock aliquot of HDAC4 catalytic domain (thawed on ice) diluted to 0.86
µg/ml with assay buffer (50 mM Tris-HCI, 137 mM NaCl, 2.7 mM KCI, and 1 mM
MgCl2 at pH 8 and equilibrated to room temperature) just prior to the addition of
the enzyme to the assay.
Prepare 5x (50 µM) Boc-Lys(Tfa)-AMC substrate. 5x (50 µM)
substrate is prepared just prior to the addition to the assay. A 1 mM substrate
stock is made by diluting a 100 mM Boc-Lys(Tfa)-AMC in DMSO solution 1 :100
by adding it drop-wise to assay buffer (equilibrated to room temperature) while
vortexing at slow speed to prevent precipitation. The 5x substrate is prepared by
diluting the 1 mM substrate solution 1 :20 by adding it drop-wise to assay buffer
(equilibrated to room temperature) while vortexing at slow speed to prevent
precipitation.
Prepare 3x (30 µM) Developer/Stop Solution. 3x (30 µM)
Developer/Stop Solution is prepared just prior to addition to the plate by diluting a
stock solution of 10 mM reference compound 1 :333 in 25 mg/ml trypsin (PAA
Laboratories Ltd.) equilibrated to room temperature.
Assay. 5 µI of each solution of 1 :20 diluted compound from above
is transferred to a clear bottomed, black, 384-well assay plate using the Bravo or
the Janus (384-well MDT head from Perkin Elmer). Using a 16-channel Matrix
multi-channel pipette, 35 µI of the working solution of HDAC4 catalytic domain
enzyme (0.86 µg/ml in assay buffer) is transferred to the assay plate. The assay
is then started by adding 10 µI of 5x (50 µM) substrate to the assay plates using
either the Bravo, Janus or 16-channel Matrix multi-channel pipette. The assay
plate is then shaken for two minutes on an orbital shaker at 900 rpm (rotations
per minute). Next the plate is incubated for 15 minutes at 37°C. The reaction is
stopped by adding 25 µI of 3x (30 µM) developer/stop solution to the assay plates
using either the Bravo, Janus or a 16-channel Matrix multi-channel pipette.
Assay plates are then shaken for 5 minutes on an orbital shaker at 1200 rpm.
Next, the assay plates are incubated at 37°C for 1 hour in a tissue culture
incubator. Finally, the fluorescence is measured (Excitation: 355 nm, Emission:
460 nm) using PerkinElmer EnVision in top read mode.
Example 43: Analysis of inhibition of HDAC5 with Class Ila Histone
Deacetylase (HDAC) inhibitors.
The potency of Class Ila Histone Deacetylase (HDAC) inhibitors is
quantified by measuring the Histone Deacetylase 5 (HDAC5) enzymatic activity
using the Class Ila selective substrate, Boc-Lys(Tfa)-AMC. The substrate is
deacetylated to Boc-Lys-AMC by HDAC5. Cleavage by trypsin results in the
release of the fluorophore AMC from the deacetylated substrate. The
fluorescence of the sample is directly related to the histone deacetylase activity in
the sample.
Serially dilute HDAC inhibitor compounds. Serial dilutions of the
HDAC inhibitors and control reference compound (1-(5-(3-((4-(1,3,4-oxadiazol
yl )phenoxy)methyl )-1 ,2,4-oxad iazolyl )th iophenyl )-2,2,2-trifluoroethanone)
are made by first resuspending the lyophilized compound to a final concentration
of 10 mM in 100% DMSO. Stocks of 60 µI aliquots of the 10 mM compound in
DMSO are prepared and stored at -20°C. From one stock aliquot of each
compound to be tested and the reference compound, a 16-point serial dilution is
prepared according to Table 7 using a 125 µI 16-channel Matrix multi-channel
pipette.
2 µI (200x) of each diluted solution and each control (full activity:
100% DMSO alone or full inhibition 1 mM) is stamped into V-bottom
polypropylene 384-well compound plates using either Bravo, Janus, or a 12.5 µI
16-channel Matrix multi-channel pipette. Each well with the 2 µI of the 200x
stamped compound solution is diluted 1 :20 by the addition of 38 µI assay buffer+
DMSO (10.5 % DMSO, 45 mM Tris-HCI, 123 mM NaCl, 2.4 mM KCI, and 0.9 mM
MgCl2 at pH 8.0 and equilibrated to 37°C).
Prepare HDAC5 catalytic domain enzyme (0.57 µg/ml). The
HDAC5 catalytic domain enzyme is human HDAC5 catalytic domain (GenBank
Accession No. NM_001015053), amino acids 657-1123 with a C-terminal His tag
and can be obtained from BPS Bioscience. The protein is 51 kDa and is
expressed in a baculovirus expression system. A working solution of enzyme is
prepared from a 1.65 mg/ml stock aliquot of HDAC5 catalytic domain (thawed on
ice) diluted to 0.57 µg/ml with assay buffer (50 mM Tris-HCI, 137 mM NaCl, 2.7
mM KCI, and 1 mM MgCl2 at pH 8 and equilibrated to 37°C) just prior to the
addition of the enzyme to the assay.
Prepare 5x (40 µM) Boc-Lys(Tfa)-AMC substrate. 5x (40 µM)
substrate is prepared just prior to the addition to the assay. The 5x substrate is
prepared by diluting the 100 mM Boc-Lys(Tfa)-AMC in DMSO solution 1 :2500 by
adding it drop-wise to assay buffer (equilibrated to 37°C) while vortexing at slow
speed to prevent precipitation.
Prepare 3x (30 µM) Developer/Stop Solution. 3x (30 µM)
Developer/Stop Solution is prepared just prior to addition to the plate by diluting a
stock solution of 10 mM reference compound 1 :333 in 25 mg/ml trypsin
equilibrated to 37°C.
Assay. 5 µI of each solution of the 1 :20 diluted inhibitor compounds
and controls from above is transferred to a clear bottomed, black, 384-well assay
plate using the Bravo or Janus. Using a 16-channel Matrix multi-channel pipette,
µI of the working solution of the HDAC5 catalytic domain enzyme (0.57 µg/ml
in assay buffer) is transferred to the assay plate. The assay is then started by
adding 10 µI of 5x (40 µM) substrate to the assay plates using either the Bravo,
Janus or 16-channel Matrix multi-channel pipette. The assay plate is then
shaken for one minute on an orbital shaker at 900 rpm. Next, the plates are
incubated for 15 minutes at 37°C. The reaction is stopped by adding 25 µI of 3x
(30µM) developer/stop solution to the assay plates using either the Bravo, Janus
or a 16-channel Matrix multi-channel pipette. Assay plates are then shaken for 2
minutes on an orbital shaker at 900 rpm. Next, the assay plates are incubated at
37°C for 1 hour in a tissue culture incubator followed by shaking for 1 minute at
the maximum rpm on an orbital shaker before reading on the EnVision. Finally,
the fluorescence is measured (Excitation: 355 nm, Emission: 460 nm) using
PerkinElmer EnVision in top read mode.
Example 44: Analysis of inhibition of HDAC7 with Class Ila Histone
Deacetylase (HDAC) inhibitors.
The potency of Class Ila Histone Oeacetylase (HOAG) inhibitors is
quantified by measuring the Histone Oeacetylase 7 (HOAC7) enzymatic activity
using the Class Ila selective substrate, Boc-Lys(Tfa)-AMC. The substrate is
deacetylated to Boc-Lys-AMC by HOAC7. Cleavage by trypsin results in the
release of the fluorophore AMC from the deacetylated substrate. The
fluorescence of the sample is directly related to the histone deacetylase activity in
the sample.
Serially dilute HDAC inhibitor compounds. Serial dilutions of the
HOAG inhibitors and control reference compound (1-(5-(3-((4-(1,3,4-oxadiazol
yl )phenoxy)methyl )-1 ,2,4-oxad iazolyl )th iophenyl )-2,2,2-trifluoroethanone)
are made by first resuspending the lyophilized compound to a final concentration
of 10 mM in 100% OMSO. Stocks of 60 µI aliquots of the 10 mM compound in
OMSO are prepared and stored at -20°C. From one stock aliquot of each
compound to be tested and the reference compound, a 16-point serial dilution is
prepared according to Table 7 using a 125 µI 16-channel Matrix multi-channel
pipette.
2 µI (200x) of each diluted solution and each control (full activity:
100% OMSO alone or full inhibition 1 mM) is stamped into V-bottom
polypropylene 384-well compound plates using either the Bravo, Janus, or a 12.5
µI 16-channel Matrix multi-channel pipette. Each well with the 200x compound
solution is diluted 1 :20 by the addition of 38 µI assay buffer+ DMSO (10.5 %
DMSO, 45 mM Tris-HCI, 123 mM NaCl, 2.4 mM KCI, and 0.9 mM MgCl2 at pH 8.0
and equilibrated to 37°C).
Prepare HDAC7 enzyme (71 ng/ml). The HDAC7 enzyme is
human HDAC7 (GenBank Accession No. AY302468) amino acids 518-end with a
N-terminal Glutathione S-transferase (GST) tag and can be obtained from BPS
BioScience. The protein is 78 kDa and is expressed in a baculovirus expression
system. A working solution of enzyme is prepared from a 0.5 mg/ml stock aliquot
of HDAC7 (thawed on ice) diluted to 71 ng/ml with assay buffer (50 mM Tris-HCI,
137 mM NaCl, 2.7 mM KCI, and 1 mM MgCl2 at pH 8 and equilibrated to 37°C)
just prior to the addition of enzyme to the assay.
Prepare 5x (50 µM) Boc-Lys(Tfa)-AMC substrate. 5x (50 µM)
substrate is prepared just prior to the addition to the assay. The 5x substrate is
prepared by diluting a 100 mM Boc-Lys(Tfa)-AMC in DMSO solution 1 :2000 by
adding it drop-wise to assay buffer (equilibrated to 37°C) while vortexing at slow
speed to prevent precipitation.
Prepare 3x (30 µM) Developer/Stop Solution. 3x (30 µM)
Developer/Stop Solution is prepared just prior to addition to the plate by diluting a
stock solution of 10 mM reference compound 1 :333 in 25 mg/ml trypsin
equilibrated to 37°C.
Assay. 5 µI of each solution of 1 :20 diluted compound from above
is transferred to a clear bottomed, black, 384-well assay plate using the Bravo or
Janus. Using a 16-channel Matrix multi-channel pipette, 35 µI of the working
solution of the HDAC7 enzyme (71 ng/ml in assay buffer) is transferred to the
assay plate. The assay is then started by adding 10 µI of 5x (50 µM) substrate to
the assay plate using either the Bravo, Janus or 16-channel Matrix multi-channel
pipette. The assay plate is then shaken for one minute on an orbital shaker at
900 rpm. Next, the plate is incubated for 15 minutes at 37°C. The reaction is
then stopped by adding 25 µI of 3x (30 µM) developer/stop solution to the assay
plates using either the Bravo, Janus or a 16-channel Matrix multi-channel pipette.
The assay plate is then shaken for 2 minutes on an orbital shaker at 900 rpm.
Next, the assay plate is incubated at 37°C for 1 hour in a tissue culture incubator
followed by shaking for 1 minute at maximum rpm on an orbital shaker. Finally,
the fluorescence is measured (Excitation: 355 nm, Emission: 460 nm) using
PerkinElmer EnVision in top read mode.
Example 45: Analysis of inhibition of HDAC9 with Class Ila Histone
Deacetylase (HDAC) inhibitors.
The potency of Class Ila Histone Oeacetylase (HOAG) inhibitors is
quantified by measuring the Histone Oeacetylase 9 (HOAC9) enzymatic activity
using the Class Ila selective substrate, Boc-Lys(Tfa)-AMC. The substrate is
deacetylated to Boc-Lys-AMC by HOAC9. Cleavage by trypsin results in the
release of the fluorophore AMC from the deacetylated substrate. The
fluorescence of the sample is directly related to the histone deacetylase activity in
the sample.
Serially dilute HDAC inhibitor compounds. Serial dilutions of the
HOAG inhibitors and control reference compound (1-(5-(3-((4-(1,3,4-oxadiazol
yl )phenoxy)methyl )-1 ,2,4-oxad iazolyl )th iophenyl )-2,2,2-trifluoroethanone)
are made by first resuspending the lyophilized compound to a final concentration
of 10 mM in 100% OMSO. Stocks of 60 µI aliquots of the 10 mM compound in
OMSO are prepared and stored at -20°C. From one stock aliquot of each
compound to be tested and the reference compound, a 16-point serial dilution is
prepared according to Table 7 using a 125 µI 16-channel Matrix multi-channel
pipette.
2 µI (200x) of each diluted solution and each control (full activity:
100% OMSO alone or full inhibition 1 mM) is stamped into V-bottom
polypropylene 384-well compound plates using either the Bravo, Janus, or 12.5 µI
16-channel Matrix multi-channel pipette. Each well with the stamped 200x
compound solution is diluted 1 :20 by the addition of 38 µI assay buffer+ OMSO
(10.5 % OMSO, 45 mM Tris-HCI, 123 mM NaCl, 2.4 mM KCI, and 0.9 mM MgCl2
at pH 8.0 and equilibrated to 37°C).
Prepare HDAC9 enzyme (0.57 µg/ml). The HOAC9 enzyme is
human HOAC9 (Gen Bank Accession No. NM_ 178423) amino acids 604-1066
with a C-terminal His tag and can be obtained from BPS BioScience. The protein
is 50.7 kOa and is expressed in a baculovirus expression system. A working
solution of enzyme is prepared from a 0.5 mg/ml stock aliquot of HOAC9 (thawed
on ice) diluted to 0.57 µg/ml with assay buffer (50 mM Tris-HCI, 137 mM NaCl,
2.7 mM KCI, and 1 mM MgCl2 at pH 8 and equilibrated to 37°C) just prior to the
addition of enzyme to the assay.
Prepare 5x (125 µM) Boc-Lys(Tfa)-AMC substrate. 5x (125 µM)
substrate is prepared just prior to the addition to the assay. The 5x substrate is
prepared by diluting a 100 mM Boc-Lys(Tfa)-AMC in DMSO solution 1 :800 by
adding it drop-wise to assay buffer (equilibrated to 37°C) while vortexing at slow
speed to prevent precipitation.
Prepare 3x (30 µM) Developer/Stop Solution. 3x (30 µM)
Developer/Stop Solution is prepared just prior to addition to the plate by diluting a
stock solution of 10 mM reference compound 1 :333 in 25 mg/ml trypsin
equilibrated to 37°C.
Assay. 5 µI of each solution of 1 :20 diluted compound from above
is transferred to a clear bottomed, black, 384-well assay plate using the Bravo or
Janus. Using a 16-channel Matrix multi-channel pipette, 35 µI of the working
solution of the HDAC9 enzyme (0.57 µg/ml in assay buffer) is transferred to the
assay plate. The assay is then started by adding 10 µI of 5x (125 µM) substrate
to the assay plate using either the Bravo, Janus or 16-channel Matrix multi
channel pipette. The assay plate is then shaken for one minute on an orbital
shaker at 900 rpm. Next, the plate is incubated for 15 minutes at 37°C. The
reaction is stopped by adding 25 µI of 3x developer/stop solution to the assay
plates using either the Bravo, Janus or a 16-channel Matrix multi-channel pipette.
The assay plate is then shaken for 2 minutes on an orbital shaker at 900 rpm.
Next, the assay plate is incubated at 37°C for 1 hour in a tissue culture incubator
followed by shaking for 1 minute at maximum rpm on an orbital shaker before
reading on the envision. Finally, the fluorescence is measured (Excitation: 355
nm, Emission: 460 nm) using PerkinElmer EnVision in top read mode.
Example 46: Analysis of inhibition of cellular HDAC activity with Class Ila
Histone Deacetylase (HDAC) inhibitors.
The potency of Class Ila Histone Deacetylase (HDAC) inhibitors is
quantified by measuring the cellular histone deacetylase enzymatic activity using
the Class Ila selective substrate, Boc-Lys(Tfa)-AMC. After penetration in Jurkat
E6-1 cells, the substrate is deacetylated to Boc-Lys-AMC. After cell lysis and
cleavage by trypsin, the fluorophore AMC is released from the deacetylated
substrate only. The fluoresence of the sample is directly related to the histone
deacetylase activity in the sample.
Jurkat E6.1 cell culture and plating. Jurkat E6.1 cells are
cultured according to standard cell culture protocols in Jurkat E6.1 Growth Media
(RPMI without phenol red, 10% FBS, 10 mM HEP ES, and 1 mM Sodium
Pyruvate). Jurkat E6.1 cells are counted using a Coulter Counter and
resuspended in Jurkat E6.1 growth media at a concentration of 75,000 cells/35 µI.
µI or 75,000 cells is seeded into Greiner microtitre assay plates. The plates
are then incubated at 37°C and 5% C02 while other assay components are being
prepared.
Serially dilute HDAC inhibitor compounds. Serial dilutions of the
HDAC inhibitors and control reference compound (1-(5-(3-((4-(1,3,4-oxadiazol
yl )phenoxy)methyl )-1 ,2,4-oxad iazolyl )th iophenyl )-2,2,2-trifluoroethanone)
are made by first resuspending the lyophilized compound to a final concentration
of 10 mM in 100% DMSO. Stocks of 70 µI aliquots of the 10 mM compound in
DMSO are prepared and stored at -20°C. From one stock aliquot of each
compound to be tested and the reference compound, a 16-point serial dilution is
prepared according to Table 7 using a 125 µI 16-channel Matrix multi-channel
pipette.
2 µI (200x) of each diluted solution and each control (full activity:
100% DMSO alone or full inhibition 1 mM) is stamped into V-bottom
polypropylene 384-well compound plates using either the Bravo, Janus, or 12.5 µI
16-channel Matrix multi-channel pipette. Each well with the 200x compound
solution is diluted 1 :20 by the addition of 38 µI Jurkat assay buffer+ DMSO (9.5
% DMSO, RPMI without phenol red, 0.09% FBS, 9 mM Hepes, and 0.9 mM
Sodium Pyruvate equilibrated to room temperature)
Prepare 5x (500 µM) Boc-Lys(Tfa)-AMC substrate. 5x (500 µM)
substrate is prepared just prior to the addition to the assay. The 5x substrate is
prepared by diluting a 100 mM Boc-Lys(Tfa)-AMC in DMSO solution 1 :200 by
adding it drop-wise to Jurkat assay medium (RPMI without phenol red, 0.1 % FBS,
mM Hepes, and 1 mM Sodium Pyruvate equilibrated to 37°C) while vortexing
at slow speed to prevent precipitation.
Prepare 3x Lysis Buffer. 10 ml of 3x lysis buffer is prepared with
8.8 ml of 3x stock lysis buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCl, 2.7 mM
KCI, 1 mM MgCl2, 1 % Nonidet P40 Substitute equilibrated to room temperature)
and 1.2 ml of 3 mg/ml Trypsin equilibrated to room temperature.
Assay. 5 µI of each solution of 1 :20 diluted compound from above
is transferred to the Greiner microtitre assay plates with 75,000 cells/well using
the Bravo. Cells are then incubated for 2 hours at 37°C and 5% C02. The assay
is then started by adding 10 µI of 5x (500 µM) substrate to the assay plate using
either the Bravo or 16-channel Matrix multi-channel pipette. The cells are then
incubated for 3 hours at 37°C and 5% C02. Next, 25 µI of 3x lysis buffer is added
to each well using either the 125 µI 16 channel pipette or the Bravo. The assay
plate is then incubated overnight (15-16 hours) at 37°C and 5% C02. The
following day, the plates are shaken on an orbital shaker for 1 minute at 900 rpm.
Finally the top read fluorescence (Excitation: 355 nm, Emission: 460 nm) is
measured using PerkinElmer EnVision.
Example 47
Using the synthetic methods similar to those described above and
the assay protocols described above, the following compounds were synthesized
and tested.
Table 8
Chemical Name Compound Biochemical Cellular
Number HDAC-4 ICso IC50
(µM) (µM)
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4- 50i 0.10 1.25
(pyrim id in
yl )phenyl )cyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)(2-Bromophenyl )-N- 16a 0.62 6.53
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylo- 18a 1.72 13.16
tolylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4- 50h 0.06 0.62
(pyrim id in
yl )phenyl )cyclopropanecarboxam ide
( 1 S* ,2R* ,3R*)(2-Fluorophenyl )-N- 13 0.94 7.67
hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)-N-Hydroxy(2-
11 a 20.57 50
Chemical Name Compound Biochemical Cellular
Number IC50
HDAC-4 ICso
(µM) (µM)
isopropoxyphenyl )
phenylcyclopropanecarboxarn ide
( 1 R* ,2R* ,3R*)(2-Fluorophenyl )-N- 11 b 0.32 1.83
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl 25c 1.81 19.68
( pyrirn id inyl )cyclopropanecarboxam ide
( 1 S* ,2R* ,3R*)Cyclopentyl-N-hydroxy- 25a 8.96 48.08
3-phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxy( 4-( 5- 50k 0.09 0.48
methyl pyrim id inyl )phenyl )
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(4-(4- 50d 0.21 0.88
Trifluoromethylpyrimidinyl)phenyl)-N-
hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(4-(5- 50c 0.22 0.81
Cyclopropylpyrimidinyl)phenyl)-N-
hydroxy
phenylcyclopropanecarboxarn ide
( 1 R* ,2R* ,3R*)( 4-( 5-Fluoropyrim id in
50a 0.06 0.39
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)(3-( 5-Fluoropyrim id in 0.10 1.02
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
( 1 R*,2R*,3R*)-N-Hyd roxyphenyl 28a 1.09 23.52
( pyridazinyl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxy(4-(oxazol 41b 0.02 0.22
yl)phenyl)
phenylcyclopropanecarboxarn ide
( 1 R,2R,3R)-N-Hydroxy(3-( oxazol 41a 0.04 0.39
yl)phenyl)
phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxy(2- 39 0.02 0.22
isopropyl benzo[ d]oxazolyl )
phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxyphenyl(5- 68 0.23 2.31
(trifl uoromethyl )pyrid in
vi )cyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxyphenyl(6- 28f 0.34 5.67
(trifl uoromethyl )pyrid in
yl )cyclopropanecarboxam ide
( 1 R,2R,3R)(2-Cyclopropylpyrid inyl )- 28b 0.02 0.67
N-hydroxy
Chemical Name Compound Biochemical Cellular
Number IC50
HDAC-4 ICso
(µM) (µM)
phenylcyclopropanecarboxam ide
( 1 R,2R,3R)(2-Cyclopropylpyrid inyl )- 25d 0.03 0.62
3-( 4-fluorophenyl )-N-
hydroxvcvclopropanecarboxamide
(1 R,2R,3R)(2,2- 28e 0.12 2.03
Difluorobenzo[d][1,3]dioxolyl)-N-
hydroxy
phenylcyclopropanecarboxarn ide
(1 R,2R,3R)(4-(2-Cyclopropyloxazol
46 0.04 0.28
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxyphenyl(2- 28g 0.30 2.58
(trifl uoromethyl )pyrid in
yl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxy(1-oxo(2,2,2- 0.03 0.34
trifl uoroethyl )isoindol inyl )
phenylcyclopropanecarboxam ide
(1 S,2R,3R)(2-Cyclopropylpyridinyl)- 28c 0.04 0.53
3-(2-fluorophenyl)-N-
hydroxycyclopropanecarboxamide
( 1 R,2R,3R)(2-Cyclopropylpyrid inyl )- 28d 0.12 0.79
3-( 4-fluorophenyl )-N-
hydroxycyclopropanecarboxamide
(1 R,2R,3R)-N-Hydroxy(1-methyl-1 H- 25b 0.54 2.62
pyrazolyl )
phenylcyclopropanecarboxam ide
(1 R,2R,3R)(4-(5- 50e 0.18 0.69
Trifluoromethylpyrimidinyl)phenyl)-N-
hydroxy
phenylcyclopropanecarboxam ide
(1 R,2R,3R)(8-Chloro-2,3-
25e 0.02 0.13
dihydrobenzo[b][1,4]dioxinyl)-N-
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4- 50f 0.08 0.62
(pyridazin
yl )phenyl )cyclopropanecarboxam ide
(1 R*,2R*,3R*)-N -Hydroxyphenyl(4- 50g 0.11 0.66
(pyridazin
vi )phenyl )cyclopropanecarboxam ide
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4- 56i 0.14 1.31
methylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*J-N-Hydroxy(4-(oxazol 58 0.05 0.35
yl)phenyl)
Chemical Name Compound Biochemical Cellular
Number IC50
HDAC-4 ICso
(µM) (µM)
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)-N -Hydroxy(4-(1-methyl- 60 0.29 2.05
1 H-imidazolyl )phenyl )
phenylcyclopropanecarboxarn ide
( 1R*,2R*,3R*)(4-( 1 H-pyrazol 65 0.09 0.97
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R *)( 4-(3,3-Dimethylazetid in-
56d 0.33 3.17
1-yl)phenyl)-N-hydroxy
phenylcyclopropanecarboxam ide
( 1R*,2R*,3R*)-N-Hydroxy(4-( 4-
56a 0.09 0.76
isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)-N-Hydroxy(4-(3,3- 0.15 1.77
d ifluoropyrrol id inyl )phenyl )
phenylcyclopropanecarboxam ide
( 1R*,2R*,3R*)(4-(2-0xa 0.15 1.33
azaspiro[3.3]heptanyl)phenyl)-N-
hydroxy
phenylcyclopropanecarboxam ide
(1R,2R,3R)(3'-(Benzyloxy)-[1,1 '- 54a 0.99 8.85
biphenyl]yl)-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R,2R,3R)(4-(1-Benzyl-1,2,3,6- 71 0.35 0.75
tetrahyd ropyrid inyl )phenyl )-N-hyd roxy-
3-phenylcyclopropanecarboxam ide
( 1R,2R,3R)-N-hydroxy(4-( 4-methyl-3,4- 54c 0.26 1.43
dihydro-2H-benzo[b][1,4]oxazin
yl)phenyl)
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(4-(2- 52 0.48 1.79
cyclopropyl isoindol inyl )phenyl )-N-
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)( 4'-(9H-carbazolyl )- 54b 5.66 50
[1, 1 '-biphenyl]yl)-N-hydroxy
phenylcyclopropanecarboxam ide
( 1R*,2S*,3S*)(4-( 5-Fluoropyrim id in 63 0.27 1.55
yl )phenyl )-N-hydroxymethyl
phenylcyclopropanecarboxarn ide
( 1R*,2R*,3R*)-N-Hydroxy(3-(4- 56b 1.43 5.08
isopropylpiperazinyl )phenyl )
phenylcyclopropanecarboxam ide
( 1R,2R,3R)(3-(6,7- 56h 0.17 0.77
Dihydropvrazolo[1 ,5-a]pvrim id in-4( 5H )-
Chemical Name Compound Biochemical Cellular
Number IC50
HDAC-4 ICso
(µM) (µM)
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(3- 56f 0.63 1.85
(Hexahydropyrrolo[1,2-a]pyrazin-2(1 H)-
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)-N-Hydroxyphenyl(3- 56g 0.39 2.18
(4-(pyrrolidinyl)piperidin
yl )phenyl )cyclopropanecarboxam ide
(1 R,2R,3R)(4-(5-Chloropyrimidin 50j 0.14 0.42
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
( 1R*,2R*,3R*)-N-Hydroxy(4-( 5-methyl-
501 0.10 0.46
1 H-imidazolyl )phenyl )
phenylcyclopropanecarboxam ide
(1 S,2R,3R)(8-Chloro-2,3- 25f 0.03 0.24
d ihydrobenzo[b ][1 ,4 ]d ioxinyl )(2-
fluorophenyl )-N-
hydroxycyclopropanecarboxamide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenyl( 4- 48 0.28 1.26
(2-phenyloxazol
yl )phenyl )cyclopropanecarboxam ide
trans-N-Hydroxy-2,3- 2 0.34 2.52
d iphenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)Cyclohexyl-N-hydroxy 5 6.22 36.91
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)( 4-Bromophenyl )-N- 16c 0.37 2.87
hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(4-(1 H-imidazol 42 0.20 1.63
yl )phenyl )-N-hydroxy
phenylcyclopropanecarboxam ide
(1 R*,2R*,3R*)(4- 22 0.05 1.32
(cyclopropanesulfonamido )phenyl)-N-
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylp- 18c 0.15 2.25
tolylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)(3-Bromophenyl )-N- 16b 0.07 1.41
hydroxy
phenylcyclopropanecarboxam ide
( 1 R* ,2R* ,3R*)-N-Hydroxyphenylm- 18b 0.15 2.74
tolylcyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxy(4-(2- 75a 0.03 0.33
methyloxazolyl )phenyl )
Chemical Name Compound Biochemical Cellular
Number IC50
HDAC-4 ICso
(µM) (µM)
phenylcyclopropanecarboxam ide
(1 S,2R,3R)(2-Fluorophenyl)-N- 75b 0.05 0.47
hyd roxy( 4-(2-methyloxazol
vi )phenyl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxy(3-(5- 77 0.16 0.78
methyl pyrim id inyl )phenyl )
phenylcyclopropanecarboxam ide
(1 S,2R,3R)(2,6-Dicyclopropylpyridin
88 0.20 1.48
yl )(2-fluorophenyl )-N-
hydroxycyclopropanecarboxamide
( 1R,2R,3R)-N-Hydroxy(4-(3-methyl- 79 0.09 0.65
1 H-pyrazolyl )phenyl )
phenylcyclopropanecarboxam ide
(1 S, 2R, 3R)(2-Fluorophenyl)-N- 0.12 0.75
hydroxy(6-( 4-isopropylpiperazin
yl )pyrid inyl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxyphenyl(1-(5- 92b 0.18 1.17
(trifluoromethyl)pyrid inyl )-1 H-pyrazol
yl )cyclopropanecarboxam ide
(1 R,2R,3R)-N-hydroxy(imidazo[1,2- 115 0.55 6.66
a] pyrid i nyl )
phenylcyclopropanecarboxam ide
(1 R,2R,3R)-N-Hydroxyphenyl(2- 109 0.23 2.5
(trifluoromethyl )im idazo[1 ,2-a]pyrid in
yl )cyclopropanecarboxam ide
(1 S,2R,3R)(2-Cyclopropylpyridinyl)- 100b 0.02 0.42
3-(3-fluorophenyl)-N-
hydroxvcvclopropanecarboxamide
(1 R,2R,3R)-N-hydroxy(4-(5- 102 0.04 0.44
methyl th iazolyl )phenyl )
phenylcyclopropanecarboxam ide
(1 S, 2R, 3R)(2-Fluorophenyl)-N- 106 0.17 1.41
hydroxy(6-((2,2,2-
trifluoroethyl)amino )pyridin
yl )cyclopropanecarboxam ide
While some embodiments have been shown and described, various
modifications and substitutions may be made thereto without departing from the
spirit and scope of the invention. For example, for claim construction purposes, it
is not intended that the claims set forth hereinafter be construed in any way
narrower than the literal language thereof, and it is thus not intended that
exemplary embodiments from the specification be read into the claims.
Accordingly, it is to be understood that the present invention has been described
by way of illustration and not limitations on the scope of the claims.
Throughout this specification and the claims which follow, unless the
context requires otherwise, the word "comprise", and variations such as
"comprises" and "comprising", will be understood to imply the inclusion of a stated
integer or step or group of integers or steps but not the exclusion of any other
integer or step or group of integers or steps.
The reference in this specification to any prior publication ( o r
information derived from it), or to any matter which is known, is not, and should not
be taken as an acknowledgment or admission or any form of suggestion that that
prior publication (o r information derived from it) or known matter forms part of the
common general knowledge in the field of endeavour to which this specification
relates.
Claims (31)
1. A compound of Formula I 3 3a Formula I or a pharmaceutically acceptable salt thereof wherein R and R are independently chosen from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R is–C(O )N H(O H); R is chosen from hydrogen and lower alkyl optionally substituted with halo; where each optionally substituted group for R and R is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C1C4 alkyl, C3C6 cycloalkyl, aryl, heteroaryl, arylC1C4 alkyl, heteroarylC1C4 alkyl, C1C4 haloalkyl- , OC1C4 alkyl, OC1C4 alkylphenyl, -C1C4 alkylOH, -C1C4 alkylO- C1C4 alkyl, OC1C4 haloalkyl, halo, OH, NH2, C1C4 alkylNH2, N(C 1C4 alkyl)( C 1C4 alkyl) , NH( C 1C4 alkyl), N(C 1C4 alkyl)( C1C4 alkylphenyl), NH(C 1C4 alkylphenyl) , cyano, nitro, oxo (a s a substitutent for heteroaryl), CO2H, C(O )O C1C4 alkyl, CON(C 1C4 alkyl) ( C 1C4 alkyl), CONH(C 1C4 alkyl) , CONH2, NHC(O)( C 1C4 alkyl), NHC(O ) ( p henyl), N(C 1C4 alkyl) C ( O ) ( C 1C4 alkyl) , N( C 1C4 alkyl) C(O ) ( p henyl) , C(O)C 1C4 alkyl, C( O )C1C4 phenyl, C(O ) C 1C4 haloalkyl, OC( O )C 1C4 alkyl, -SO2( C 1C4 alkyl), -SO2(p henyl) , - SO2(C 1C4 haloalkyl), -SO2NH2, SO2NH(C 1C4 alkyl), SO2NH(p henyl) , -NHSO2( C 1C4 alkyl), -NHSO2( p henyl), and NHSO2( C 1C4 haloalkyl) .
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is chosen from compounds of Formula II. Formula II
3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is chosen from compounds of Formula III. Formula III
4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl.
5. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is –CF . 3a 3
6. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is chosen from compounds of Formula IV Formula IV
7. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is chosen from compounds of Formula V. Formula V
8. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R is chosen from cycloalkyl, heterocycloalkyl, alkyl, aryl and heteroaryl, each of which is optionally substituted with one, two, or three groups independently chosen from R , OR , halo, and NR SO R , wherein 22 23 2 21 R is chosen from optionally substituted C C alkyl, optionally 21 1 6 substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl; R is chosen from H, optionally substituted C C alkyl, optionally 22 1 6 substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; and R is chosen from hydrogen and optionally substituted C C alkyl; 23 1 4 where each optionally substituted group mentioned for R , R or R , is 21 22 23 unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C1C4 alkyl, C3C6 cycloalkyl, aryl, heteroaryl, arylC1C4 alkyl, heteroarylC1C4 alkyl, C1C4 haloalkyl-, OC1C4 alkyl, OC1C4 alkylphenyl, -C1C4 alkylOH, - C1C4 alkylO-C1C4 alkyl, OC1C4 haloalkyl, halo, OH, NH2, C1C4 alkylNH2, N(C 1C4 alkyl)( C 1C4 alkyl) , NH( C1C4 alkyl) , N(C 1C4 alkyl) (C 1C4 alkylphenyl), NH(C 1C4 alkylphenyl), cyano, nitro, oxo ( a s a substitutent for heteroaryl), CO2H, C(O ) O C1C4 alkyl, CON(C1C4 alkyl) (C 1C4 alkyl) , CONH(C 1C4 alkyl), CONH2, NHC(O ) ( C 1C4 alkyl) , NHC(O ) (p henyl), N( C 1C4 alkyl) C (O )( C 1C4 alkyl), N(C 1C4 alkyl)C(O ) ( p henyl), C(O) C 1C4 alkyl, C(O )C1C4 phenyl, C(O )C 1C4 haloalkyl, OC(O ) C 1C4 alkyl, -SO2( C 1C4 alkyl), -SO2( p henyl) , - SO2(C 1C4 haloalkyl), -SO2NH2, SO2NH( C 1C4 alkyl), SO2NH( p henyl), - NHSO2( C 1C4 alkyl), -NHSO2( p henyl) , and NHSO2(C 1C4 haloalkyl) .
9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R is chosen from cyclohexyl, thiophenyl, thiazolyl, and phenyl, each of which is optionally substituted with one, two, or three groups independently chosen from R , OR , and halo, 21 22
10. A compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R is thiophenyl or phenyl, each of which is optionally substituted with one, two, or three groups independently chosen from lower alkyl, lower alkoxy, trifluoromethyl, and halo.
11. A compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R is chosen from phenyl, 2-chlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 3-fluorophenyl, 3-methylphenyl, 3- trifluoromethylphenyl, 4-fluorophenyl, 5-methylthiophenyl, 3-fluoro methylthiophenyl, 5-methyl(t rifluoromethyl) t hiophenyl, and 5- (t rifluoromethyl)t hiophenyl.
12. A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, and 4-fluorophenyl.
13. A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R is phenyl.
14. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R is chosen from alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl, each of which is optionally substituted with one, two, or three groups independently chosen from R , OR , halo, 11 12 NR R , -C( O ) R , C( O )O R , C(O )N R R , OC(O )R , OC(O ) OR , 12 13 12 12 12 13 12 11 OC(O )N R R , NR C( O )R , NR C(O ) O R , NR C(O )NR R , 12 13 13 12 13 11 13 12 13 S(O )R , SO R , SO NR R , and NR SO R , wherein 11 2 11 2 12 13 13 2 11 R is chosen from optionally substituted C C alkyl, optionally 11 1 6 substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, and optionally substituted heteroaryl; R is chosen from H, optionally substituted C C alkyl, optionally 12 1 6 substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; and R is chosen from hydrogen and optionally substituted C C alkyl; 13 1 4 where each optionally substituted group mentioned for R , R or R , is 11 12 13 unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C1C4 alkyl, C3C6 cycloalkyl, aryl, heteroaryl, arylC1C4 alkyl, heteroarylC1C4 alkyl, C1C4 haloalkyl-, OC1C4 alkyl, OC1C4 alkylphenyl, -C1C4 alkylOH, - C1C4 alkylO-C1C4 alkyl, OC1C4 haloalkyl, halo, OH, NH2, C1C4 alkylNH2, N(C 1C4 alkyl)( C 1C4 alkyl) , NH(C1C4 alkyl) , N(C 1C4 alkyl)(C 1C4 alkylphenyl) , NH( C 1C4 alkylphenyl) , cyano, nitro, oxo (a s a substitutent for heteroaryl), CO2H, C(O ) O C1C4 alkyl, CON( C1C4 alkyl) (C 1C4 alkyl), CONH(C 1C4 alkyl), CONH2, NHC( O ) ( C 1C4 alkyl), NHC(O )(p henyl), N(C 1C4 alkyl)C (O )( C 1C4 alkyl), N(C 1C4 alkyl)C(O ) ( p henyl), C(O)C 1C4 alkyl, C(O )C1C4 phenyl, C( O ) C 1C4 haloalkyl, OC(O ) C 1C4 alkyl, -SO2(C 1C4 alkyl), -SO2( p henyl) , - SO2(C 1C4 haloalkyl), -SO2NH2, SO2NH(C 1C4 alkyl), SO2NH(p henyl) , - NHSO2(C 1C4 alkyl) , -NHSO2(p henyl), and NHSO2( C 1C4 haloalkyl).
15. A compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R is phenyl optionally substituted with one, two, or three groups independently chosen from R , OR , halo, -C( O ) R , NR R , 11 12 12 12 13 and NR SO R . 13 2 11
16. A compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein R is phenyl optionally substituted with one, two or three groups independently selected from halo, lower alkyl, aryl optionally substituted with one or two groups independently chosen from lower alkyl, trifluoromethyl,cycloalkyl, phenyl, and benzyloxy, heteroaryl optionally substituted with one or two groups independently chosen from lower alkyl, trifluoromethyl, cycloalkyl, and phenyl, (cy cloalkyl)su lfonamido, and heterocycloalkyl optionally substituted with one or two groups independently chosen from halo, lower alkyl, trifluoromethyl, cycloalkyl, heterocycloalkyl, and phenyl.
17. A compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein R is phenyl optionally substituted with one, two or three groups independently selected from halo, lower alkyl, oxazolyl, oxazol yl, pyrimidinyl, pyrimidinyl, pyridazinyl, pyridazinyl, 1H-pyrazol yl, (c ycloalkyl)su lfonamido, 1H-imidazolyl, imidazolyl, 1,2,3,6- tetrahydropyridinyl, azetidinyl, pyrrolidinyl, 2-oxa azaspiro[3.3]heptanyl, phenyl, hexahydropyrrolo[1,2-a]pyrazin-2( 1H) - yl, piperidinyl, piperazinyl, and 6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5 H)- yl, each of which is optionally substituted with one or two groups independently chosen from halo, lower alkyl, trifluoromethyl, phenyl, cycloalkyl, benzyl, benzyloxy, and pyrrolidinyl.
18. A compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein R is chosen from phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2- bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-(1 -benzyl-1,2,3,6- tetrahydropyridinyl)phenyl, 4-(p yrimidinyl)p henyl, 4-(p yrimidin yl)p henyl, 4-(5 -methylpyrimidinyl)p henyl,3-(5-fluoropyrimidinyl)p henyl, 4-(5 -chloropyrimidinyl)p henyl, 4-( 5 -fluoropyrimidinyl)p henyl, 4-( 4- ( t rifluoromethyl)p yrimidinyl)p henyl, 4-(5 -trifluoromethylpyrimidin yl) p henyl, 4-( 5 -cyclopropylpyrimidinyl)p henyl, 4-( p yridazinyl) p henyl, 4- (p yridazinyl)p henyl, 4-(1 H-imidazolyl)p henyl, 4-(1 -methyl-1H-imidazol- 2-yl) p henyl, 4-(5 -methyl-1H-imidazolyl)p henyl), 4-(1 H-pyrazol yl)p henyl, 4-(3 -methyl-1H-pyrazolyl)p henyl, 4-( 3 -(t rifluoromethyl)-1H- pyrazolyl)p henyl, 3-(oxazolyl)p henyl, 4-( o xazolyl)p henyl, 4-( o xazol- 5-yl)p henyl, 4-(2 -methyloxazolyl)p henyl,4-(2 -cyclopropyloxazol yl)p henyl, 4-(2 -phenyloxazolyl)p henyl, 4- (cy clopropanesulfonamido)p henyl, 4-( 3 ,3-dimethylazetidinyl)p henyl, 4- ( 3 ,3-difluoropyrrolidinyl)p henyl, 4-(2 -oxaazaspiro[3.3]heptan yl)p henyl, 3' -(b enzyloxy) b iphenylyl, 3-( h exahydropyrrolo[1,2-a]pyrazin- 2(1 H)- yl)p henyl, 3-(4 -( pyrrolidinyl) p iperidinyl)p henyl, 4-(4 - methylpiperazinyl)p henyl, 4-(4 -isopropylpiperazinyl)p henyl, and 3- (6 ,7-dihydropyrazolo[1,5-a]pyrimidin-4(5 H)- yl)phenyl.
19. A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R is chosen from 4-(1 -benzyl-1,2,3,6-tetrahydropyridin yl)p henyl, 4-( p yrimidinyl)p henyl, 4-(5 -methylpyrimidinyl)p henyl, 4-(5 - chloropyrimidinyl)p henyl, 4-( 5 -fluoropyrimidinyl)p henyl, 4-(4 - (t rifluoromethyl)p yrimidinyl)p henyl, 4-(5 -cyclopropylpyrimidinyl)phenyl, 4-(p yridazinyl) p henyl, 4-( p yridazinyl) p henyl, 4-( 5 -methyl-1H-imidazol- 2-yl)p henyl), 4-(5 -( t rifluoromethyl)-1H-imidazolyl)p henyl, 3-chloro(5 - methyl-1H-imidazolyl) p henyl, 3-fluoro(5 -methyl-1H-imidazol yl) p henyl, 4-(1 H-pyrazolyl) p henyl, 3-(o xazolyl) p henyl, 4-( o xazol yl) p henyl, 4-(o xazolyl) p henyl, 4-(2 -cyclopropyloxazolyl)p henyl, 4-( 4 - isopropylpiperazinyl)p henyl, and 3-(6 ,7-dihydropyrazolo[1,5-a]pyrimidin- 4(5 H)- yl)p henyl.
20. A compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R is chosen from 1,2,3,4-tetrahydroquinolinyl, 2,3,4,5- tetrahydrobenzo[f][1,4]oxazepinyl, 1,2,3,4-tetrahydropyrrolo[1,2- a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, 1,5-naphthyridinyl, 2,3- dihydrobenzo[b][1,4]dioxinyl, benzo[d][1,3]dioxolyl, and 1-oxo- isoindolinyl, each of which is optionally substituted with one or two groups independently chosen from halo and lower alkyl optionally substituted with one, two, or three halo groups.
21. A compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R is heteroaryl optionally substituted with one, two, or three groups independently chosen from R , OR , halo, and 11 12 NR SO R . 13 2 11
22. A compound according to claim 21, or a pharmaceutically acceptable salt thereof, wherein R is chosen from pyridinyl, pyridinyl, 1H-pyrazolyl, pyrimidinyl, pyridazinyl, benzo[d]isoxazolyl, benzo[d]oxazolyl, and thiazolyl, each of which is optionally substituted with one, two, or three groups independently chosen from R , OR , halo, and 11 12 NR SO R . 13 2 11
23. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R is chosen from pyridinyl, pyridinyl, 1H-pyrazolyl, pyrimidinyl, pyridazinyl, benzo[d]isoxazolyl, benzo[d]oxazolyl, and thiazolyl, each of which is optionally substituted with one or two groups independently chosen from halo, lower alkyl, 2,2,2- trifluoroethylamino, trifluoromethyl, 2,2,2-trifluoroethyl, cycloalkyl, cyclopropylmethyl, 1H-pyrazolyl optionally substituted with lower alkyl, pyrimidinyl optionally substituted with lower alkyl or halo, oxazolyl optionally substituted with lower alkyl, piperazinyl optionally substituted with lower alkyl, piperidinyl optionally substituted with 2,2,2-trifluoroethyl, and pyridinyl optionally substituted with lower alkyl or trifluoromethyl.
24. A compound according to claim 23, or a pharmaceutically acceptable salt thereof, wherein R is chosen from 2-cyclopropylpyridinyl, 6- (t rifluoromethyl)p yridinyl, 2-(t rifluoromethyl) p yridinyl, 5- (t rifluoromethyl)p yridinyl, 2-(2 ,2,2-trifluoroethylamino)p yridinyl, 6- (2 ,2,2-trifluoroethylamino)p yridinyl, 6-( 3 -methyl-1H-pyrazolyl)p yridin yl, 6-( 5 -methylpyrimidinyl)p yridinyl, 6-(2 -methyloxazolyl) p yridinyl, 6-(5 -chloropyrimidinyl) p yridinyl, 6-(4 -isopropylpiperazinyl) p yridin yl, 2,6-dicyclopropylpyridinyl, 6-( 5 -fluoropyrimidinyl)p yridinyl, 2-(5 - chloropyrimidinyl)cyclopropylpyridinyl, 1-methyl-1H-pyrazolyl, 1- ( 2 ,2,2-trifluoroethyl) -1H-pyrazolyl, 1-(c yclopropylmethyl)-1H-pyrazolyl, 1-cyclopropyl-1H-pyrazolyl, 1,3-dimethyl-1H-pyrazolyl, 1-(1 -(2 ,2,2- trifluoroethyl)p iperidinyl)-1H-pyrazolyl, 1-( 5 -(t rifluoromethyl)p yridin yl)- 1H-pyrazolyl, 1-(5-( t rifluoromethyl) p yridinyl) -1H-pyrazolyl, pyrimidinyl, 2-cyclopropylpyrimidyl, 3-cyclopropylpyrimidyl, pyridazinyl, 6-cyclopropylpyridazinyl, benzo[d]isoxazolyl, 2- isopropylbenzo[d]oxazolyl, and 2-methylthiazolyl.
25. A compound chosen from trans-N-Hydroxy-2,3-diphenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- 2-Cyclohexyl-N-hydroxyphenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- N-Hydroxy( 2 -isopropoxyphenyl) phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-(2 -Fluorophenyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 S*,2R*,3R*)- 2-( 2 -Fluorophenyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-( 2 -Bromophenyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-(3 -Bromophenyl)- N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-(4 -Bromophenyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- N-Hydroxyphenylo-tolylcyclopropanecarboxamide; (1 R*,2R*,3R*)- N-Hydroxyphenylm-tolylcyclopropanecarboxamide; (1 R*,2R*,3R*)- N-Hydroxyphenylp-tolylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- 2-(4 -( cycl opropanesulfonamido)p henyl) -N-hydroxy phenylcyclopropanecarboxamide; ( 1 S*,2R*,3R*)Cyclopentyl-N-hydroxyphenylcyclopropanecarboxamide; ( 1 R,2R,3R)- N-Hydroxy( 1 -methyl-1H-pyrazolyl) - 3- phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)-N-Hydroxyphenyl(p yrimidin yl) c yclopropanecarboxamide; (1 R,2R,3R) - 2-(2 ,3-Dihydrobenzo[b][1,4]dioxinyl) -N-hydroxy phenylcyclopropanecarboxamide; ( 1 R,2R,3R)- 2-( 8 -Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl) - N-hydroxy phenylcyclopropanecarboxamide; (1 S,2R,3R)(8 -Chloro-2,3-dihydrobenzo[b][1,4]dioxinyl) - 3-(2 - fluorophenyl) -N-hydroxycyclopropanecarboxamide; ( 1 R*,2R*,3R*)- N-Hydroxyphenyl(p yridazin yl)c yclopropanecarboxamide; (1 R,2R,3R) - 2-(2 -Cyclopropylpyridinyl) - N-hydroxy phenylcyclopropanecarboxamide; (1 S,2R,3R)(2 -Cyclopropylpyridinyl) - 3-(2 -fluorophenyl)-N- hydroxycyclopropanecarboxamide; ( 1 R,2R,3R)- 2-(2 -Cyclopropylpyridinyl)- 3-(4 -fluorophenyl)-N- hydroxycyclopropanecarboxamide; (1 R,2R,3R) ( 2 ,2-Difluorobenzo[d][1,3]dioxolyl) - N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R)-N-Hydroxyphenyl(6 -(t rifluoromethyl)p yridin yl)c yclopropanecarboxamide; (1 R,2R,3R)-N-Hydroxyphenyl( 2 -(t rifluoromethyl)p yridin yl) c yclopropanecarboxamide; (1 R,2R,3R)-N-Hydroxy( 1 -oxo(2 ,2,2-trifluoroethyl)i soindolinyl) - 3- phenylcyclopropanecarboxamide; ( 1 R,2R,3R)-N-hydroxy(2 -isopropylbenzo[d]oxazolyl) - 3- phenylcyclopropanecarboxamide; (1 R,2R,3R)- N-Hydroxy(3 -(o xazolyl)p henyl) phenylcyclopropanecarboxamide; (1 R,2R,3R)-N-Hydroxy( 4 -( o xazolyl)p henyl) phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)(4 -(1 H-imidazolyl)p henyl)-N-hydroxy phenylcyclopropanecarboxamide; ( 1 R,2R,3R) (4 -(2 -Cyclopropyloxazolyl)p henyl)-N-hydroxy phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)-N-Hydroxyphenyl(4 -( 2 -phenyloxazol yl)p henyl)c yclopropanecarboxamide; (1 R*,2R*,3R*)(4 -( 5 -Fluoropyrimidinyl)p henyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)( 3 -(5 -Fluoropyrimidinyl) p henyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)( 4 -(5 -Cyclopropylpyrimidinyl) p henyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)(4 -( 4 -Trifluoromethylpyrimidinyl)p henyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R)(4 -(5 -Trifluoromethylpyrimidinyl)p henyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)-N-Hydroxyphenyl(4 -(p yridazin yl)p henyl)c yclopropanecarboxamide; (1 R*,2R*,3R*)-N -Hydroxyphenyl(4 -(p yridazin yl) p henyl) c yclopropanecarboxamide; ( 1 R*,2R*,3R*)-N-Hydroxyphenyl( 4 -(p yrimidin yl)p henyl)c yclopropanecarboxamide; ( 1 R*,2R*,3R*)-N-Hydroxyphenyl( 4 -(p yrimidin yl) p henyl)c yclopropanecarboxamide; (1 R,2R,3R) ( 4 -(5 -Chloropyrimidinyl) p henyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)-N-Hydroxy(4 -( 5 -methylpyrimidinyl)p henyl) phenylcyclopropanecarboxamide; (1 R*,2R*,3R*) - N-Hydroxy( 4 -(5 -methyl-1H-imidazolyl)p henyl) phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)( 4 -(2 -cyclopropylisoindolinyl)p henyl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R) - 2-(3 ' -(B enzyloxy)-[1,1' -biphenyl]yl)-N-hydroxy phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-(4 ' -(9 H-carbazolyl) -[1,1' -biphenyl]yl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R)- N-hydroxy( 4 -( 4 -methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin yl) p henyl)phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- N-Hydroxy(4 -( 4 -isopropylpiperazinyl) p henyl) phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- N-Hydroxy( 3 -(4 -isopropylpiperazinyl) p henyl) phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*) - N-Hydroxy(4 -( 3 ,3-difluoropyrrolidinyl)p henyl) phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*) - 2-(4 -(3 ,3-Dimethylazetidinyl) p henyl)-N-hydroxy phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- 2-(4 -(2 -Oxaazaspiro[3.3]heptanyl)p henyl) -N-hydroxy phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*) - 2-( 3 -(H exahydropyrrolo[1,2-a]pyrazin-2(1 H)- yl) p henyl) -N- hydroxyphenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- N-Hydroxyphenyl(3 -( 4 -(pyrrolidinyl)p iperidin yl) p henyl) c yclopropanecarboxamide; (1 R,2R,3R)- 2-(3 -( 6 ,7-Dihydropyrazolo[1,5-a]pyrimidin-4(5 H)- yl) p henyl)-N- hydroxyphenylcyclopropanecarboxamide; (1 R*,2R*,3R*) - N-Hydroxy(4 -(4 -methylpiperazinyl) p henyl) phenylcyclopropanecarboxamide; ( 1 R*,2R*,3R*)- N-Hydroxy(4 -(o xazolyl)p henyl) phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)-N -Hydroxy(4 -( 1 -methyl-1H-imidazolyl)p henyl) phenylcyclopropanecarboxamide; (1 R*,2S*,3S*) - 2-(4 -( 5 -Fluoropyrimidinyl) p henyl)-N-hydroxymethyl phenylcyclopropanecarboxamide; (1 R*,2R*,3R*)- 2-(4 -( 1 H-pyrazolyl) p henyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R)-N-Hydroxyphenyl(5 -(t rifluoromethyl) p yridin yl)c yclopropanecarboxamide; (1 R,2R,3R) - 2-(4 -(1 -Benzyl-1,2,3,6-tetrahydropyridinyl)p henyl)- N-hydroxy phenylcyclopropanecarboxamide; ( 1 S,2R,3R)(2 -fluorophenyl) -N-hydroxy( 4-( 2 -methyloxazol yl) p henyl) c yclopropanecarboxamide; (1 S,2R,3S)- 2-(2 -fluorophenyl)-N-hydroxymethyl(4 -(2 -methyloxazol yl)p henyl) c yclopropanecarboxamide; (1 S,2R,3R) - 2-(2 -fluorophenyl) -N-hydroxy(4-(3 -methyl-1H-pyrazol yl) p henyl) c yclopropanecarboxamide; ( 1 S,2R,3R)- 2-(2 -fluorophenyl)-N-hydroxy(4-( 3 -(t rifluoromethyl)-1H- pyrazolyl)p henyl)c yclopropanecarboxamide; (1 S,2R,3R)- 2-(2 -fluorophenyl) -N-hydroxy(4-(i sopropyl(2 - morpholinoethyl)a mino) p henyl)cy clopropanecarboxamide; (1 R,2R,3R) - 2-(2 -cyclopropylpyrimidinyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R)( b enzo[d]isoxazolyl) - N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R) - 2-( 6 -cyclopropylpyridazinyl)-N-hydroxy phenylcyclopropanecarboxamide; ( 1 S,2R,3R) - 2-( 2 -fluorophenyl)-N-hydroxy( 6-(3 -methyl-1H-pyrazol yl)p yridinyl)c yclopropanecarboxamide; ( 1 S,2R,3R)- 2-( 6 -(5 -chloropyrimidinyl) p yridinyl) (2 -fluorophenyl)- N- hydroxycyclopropanecarboxamide; (1 R,2R,3R)( 5 -chloro(4 -isopropylpiperazinyl)p yridinyl) - N-hydroxy- 3-phenylcyclopropanecarboxamide; (1 S,2R,3R)- 2-(2 -fluorophenyl)- 3-( 6 -( 5 -fluoropyrimidinyl) p yridinyl) - N- hydroxycyclopropanecarboxamide; (1 S,2R,3R)- 2-( 2 -fluorophenyl)-N-hydroxy(6-( 5 -methylpyrimidin yl) p yridinyl) c yclopropanecarboxamide; (1 R,2R,3R) - N-hydroxy( 6 -(2 -methyloxazolyl)p yridinyl) - 3- phenylcyclopropanecarboxamide; (1 R,2R,3R) (5 -chloro( 2 -methyloxazolyl)p yridinyl)- N-hydroxy phenylcyclopropanecarboxamide; ( 1 S,2R,3R) - 2-(2 -fluorophenyl)-N-hydroxy(2-( 2 ,2,2- trifluoroethylamino)p yridinyl)c yclopropanecarboxamide; ( 1 R,2R,3R) - N-hydroxyphenyl(1 -(2 ,2,2-trifluoroethyl) -1H-pyrazol yl)c yclopropanecarboxamide; (1 R,2R,3R)- 2-( 1 -cyclopropyl-1H-pyrazolyl) -N-hydroxy phenylcyclopropanecarboxamide; (1 R,2R,3R) - N-hydroxyphenyl(1 -(1 -(2 ,2,2-trifluoroethyl)p iperidinyl)- 1H-pyrazolyl) c yclopropanecarboxamide; (1 R,2R,3R) - 2-(1 ,3-dimethyl-1H-pyrazolyl)- N-hydroxy phenylcyclopropanecarboxamide; ( 1 R,2R,3S)- N-hydroxy( 2 -methylthiazolyl) phenylcyclopropanecarboxamide; (1 R,2R,3R) - 2-(8 -chloro-1,2,3,4-tetrahydroquinolinyl)-N-hydroxy phenylcyclopropanecarboxamide; ( 1 R,2R,3R) - N-hydroxyphenyl( 4 -(2 ,2,2-trifluoroethyl)-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepinyl)c yclopropanecarboxamide; (1 R,2R,3R)- N-hydroxy(1 -methyl(2 ,2,2-trifluoroethyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazinyl)- 3- phenylcyclopropanecarboxamide; ( 1 R,2R,3R) - 2-(1 -fluoro(2 ,2,2-trifluoroethyl)-1,2,3,4-tetrahydropyrrolo[1,2- a]pyrazinyl) - N-hydroxyphenylcyclopropanecarboxamide; (1 R,2R,3R)- N-hydroxyphenyl( 2 -( 2 ,2,2-trifluoroethyl) -1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazinyl) c yclopropanecarboxamide; ( 1 R,2R,3R)-N-hydroxyphenyl( 7 -(2 ,2,2-trifluoroethyl)-5,6,7,8- tetrahydroimidazo[1,2-a]pyrazinyl) c yclopropanecarboxamide; (1 R,2R,3R) - N-hydroxyphenyl(2 -( t rifluoromethyl) i midazo[1,2-a]pyridin- 7-yl)c yclopropanecarboxamide (1 R,2R,3R) - N-hydroxy(i midazo[1,2-a]pyridinyl) phenylcyclopropanecarboxamide; ( 1 R,2R,3R) - N-hydroxyphenyl( p yrrolo[1,2-a]pyrimidin yl)c yclopropanecarboxamide; ( 1 R,2R,3R)- N-hydroxy( 1 ,5-naphthyridinyl)- 3- phenylcyclopropanecarboxamide; ( 1 S,2S,3R)( 2 -cyclopropylpyridinyl)- N-hydroxy( 2 -methylthiazol yl)c yclopropanecarboxamide; (1 S,2S,3R) - 2-(2 -cyclopropylpyridinyl)- N-hydroxy(5 - ( t rifluoromethyl)t hiophenyl)c yclopropanecarboxamide; (1 R,2R,3R)(1 -(( 5 -fluoropyridinyl)m ethyl) -1H;pyrazolyl)- N-hydroxy phenylcyclopropanecarboxamide (1 S,2R,3S) - 2-(3 -fluoromethylthiophenyl)-N-hydroxy( 1 -methyl-1H- pyrazolyl)c yclopropanecarboxamide; ( 1 S,2S,3R)- N-hydroxy( 1 -methyl-1H-pyrazolyl) - 3-( 5 -methyl (t rifluoromethyl) t hiophenyl)c yclopropanecarboxamide; ( 1 S,2S,3R)- N-hydroxy( 1 -methyl-1H-pyrazolyl)- 3-(5 -methylthiophen yl)c yclopropanecarboxamide; (1 R,2R,3R)- N-hydroxy(1 -methyl-1H-pyrazolyl)- 3-o- tolylcyclopropanecarboxamide; (1 R,2R,3R) - N-hydroxy(1 -methyl-1H-pyrazolyl) - 3-( 2 - (t rifluoromethyl)phenyl) cyclopropanecarboxamide; (1 S,2R,3R)- 2-( 2 -chlorophenyl)- N-hydroxy(1-methyl-1H-pyrazol yl)c yclopropanecarboxamide; (1 R,2R,3R)- 2-(3 -fluorophenyl)- N-hydroxy(1-methyl-1H-pyrazol yl)c yclopropanecarboxamide; (1 R,2R,3R)- N-hydroxy(1 -methyl-1H-pyrazolyl)- 3-m- tolylcyclopropanecarboxamide; (1 R,2R,3R)- N-hydroxy(1 -methyl-1H-pyrazolyl)- 3-(3 - (t rifluoromethyl) p henyl)cyclopropanecarboxamide; (1 R,2R,3R)- 2-(3 -chlorophenyl)-N-hydroxy(1-methyl-1H-pyrazol yl)c yclopropanecarboxamide; (1 S,2S,3R)- 2-(2 -cyclopropylpyridinyl)- 3-( 3 -fluoromethylthiophenyl) - N-hydroxycyclopropanecarboxamide; (1 S,2S,3R) - 2-(2 -cyclopropylpyridinyl)- N-hydroxy( 5 -methyl ( t rifluoromethyl)t hiophenyl)c yclopropanecarboxamide; ( 1 S,2S,3R)- 2-( 2 -cyclopropylpyridinyl) - N-hydroxy(5 -methylthiophen yl) c yclopropanecarboxamide; (1 R,2R,3R)- N-hydroxyphenyl( 4 -( 5 -(t rifluoromethyl) -1H-imidazol yl)p henyl)cyclopropanecarboxamide; (1 R,2R,3R)- 2-( 3 -chloro(5 -methyl-1H-imidazolyl)p henyl) -N-hydroxy phenylcyclopropanecarboxamide; and ( 1 R,2R,3R) ( 3 -fluoro( 5 -methyl-1H-imidazolyl) p henyl) -N-hydroxy phenylcyclopropanecarboxamide, or a pharmaceutically acceptable salt thereof.
26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
27. Use of a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition or disorder mediated by at least one histone deacetylase in a subject in need of such a treatment.
28. Use according to claim 27 wherein the at least one histone deacetylase is HDAC-4.
29. Use according to claim 27 wherein said condition or disorder involves a neurodegenerative pathology.
30. Use according to claim 29 wherein the condition or disorder is Huntington’s disease.
31. A compound, composition or use according to any of claims 1, 26 or 27 substantially as hereinbefore described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161435678P | 2011-01-24 | 2011-01-24 | |
US61/435,678 | 2011-01-24 | ||
PCT/US2012/022216 WO2012103008A1 (en) | 2011-01-24 | 2012-01-23 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613087A NZ613087A (en) | 2015-02-27 |
NZ613087B2 true NZ613087B2 (en) | 2015-05-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9765054B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
US10457675B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
US9855267B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
US9783488B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
WO2014159214A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
US10106535B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
AU2016258188B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
NZ613087B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof |